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Abstract
Background: Herpes zoster (HZ) is a prevalent viral disease that inflicts substantial morbidity and associated
healthcare and socioeconomic burdens. Current treatments are not fully effective, especially among the most
vulnerable patients. Although widely recommended, vaccination against HZ is not routine; barriers in Asia-Pacific
include long-standing neglect of adult immunisation and sparse local data. To address knowledge gaps, raise
awareness, and disseminate best practice, we reviewed recent data and guidelines on HZ from the Asia-Pacific region.
Methods: We searched PubMed, Scopus, and World Health Organization databases for articles about HZ published
from 1994 to 2014 by authors from Australia, China, Hong Kong, India, Indonesia, Japan, Korea, Malaysia, New Zealand,
the Philippines, Singapore, Taiwan, Thailand, and Vietnam. We selected articles about epidemiology, burden,
complications, comorbidities, management, prevention, and recommendations/guidelines. Internet searches retrieved
additional HZ immunisation guidelines.
Results: From 4007 retrieved articles, we screened-out 1501 duplicates and excluded 1264 extraneous articles, leaving
1242 unique articles. We found guidelines on adult immunisation from Australia, India, Indonesia, Malaysia, New
Zealand, the Philippines, South Korea, and Thailand.
HZ epidemiology in Asia-Pacific is similar to elsewhere; incidence rises with age and peaks at around 70 years – lifetime
risk is approximately one-third. Average incidence of 3–10/1000 person-years is rising at around 5% per year. The
principal risk factors are immunosenescence and immunosuppression. HZ almost always causes pain, and post-herpetic
neuralgia is its most common complication. Half or more of hospitalised HZ patients have post-herpetic neuralgia,
secondary infections, or inflammatory sequelae that are occasionally fatal. These disease burdens severely diminish
patients’ quality of life and incur heavy healthcare utilisation.
Conclusions: Several countries have abundant data on HZ, but others, especially in South-East Asia, very few. However,
Asia-Pacific countries generally lack data on HZ vaccine safety, efficacy and cost-effectiveness. Physicians treating HZ
and its complications in Asia-Pacific face familiar challenges but, with a vast aged population, Asia bears a unique and
growing burden of disease. Given the strong rationale for prevention, most adult immunisation guidelines include HZ
vaccine, yet it remains underused. We urge all stakeholders to give higher priority to adult immunisation in general and
HZ in particular.
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Background
Herpes zoster (HZ) is a prevalent and debilitating viral
disease that often causes serious complications and
proves challenging to treat. Consequently, HZ results in
substantial morbidity, healthcare expenditure, loss of
productivity, and diminished quality of life (QoL). Older
people bear the greatest burden of disease, which is in-
creasing as populations age. Despite a strong rationale
for prevention, availability of an effective vaccine, and
guidelines recommending HZ immunisation, vaccination
has not become routine practice. One reason was limited
availability of HZ vaccine after its launch in 2006 [1, 2].
Although an ample supply was restored, a fundamental
barrier in Asia is long-standing neglect of preventive adult
healthcare. Since Ilina Isahak highlighted this issue in
2000 [3], progress been limited and adult immunisation is
still not given the priority that it merits [4, 5, 6]. Moreover,
existing HZ immunisation guidelines are based on evi-
dence from Western populations, which creates a percep-
tual barrier to changing management practices in Asia.
Conversely, more locally-relevant data may promote
guideline implementation; however, many Asian countries
lack such data [7]. To address these concerns, we system-
atically reviewed literature on HZ from the Asia-Pacific
region. Our objectives were: 1) To provide a comprehen-
sive overview of the epidemiology, burden, and current
management of HZ; 2) To disseminate best practice in
HZ immunisation; and 3) To provide an up-to-date source
of reference and information for stakeholders concerned
with reducing the burden of HZ in Asia-Pacific. This re-
view summarises our key findings and recommendations.
Methodology
Literature search strategy
We reviewed literature on HZ published over 21 years
by authors from 14 Asia-Pacific countries. We searched
three databases: PubMed (United States [US] National
Library of Medicine National Institutes of Health), Scopus
(Elsevier), and the World Health Organization (WHO)
Global Health Library Regional Indexes. PubMed and Sco-
pus searches used the search term ‘zoster’ in title, abstract,
and author keywords fields, AND the term ‘country name’
in the affiliation field. The countries/regions were:
Australia, China, Hong Kong, India, Indonesia, Japan,
Korea, Malaysia, New Zealand, the Philippines, Singapore,
Taiwan, Thailand, and Vietnam OR Viet Nam. WHO
searches used the terms ‘country name’ AND ‘zoster’.
Searches were limited to articles with abstracts in English
published electronically since 1 January 1994 and before 31
December 2014; alerts were set to capture eligible articles
added to PubMed and Scopus after the initial search dates.
We performed separate internet searches for guidelines
on HZ immunisation. These used the country names and
also vernacular terms for their inhabitants, eg, Thai,
Filipino, Malay, combined with the terms herpes zoster,
guidelines, recommendations, adult immunisation, vac-
cine, vaccination.
Data management
PubMed and Scopus results were downloaded in
Comma Separated Value format then saved to Microsoft
Excel files. WHO Global Health Library searches were
exported as text files then imported into Microsoft Excel.
Results from each database were screened to remove du-
plicates before entering the results for each country into a
Microsoft Excel workbook. Duplicates between databases
were identified by using conditional formatting to high-
light entries with the same title. Duplicates between coun-
tries were identified similarly, by highlighting entries with
the same database identity codes.
Inclusion and inclusion criteria
We included articles about four topics: epidemiology and
burden; complications and comorbidities; management
and prevention; and recommendations/guidelines. We
excluded articles about: subjects only younger than
18, or from another country; primary varicella zoster
virus (VZV) infection or not specifying that VZV
infection was reactivated; negative disease associations,
cases of coincidental HZ, or diseases other than HZ;
extraneous research topics, eg, basic/molecular/experimental,
diagnosis, technology; or reviews without country-specific
information. Miscellaneous exclusions were editorials,
correspondence or errata concerning included articles;
study protocols, and articles on terminology, hypotheses,
non-human subjects, or knowledge, attitudes and
behaviour relating to HZ and its treatment.
Literature search results
The database searches returned 4007 articles (Fig. 1a).
Having excluded 1493 duplicates and 1264 non-relevant
articles, 1250 were assigned to four categories: epidemi-
ology and burden (421); complications and comorbidities
(538); management and prevention (287); and guidelines
(4) (Fig. 1b). The separate search for guidelines found rec-
ommendations on adult immunisation from Australia,
India, Indonesia, Malaysia, New Zealand, the Philippines,
South Korea, Taiwan, and Thailand.
‘Grey literature’ included other key studies/data cited
in retrieved articles or not stored in the searched data-
bases, eg, national statistics or reports published locally;
16 such sources were added.
Clinicopathology
Herpes zoster is caused by reactivation of VZV dormant
in nerve root ganglia since a primary varicella infection
(Chickenpox). The cardinal symptom is neuropathic
pain, often accompanied by a self-limiting vesicular rash
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and/or inflammation disclosing the source nerve [8–10].
In Asia, as elsewhere, the classic presentation is unilateral
HZ affecting a single thoracic dermatome, although HZ
frequently involves the trigeminal, cranial, or cervical
nerves; lumbosacral HZ is less common (Fig. 2) [11–31].
The presentations and course of HZ also vary depending
on patients’ age, health, and immune status. Older people
are more likely to have trigeminal VZV reactivation and
worse and longer-lasting rash and pain [20, 32], whereas
immunocompromised patients tend to have relatively
more thoracic HZ [14, 33]. All physicians should therefore
beware that HZ assumes an array of guises.
Atypical HZ
Reactivated VZV can affect any part of the body. Ocular
symptoms due to involvement of the ophthalmic division
of the trigeminal nerve are common [34]; however, the
maxillary and mandibular branches may occasionally be af-
fected, resulting in oro-cutaneous manifestations [35, 36].
Atypical presentations usually reflect underlying immuno-
compromise, and other unusual locations have included the
eardrum [37], genitalia [38, 39], papilla [40], and finger [41].
Zoster sine herpete
VZV reactivation does not always manifest cutaneously.
Zoster “sine herpete” causes unexplained pathologies, in-
cluding neuralgia [42], ocular [43], facial [44], or
neuromotor palsy or paralysis [45, 46], and cerebral or
ocular inflammations [47, 48].
Multidermatomal, disseminated and visceral HZ
Rarely, especially in patients who are elderly or other-
wise immunocompromised, HZ involves two or more
distinct dermatomes [49, 50], spreads across multiple
sites [51, 52], appears as a generalised rash [53, 54], or
worse, affects internal organs [9, 10]. Although occasion-
ally seen in immunocompetent individuals [55–64], such
unusual presentations constitute fewer than 1% of total
cases, being particularly characteristic of iatrogenic
immunosuppression in transplant recipients [65, 66] or
cancer patients [67–71], or human immunodeficiency virus
(HIV) infection, in which bilateral [72, 73], multidermatomal
[74], disseminated [75], or recurrent [73, 76, 77] HZ are
often the presenting symptom [72, 78–80].
Disseminated HZ predicts higher risk of complications
[81] and may portend abdominal HZ, which has high
mortality despite antiviral therapy, especially in profoundly
immunocompromised patients [9, 10, 82]. For example,
haematopoietic stem cell transplant (HSCT) recipients
have died of fulminant VZV hepatitis [83, 84]. Such pa-
tients may present with severe abdominal pain [82, 85–87]
either sine herpete or before lesions appear [9, 10]. Besides
hepatitis, viscerally disseminated HZ may also cause pan-
creatitis [88, 89], colitis [90], pneumonitis [91, 92], or
pneumonia [69, 93], which causes most fatalities [10].
a
Total individual articles/sources: 1268
Database articles included: 1250
Database articles reviewed: 2514
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Fig. 1 a Literature search and selection; b) Included articles by country and topic. WHO-GHL, World Health Organization Global Health Library
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Pain
Irrespective of its outward appearance, pain is the hall-
mark of HZ in adulthood. Acute pain and post-herpetic
neuralgia (PHN) are its most unbearable and debilitating
symptoms and severely impair QoL and everyday activities
[15, 18, 20, 30]. Pain is notoriously challenging to manage,
especially once established, making this the most compel-
ling reason for early intervention [9, 25, 94, 95].
Almost all adult HZ patients suffer pain, which can be
excruciating and is often described as the worst ever expe-
rienced [10, 96]. Many cases are presaged by prodromal
neuralgia or malaise, with abnormal sensations such as
itching, paraesthesia and hyperaesthesia [10, 18]. In India,
Korea, Singapore and Taiwan, around two-thirds of pa-
tients reported prodromal pain, which more than 90%
rated moderate-to-severe [18, 20, 25, 31]. Among 150
Taiwanese patients, 98% had acute pain at enrolment
(87% moderate-to-severe) [20]; similarly, 95% of Indian
and Singaporean patients experienced pain during the
course of disease [12, 18]. Pain is more frequent and se-
vere in older patients and can have devastating impacts;
patients feel anxious and miserable, have disturbed sleep
and cannot work normally or enjoy life [10, 12, 15, 18, 20,
25, 30]. Besides age, the severity and duration of acute
herpetic pain correlates with the degree of prodromal
pain, the severity of skin lesions, trigeminal/ophthalmic
involvement, anxiety or depression, and comorbid disease
[23, 32, 33, 97–100].
Epidemiology and risk factors
Seroepidemiology
The aetiologic prerequisite of HZ is prior VZV infection,
which most people contract in childhood, unless vacci-
nated preemptively [2, 7, 101, 102]. Although acquisition
may be delayed in tropical climes, around 90% of adults
age 30–39 in Asia-Pacific countries/regions have sero-
converted, with almost all aged ≥40 years VZV seroposi-
tive and therefore at risk of HZ (Fig. 3) [7, 103–135].
Incidence
HZ is very common in the Asia-Pacific region. Alike
Western populations, estimated lifetime risk is approxi-
mately one-third [10, 136], and incidence of 3–10/1000
person-years (PY) rises steeply above age 40 and peaks
between 70–80 years (Table 1, Fig. 4); there is female





































Fig. 2 Nerve branches affected by herpes zoster. HIV+, human immunodeficiency virus positive; HSCT, haematopoietic stem cell transplant
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especially between ages 50–70 [11, 17, 26, 104, 126, 132,
133, 136–144]. Authors ascribe higher age-specific inci-
dence rates in Korea than other countries, to heavy use
of state-insured healthcare by patients with mild HZ
symptoms, besides being based on data from recent
years during which HZ incidence has risen steeply [138,
140]; on the other hand, much lower incidence in
Thailand [30, 144] probably reflects under-reporting.
As in other populations, HZ incidence rates are in-
creasing in countries across Asia-Pacific (Table 2, Fig. 5)
[2, 102, 139–150]; the principal cause is most likely ris-
ing incidence in ageing populations, especially among
women, together with growing prevalence of chronic dis-
eases and use of immunosuppressive medications [2, 102,
139–141, 143, 147]. HZ incidence in Taiwan rose by 20%
from 2004–05 to 2006–08 despite remaining stable in 10–
49 year-olds, with a significant increase in older people
[143]. Hypothetically, mass varicella immunisation might
also contribute to this trend; if natural exposure to VZV
strengthens immunity to HZ – exogenous boosting – HZ
incidence in countries that institute routine childhood
varicella immunisation (Table 3) would be expected to rise
subsequently among the unvaccinated population, due to
declining prevalence of varicella [2, 141, 146, 151, 152].
Although there is some evidence that exogenous boosting
does occur [151], there is very little for a substantive con-
tribution to HZ, and its role, if any, in HZ epidemiology
remains obscure [2, 141, 143, 146, 147, 151, 152]. Rising
HZ rates predating mass varicella immunization (Fig. 5)
suggest that other factors are more important; besides
those already mentioned, these may also include changes
in health-seeking behaviour and more comprehensive and
accurate disease surveillance [151, 152].
Recurrence
Reported HZ recurrence rates range from 2.3% to 8.0%
overall [13, 153, 154] and are higher in women,
immunocompromised patients, and individuals aged
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Fig. 3 Ages of varicella zoster virus seroconversion among adultsa in tropical, subtropical and temperate Asia-Pacific countries.
NIID, National Institute of Infectious Diseases, Japan. a Reported seroprevalence in age-groups including individuals ≥18 years old
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Risk factors and comorbidities
The constitutional cause of HZ is failing cell-mediated
immunity (CMI) that becomes too weakened to suppress
latent VZV [155]. CMI wanes naturally with age [156],
explaining why advanced age is the preeminent risk
factor for HZ and PHN among all populations [10, 95].
Besides immune senescence, other conditions that di-
minish CMI likewise increase the risk of HZ. The princi-
pal predisposing factors are iatrogenic or pathologic
immunosuppression (Fig. 6) [137, 157–167]. Inpatients
with severe illnesses or recovering from surgery develop
HZ more frequently than others [168].
Immunosuppressant therapies
Transplantation Organ, tissue or cell transplant recipients
require immunosuppressive therapy with cyclosporine and/
or other drugs that prevent transplant rejection.
Consequently, they often develop HZ or other opportunistic
infections, especially within the first year following
transplantation [16, 66, 169–180]. HZ rates of up to
>80% have been reported [170, 181], and transplant
recipients are especially prone to disseminated and
visceral HZ with potentially fatal inflammatory com-
plications [70, 82, 181–186].
Anti-inflammatory and cytotoxic agents
Corticosteroids Systemic glucocorticosteroids are im-
munosuppressant and have been associated with HZ
rates above 30% in long-term use [187–189].
Cyclophosphamide and others Cyclophosphamide-based
and other chemotherapeutic regimens substantially in-
crease the risk of HZ in patients with lymphoma
[190–192]. High rates have also been reported in leukae-
mia patients treated with arsenic trioxide [193–196].
Systemic lupus erythematosus (SLE) and lupus nephritis
are also treated with cyclophosphamide, often combined
sequentially with azathioprine and prednisolone or myco-
phenolate mofetil. HZ is the most common drug-related
infection, with rates of up to 40% [166, 197–201].
HZ is also an adverse effect of azathioprine and myco-

















Taiwan (Jih 2009): 4.89; 4.71 5.09
New Zealand (Reid 2014): 2.97
NZ (Reid 2014): 50  years 5.75
Korea (Kim 2014): 10.4; 8.3 12.6
NZ (Reid 2014): 50 years 6.38
Korea (Kang 2008): 19–24 years 1.4
Taiwan (Lin 2010): 4.97; 4.72 5.20
Japan (Toyama 2009): 5.48
Japan (Toyama 2009): 4.15
Japan (Toyama 2009): 3.67







Fig. 4 Age-specific incidence of herpes zoster in Asia-Pacific countries. NZ, New Zealand; ♀, female; ♂, male
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[202–214]. Cases of disseminated HZ have occurred in
rheumatoid arthritis patients treated with leflunomide,
with increased risk in those taking concomitant metho-
trexate and corticosteroids [215, 216]. HZ was the most
common infection in leflunomide-treated lupus nephritis
[217]. The multiple sclerosis drug cladribine is associ-
ated with an increased rate of HZ versus placebo [218].
Biologic agents Antibody therapies for cancer, transplant
rejection and other conditions are associated with elevated
rates of VZV reactivation, both alone and combined
with other biologics or chemotherapies. These include
alemtuzumab [219], rituximab [220–224], and abatacept
[225]. Tofacitinib is associated with significantly higher
rates HZ in Asians than other races [226, 227]. Increased
relative risk of HZ has also been reported with ustekinumab,
adalimumab and infliximab [165, 228–230].
Bortezomib Bortezomib directly impairs CMI and is an
independent risk factor for HZ [166], with incidence of
up to 40% in some Asia-Pacific studies [231–250]. HZ
prophylaxis is advisable before commencing such ther-
apy [251].
Other iatrogenic risk factors
Trauma Accidental or iatrogenic trauma can trigger HZ
[252–258]. This is particularly associated with ocular,
facial or dental surgeries [259–268], and heightened
vigilance is warranted following such procedures,
particularly in elderly or immunocompromised patients.
Ironically, neurosurgical treatment of PHN occasionally
causes HZ [269–271].
Anaesthesia General anaesthesia may compromise im-
mune function, and mothers anaesthetised for
Table 2 Trends in herpes zoster incidence, hospitalisation and healthcare costs in Asia-Pacific countries
Country (source) Metric Years compared Herpes zoster rate Annual increase (%)
























































































Median (range) 5.5 (−8.1–17.9)
Quartile range (IQR) 3.0–7.5 (4.6)
GP General practitioner, IQR Interquartile range
aPrincipal diagnosis of herpes zoster
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caesarean delivery have a small increased risk of HZ
during the following year [272].
Statin therapy Statin users have slightly increased risk
of HZ, likely due to statin-mediated immunosuppression
[273, 274].
Drug-induced hypersensitivity syndrome Drug-induced
hypersensitivity is a severe reaction to certain drugs that
involves the reactivation of herpes viruses, including
VZV. Systemic corticosteroids may contribute to this
risk, and like immune restoration syndrome, withdrawal








































































Taiwan (Wu CY 2010)




Thailand Bureau of Epidemiologyb
Taiwan: Jan 2004 
Australia: Nov 2005
Fig. 5 Trends in herpes zoster rates in Asia-Pacific countries. a Consultations. b Reported cases
Table 3 Asia-Pacific countries with national varicella immunisation programmes




Australia 1 18 months, with catch-up at 10–13 yearsa Entire population November 2005
Hong Kong 2 12 months & 6 yearsb Entire population November 2005
Japan 2 12–36 months Entire population (voluntary category)c October 2014
New Zealand 1 15 months, with catch-up at 11 yearsd Entire population July 2017
South Korea 1 12–15 months Entire population January 2005
Taiwan 1 12–18 months Entire population January 2004
aSchools programme
bPrimary 1 school age
cNot covered under the Preventive Vaccinations Act for Routine Vaccination against Category A Diseases
dFor non-vaccinated children who have not already had a varicella infection
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Infections
HIV/AIDS HIV/Acquired Immunodeficiency Syndrome
(AIDS) is a major healthcare problem in Asia. With
prevalence of up to 30% and incidence as high as 40–50/
1000 PY [276–303], HZ is so common in HIV-infected in-
dividuals that it may be a pragmatic prognostic marker [14,
27, 28, 76], especially among younger individuals [304–
309]. AIDS patients may have recurrent [73, 76, 77, 80],
disseminated [27, 78], or cerebral HZ infections [310, 311].
HZ incidence correlates with low CD4+ cell count [310,
312–314] and may be significantly reduced by highly-active
antiretroviral therapy (HAART); however rates in the post-
HAART era remain double-digit [281, 303].
Immune reconstitution syndrome Paradoxically, pa-
tients regaining immunocompetence following HAART
are at higher risk of HZ than when immunodeficient,
probably due to increasing CD8 cell count, a
phenomenon termed immune reconstitution inflamma-
tory syndrome [315–318].
Varicella zoster virus Counterintuitively, Taiwanese
healthcare workers frequently exposed to VZV did not gain
enhanced immunological protection, and had higher inci-
dence of HZ than the general population; however, this
may be because their very stressful working environment
dampened CMI, overriding any protective effect [142]. Epi-
demiology data from Japan [319] and elsewhere suggests
that varicella exposure boosts immunity to HZ [102, 151].
Nevertheless, rare localised HZ clusters suggest that VZV
re-exposure might occasionally provoke recrudescent HZ;
the mechanism is unknown, but may involve disruption of
CMI by the humoral response to VZV reinfection [320].
Although VZV transmission from patients with HZ is rare,
due to less and more localised viremia, exudate from open
HZ lesions may potentially infect close contacts who have
not had varicella or been immunised [10, 320–324].
Other pathogens Rare cases of HZ associated with
tuberculosis or malaria have been reported in China and
India [325–328].
Adjusted risk vs. controls







































































Fig. 6 Relative risk of herpes zoster in different predisposing conditions. PD, peritoneal dialysis; HD, haemodialysis; CKD, chronic kidney disease;
SLE, systemic lupus erythematosus; RA, rheumatoid arthritis; IBD, inflammatory bowel disease; COPD, chronic obstructive pulmonary disease; HIV/
AIDS, human immunodeficiency virus/acquired immunodeficiency syndrome
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Intrinsic risk factors
Pregnancy Pregnancy is another immunosuppressed
state that may potentiate HZ [120]. Although this sel-
dom occurs, HZ is the most common skin infection that
dermatologists encounter in pregnant women, account-
ing for up to 30% of cases [329]. While challenging to
treat, unlike congenital varicella, HZ poses minimal risk
to the foetus [330, 331].
Good’s syndrome Good’s syndrome is a very rare
immunodeficiency disease predisposing to HZ [332].
Nutritional deficiency Micronutrient deficiencies that
diminish CMI may increase susceptibility to HZ and
PHN; supplements, particularly vitamin D, can boost
VZV immunity [333–335].
Genetic predisposition Asians have genetic predisposi-
tions to HZ; specifically, human leukocyte antigen gene
polymorphisms have been linked to VZV reactivation in
East Asian populations [336–338].
Associated diseases
Unsurprisingly, many HZ patients have common dis-
eases of older age (Table 4), most frequently hyper-
tension, diabetes, malignancies, and pulmonary disorders
[11, 12, 15, 23, 26, 28, 137, 154, 166, 339]; however, since
comorbidities and/or complications account for high
proportion of hospitalised HZ cases [11, 12, 15, 23, 26, 28,
102, 104, 136, 137, 154, 166, 340], these may be more
prevalent among such patients than in the general
population.
Patients with certain underlying diseases have apparently
increased risk of HZ; however, it may be difficult to
ascertain whether such relationships are causal, reflect
underlying pathology, or are coincidental. In cancer,
SLE, and other diseases treated with immunosuppressants,
HZ may be largely treatment-related, although the disease
too may make an indeterminate contribution to increasing
the risk [10]. In others, for example, diabetes and renal
disease, impaired CMI may be a common factor. Adjusted
for age and other confounding variables, several comor-
bidities have been identified as independent risk factors
for HZ, most notably renal disease, malignancies, and SLE
(Fig. 6) [137, 157–167].
Renal disease The incidence of HZ increases across the
spectrum of renal disease, with transplant patients at
highest risk followed by peritoneal dialysis and haemodi-
alysis [157, 159, 160, 341–343]. The risk of HZ in
haemodialysis is heightened by corticosteroid use, but
may be mitigated by iron and vitamin D supplementation
[334, 335].
Inflammatory autoimmune diseases HZ frequently
afflicts patients with connective tissue disorders [344],
with double the risk in rheumatoid arthritis [158].
Patients with SLE have impaired CMI and are treated





Proportions with comorbidities (%)
Any Hypertension Diabetes Malignancy Pulmonary Cardiovascular
Korea (Park SY 2004) [26] Dermatology (1089) NA 36.5 12.6 7.9 0.6 1.7a 1.6c
Korea (Kim YM 2008) [11] Dermatology (297) NA 56.2 32.1 17.5 10.4 7.5a NA
China (Yuan LL 2014) [339] Hospitals (2960) Median 60 22.2 11.7 6.2b 10.7
Philippines (Jara 2010) [15] Hospital (221) Mean 43 28.0 13.6 1.8 8.1 2.7
Japan (Kurokawa 2002) [23] Hospitals (263) Mean 59 41.1 9.6 13.7
Thailand (Tunsuriyawong 2005)
[154]
Hospital (339) Mean 59 26.8 4.0 2.5 1.0
India (Abdul Latheef 2011) [12] Hospital (205) 47% >40 14.6 5.3 9.2
Taiwan (Jih 2009) [137] National (34380) 33% >60 20.6 2.7
Taiwan (Hu 2013) [166] Hospital (2306) 24.3 14.8
Taiwan (Wu CY 2010) [142] National (702932) 1.0
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with immunosuppressant anti-inflammatory drugs, which
significantly increases their risk of HZ [137, 161, 345, 346],
particularly if they have neuropsychiatric manifestations,
renal involvement, or receive cyclophosphamide [166].
Likewise, increased risk of HZ associated with inflammatory
bowel disease probably reflects iatrogenic immunosuppression
in many patients [162, 347].
Cancer Cancer patients may be immunosuppressed due
to malignancy, its treatment, or both [12, 39, 348]. Risk
of HZ is increased in both solid and haematologic can-
cers [158, 349, 350], especially leukaemia and lymphoma
[137, 158].
Pulmonary disease Both immune dysregulation and
corticosteroid therapy may account for increased risk of
HZ in chronic obstructive pulmonary disease. Patients
taking oral corticosteroids are at the greatest risk [164].
Diabetes Patients with diabetes have impaired VZV-
specific CMI [351]; however, evidence that diabetes is a
risk factor for HZ [137, 158, 352] is inconclusive.
Peptic ulcer disease Peptic ulcer disease independently
predicts HZ, having excluded confounding effects of
anti-inflammatory drugs and Helicobacter pylori infec-
tion [163].
Psychiatric disorders CMI is also diminished in
psychiatric disorders. The risk of HZ is increased in
patients with affective psychoses, neurotic illness,
personality disorders and other mental disorders, especially
among those younger than 60 [353].
Complicating presentations and disease
associations
Post-herpetic neuralgia
The most common complication of HZ in adults every-
where is pain outlasting the eruptive phase [94]. Definitions
of PHN are inconsistent, ranging from ≥1 to ≥6 months
since rash onset; however, PHN may persist for years [10].
Reported rates vary widely, depending on patients’ age
profiles and the definitions used [20]; nonetheless, the
incidence generally ranges between ≤10 to ≥25%, with
up to 20% still enduring pain after 6 months (Table 5)
[11, 12, 15, 18, 20, 21, 23, 25, 26, 28, 30, 96, 104,
130, 137, 154, 340, 354–359]. PHN correlates strongly
with advancing age [15, 18, 21, 96, 102, 137, 340,
356, 357], the other major prognostic factors being
the severity of HZ and intensity of acute pain [23, 99,
137, 356, 357, 360–362]. Comorbid risk factors in-
clude diabetes, lymphoma/leukaemia, SLE [137, 363],
peptic ulcer disease [364], and micro-nutrient defi-
ciencies [333]. There is also evidence of specific
phenotypic [358] and genotypic predispositions [365–368].
Bortezomib may aggravate PHN independently of VZV
reactivation [369].
Neuropathy, inflammation and secondary complications
HZ causes multifarious complications, especially inflam-
matory sequelae, which affect up to half or more of hos-
pitalised HZ patients. The most common besides PHN
involve the skin, eyes or, less often, ear, nose and throat
(Table 5) [11, 12, 15, 26, 30, 102, 104, 136, 340, 354].
Uncommon complications include muscular weakness
or paralysis and serious – sometimes life-threatening –
cerebral or visceral inflammation. Elderly or immuno-
compromised individuals are more frequently and often
worse affected [30, 96, 340, 370].
Eye
The most common and severe complications stem from
VZV reactivation in trigeminal ganglion, which is the
most frequently affected non-spinal location [11, 12, 23,
26, 29, 34, 371]. In particular, HZ ophthalmicus (HZO)
arising from the ophthalmic division accounts for 5% to
25% of HZ cases in Asia-Pacific countries [11, 15, 17, 22,
30, 102, 104, 136, 154, 340, 354] (Table 5). The majority
of cases, especially those accompanied by nose eruptions
(Hutchinson's sign) [372–375], are complicated by sec-
ondary inflammation such as conjunctivitis, keratitis
[376–378], scleritis, and uveitis/iridocyclitis [372–374,
379–381]. Such complications can cause glaucoma and
are potentially blinding, especially if not treated
promptly [379, 382]. However, inflammatory sequelae
may not manifest until some time after an HZ episode
[383]. Early and intensive antiviral therapy is particularly
important for patients with HIV/AIDS, who tend to have
worse and treatment-refractory inflammation, with re-
sultant vision loss [384–386].
Molecular diagnostic techniques have revealed VZV
reactivation to be a predominant cause of anterior uve-
itis in South and East Asian countries [387–389], with
significantly increased risk within 1 year following HZ,
especially HZO [390]. VZV is also a major cause of
acute retinal necrosis [391–397] in the region, and of
progressive outer retinal necrosis, which is usually seen
in severely immunocompromised patients [398–402].
Both conditions have particularly poor visual outcomes,
even when treated appropriately [375, 391, 392, 397,
399, 403–407].
Less common ocular complications include, corneal
endotheliitis [408], retinochoroiditis [381], optic neuritis
[409–411], oculomotor palsy [371], dacryoadenitis [412,
413], superior orbital fissure syndrome [414], orbital
apex syndrome [415, 416], and central retinal vein occlu-
sion [417].
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Ear, nose and throat
Occasionally, VZV reactivation in the facial nerve genicu-
lar ganglion causes HZ oticus (Ramsay Hunt syndrome)
[418, 419]. Patients often have multiple neuropathies and
diverse symptoms, depending on the cranial and facial
nerve branches involved. As elsewhere, the characteristic
triad is facial palsy, auricular rash and ear pain [418, 420–
422]; however, some cases affect the tongue, soft palate, or
throat [423, 424], and the rash may precede facial paraly-
sis, not appear until afterwards [420], or be absent [424].
Many patients experience hearing loss and vestibulo-
cochlear symptoms such as tinnitus and vertigo [418, 420,
425, 426]. The seventh and eighth cranial nerves are most
commonly affected [420, 427], but many atypical cranial
neuropathies have also been identified [428–431]; Ramsay
Hunt syndrome has been associated with dysphonia [46,
424, 429, 432, 433], laryngitis [434, 435], loss of taste
[436], chronic cough [437], hiccups [435, 438], dysphagia
[46, 424, 429, 439], and persistent vomiting [438]. Other
rare complications include jugular foramen syndrome
[440] and non-facial neuromotor deficits [441]. In addition
to Ramsay Hunt syndrome, zoster sine herpete is increas-
ingly recognised as a major aetiologic factor in idiopathic
Bell’s palsy [442–444] and Ménière's disease [445, 446].
HZ oticus generally responds to prompt antiviral therapy,
with good outcomes [421, 430]; however, half of patients
may not recover fully from facial palsy [420, 421], with even
lower rates among those who are older [427], have multiple
cranial neuropathies [420], or are not treated [419].
The diversity of manifestations, often occurring sine
herpete, creates potential for misdiagnosis [419]. It is
vital for clinicians to remain alert to the possibility of
HZ, so that treatment can begin early enough to avoid
potentially life-threatening sequelae of VZV reactivation
in the head and/or neck [438, 447].
Neuromuscular
Fewer than 5% of HZ cases in Asian patients cause
motor neuropathy [448–450]. Though more common in
the elderly or immunocompromised [450, 451], such
complications also affect immunocompetent individuals
[452, 453]. Among 711 Korean HZ patients, 2.1% had
neuromotor weakness, predominantly affecting cranial
rather than spinal nerves [448]. The incidence was 0.8%
among 1432 Japanese patients [454] and 3% in an Indian
cohort [449]. Such complications may arise before skin
lesions appear and are likely underdiagnosed because
they are masked by overriding pain [455, 456]; they may
also occur some time after HZ onset [452, 457, 458].
Other presentations include gastrointestinal or bladder
dysfunction [10], myelitis [450, 459–461], and myositis
[462]. VZV infection is implicated in the aetiology of
Guillain-Barré syndrome [463–465].
Face and eye VZV reactivation is a common cause of
Bell's palsy [466]. HZO may present as orbital myositis
preceding skin eruptions [462], and sometimes causes
complete ophthalmoplegia [467–472].
Limbs Paresis of the ipsilateral shoulder or arm [473–
477], occurs in 3–5% of HZ cases, but is underdiag-
nosed [478, 479]. Some cases are due to brachial
plexopathy [480, 481], and others to Brown-Séquard
hemiplegia [460, 482]. Lower limb neuropathy may
manifest as foot drop [449, 483], and HZ paresis-
induced femoral fracture has been reported [484].
Trunk and abdomen Cervical myelitis can cause dia-
phragmatic paralysis with resultant dyspnoea [457, 485–
487]. Segmental paresis may cause abdominal protrusion
or pseudohernia [488–492], which are associated with
gastrointestinal complications, notably constipation due to
intestinal pseudo-obstruction or colonic ileus [488, 493–
496].
Lumbosacral Voiding dysfunction associated with sacral
HZ is uncommon but not rare, especially among
immunocompromised patients [497]. The incidence
among 423 Taiwanese HZ patients was 4% overall, and
29% among those with lumbosacral HZ [498]. Urinary
problems include neuropathic bladder [499], loss of
voiding sensation [500] and occasional acute urinary
retention [461, 501–503]. Other complications include
faecal incontinence [504] rectal ulcer [505] and sciatica [506].
Vasculopathy
Though rare, vasculitic cerebral inflammation is the
most serious neurologic complication of HZ; VZV from
intracranial branches of the trigeminal nerve that in-
vades and inflames the carotid artery or its branches,
may cause fatal strokes [9, 10].
Cerebrovascular Cerebral arteritis arising from HZ, es-
pecially HZO, significantly increases the risk of
thromboembolic or haemorrhagic strokes [507, 508].
Those affected may have no visible lesions [509, 510]
and strokes may be delayed [511–516] or occur without
characteristic risk factors or symptoms [512, 513, 517,
518], leading HZ-associated stroke to be underdiagnosed
[514, 519]. HIV/AIDS might be suspected in otherwise
healthy younger individuals [518, 520].
Cerebral inflammation Rare but severe and sometimes
fatal neurologic complications include meningitis or
meningo-encephalitis [521–526], cerebellitis [527], and
encephalitis [528, 529]. Other reports include posterior re-
versible encephalopathy syndrome [530], CLIPPERS syn-
drome [531], and fatal meningo-encephalomyelitis [532].
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Again, those affected are generally immunocompromised
[9, 10], although accruing evidence suggests that such
complications affect young and/or immunocompetent in-
dividuals more often than was supposed [521, 533–538].
Ocular Cases of Horner’s syndrome and related cranial
nerve palsies [539–542] have been attributed to HZO-
induced arteritis and VZV meningitis [543]. Reported
HZ retinopathies include visual loss due to central ret-
inal artery occlusion and vasculitic chorioretinopathy
[404, 544, 545].
Cardiovascular Intriguing evidence hints at a link be-
tween HZ and cardiovascular disease in Asia. There are
modestly elevated risks of acute coronary syndrome,
arrhythmia and coronary artery disease following HZ
[546, 547]. Herpetic infections may also be associated
with atherosclerosis and thrombosis [546], with reports
of HZ-associated deep vein thrombosis [548] and per-
ipheral vascular disease [525]. Myocarditis [549] and
unexplained recurrent asystole [550] following HZ have
also been reported. Interestingly, however, Japanese
patients with prior HZ had lower blood pressure than
those with no history [551].
Skin
The most common dermatologic complications are sec-
ondary infections but numerous others have been described
[9]. Rare complications include folliculitis, syringitis, and
vasculitis [552–554]. HZ can also cause hair loss [555, 556].
Infections Secondary infections complicate up to 30%
of HZ cases [136], rising to 60% in vulnerable hospitalised
patients [340]. The most common are staphylococcus or
streptococcus superinfections [9, 10]. Other opportunistic
organisms include moraxella [557], and aspergillus [558].
Bacterial infections are more likely in patients with dia-
betes [559, 560] and potentially serious, with necrotising
fasciitis reported in one immunocompromised patient
[561]. Immunocompromised patients, particularly those
with HIV/AIDS, may rarely become reinfected by varicella
despite a history of HZ [562].
Isotopic responses HZ may render affected skin suscep-
tible to other infections or dermatoses, for example,
moloscum contagiosum, mycosis fungoides [154], ery-
thema multiforme [563], and psoriasis [564, 565]. Diverse
‘isotopic’ responses at healed HZ sites include: vitiligo
[566], fungal granuloma [567], furuncles [568], granu-
lomatous reactions [569–574], erythemas [575–578],
lichen planus [579, 580], morphea and bullae [581–583],
perforating collagenosis [584, 585], keratolysis [586] and
sarcoidosis [587, 588], reticulohystiocytosis [589], nodular
degeneration [590, 591], verrucous hyperplasia [592],
mucinosis [593], urticaria [594], prurigo nodularis [595],
graft-versus-host reaction [596], drug-induced eruption
[597], adenocarcinoma [598], leukaemia cutis [599], Kapo-
si’s sarcoma [600], and tufted angioma [601].
Dental
Jaw osteonecrosis and tooth loss are rare complications
of trigeminal HZ. Cases have been reported in both
immunocompetent and immunocompromised Asians;
the mechanism remains unknown [602–610].
Disease associations
Emerging evidence from Taiwan and Japan suggests that
patients with HZ are at increased subsequent risk of
cardiovascular disease [546, 547], lymphoma [611] and
other cancers [466, 612, 613], renal failure [614], SLE
[615], multiple sclerosis [616], chronic fatigue syndrome
[617], depression [618, 619] and erectile dysfunction
[620]; however, the causality and significance of these as-
sociations remains unclear. Prevalent comorbidities such
as metabolic syndrome disorders probably contribute to
cardiovascular risk [547], while immunosuppression may
underlie other conditions. Like HZ, kidney disease [160,
335], cancer [466, 612, 621, 622], and depression [158]
are also associated with immunosuppression, and HZ
may occur coincidentally either before or after these
conditions manifest.
Anecdotal reports implicate VZV reactivation in
rare conditions such as inappropriate secretion of
antidiuretic hormone [85, 87, 623–626], drug-induced
hypersensitivity syndrome [627], mononucleosis syndrome
[628], thrombocytopenia [629], and graft-versus-host
disease [630].
Healthcare utilisation
As in the West, HZ-associated pain, morbidity and de-
bility, result in heavy healthcare utilisation, especially
among elderly patients, which imposes major burdens
on healthcare systems and incurs substantial socio-
economic costs in Asia-Pacific countries [20, 25, 30, 96,
102, 104, 136, 137, 140]. Although uncomplicated cases
can usually be treated in community or outpatient set-
tings, this usually entails several visits [20, 30, 96, 102];
Korean HZ patients averaged seven visits to a primary
physician [96], and among 150 elderly Taiwanese
patients, more than 80% consulted a doctor, with 20%
hospitalised [20].
Hospitalisation
Throughout Asia-Pacific, HZ is consistently among the
disorders that dermatologists or pain specialists treat
most often, and is the most common dermatosis in pa-
tients aged 60–70 years [149, 631–641]. Hospitalisation
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rates for HZ range from ~9–51/100000 PY (Table 6)
[2, 7, 102, 104, 136–138, 140, 147]; complications
account for around half of admissions (Table 5) [102,
104, 136] and, therefore, hospitalisation rates likewise
increase with age and are highest among elderly or
immunocompromised patients [96, 102, 104, 136, 138, 140,
147, 642]. Older patients and those with complications stay
longer in hospital [136, 137].
Healthcare expenditure
Accordingly, HZ-related healthcare costs also increase
proportionally with patients’ age and parallel rising inci-
dence [136, 137]. Total expenditure in Taiwan rose by
1.22-fold from US$7.7 million in 2000 to $US 9.8 million
in 2004 [136], and in Korea by 20% between 2003 and
2007 (Table 6) [140]. Direct healthcare costs in Thailand
are equivalent to 1.1% of annual per capita income, a
similar ratio to that in developed nations [30].
HZ in the Asia-Pacific region evidently imposes very sub-
stantial burdens on both patients and the wider commu-
nity, strongly supporting the case for early intervention and
prevention to reduce both HZ-related morbidity and asso-
ciated healthcare expenditure [20, 25, 30, 96, 102, 104, 140].
Management and prevention
Routine HZ management in Asia-Pacific is the same as
elsewhere, mainly relying on antiviral and analgesic
drugs to reduce the severity and duration of acute her-
petic rash and pain, which may in turn decrease the risk
and intensity of PHN [643, 644].
Antiviral therapies
Standard care entails aciclovir, valaciclovir, or famciclovir
for 7 days [643]. These are most effective if commenced
within 3 days of onset [645] but as starting later may
still be beneficial, patients with HZO, who are
immunocompromised, have disseminated HZ, or are
at high risk for PHN, should start antiviral therapy
even beyond 72 hours [643–646]. Topical or oral aciclovir
are effective in most mild-moderate HZ, including HZO
[647–651]; nevertheless aciclovir is least favoured
nowadays because its lower bioavailability necessitates
more frequent dosing [9, 644, 652]. Though comparative
data are sparse [643, 652], Asian studies support the use
of other antivirals.
A meta-analysis including data from Taiwan [653, 654]
and China, found valaciclovir and famciclovir superior to
aciclovir in reducing HZ-associated pain, with comparable
safety [652]. Valaciclovir resolves pain significantly faster
than aciclovir [31, 653–655], while famciclovir has com-
parable efficacy but fewer adverse effects, and may also be
more cost-effective [656, 657]. Penciclovir is also effective
at lower doses than aciclovir, with better safety [658]. Spe-
cifically, aciclovir or its prodrug valaciclovir have been
associated with neurotoxicity, and nephrotoxicity in East
Asian patients with renal impairment [659–669], whereas
famciclovir was safe and effective in patients with renal
dysfunction [670, 671]. Treating HZ keratopathy with aci-
clovir ointment has been reported to cause superficial
punctate keratopathy [672]. Ganciclovir may be a more
effective alternative [673, 674], especially in aciclovir-
resistant acute retinal necrosis [675]; success with
intravitreal foscarnet following acyclovir failure has also
been reported [676]. Valaciclovir and famciclovir are
thought to have similar efficacy [643, 677], but Japanese
researchers reported significantly faster pain relief with
famciclovir [678]. In Caucasians, sirovudine treated acute
HZ as safely and effectively as aciclovir but with fewer re-
currences [679]; however, sirovudine has potentially
fatal interactions with 5-fluorouracil prodrugs, which
killed 18 Japanese cancer patients [680].
Pain relief
Pain control is crucial to HZ management, not only for
acute analgesia, but also because pain severity predicts
PHN [9, 643, 644]. Although prompt antiviral therapy
reduces acute HZ-associated pain, an updated meta-
analysis concluded that aciclovir does not reduce the in-
cidence of PHN and found insufficient evidence to
evaluate the effect of other antiviral agents [681]. In
practice, antiviral therapy is usually given concomitantly
with corticosteroids or analgesics, according to the de-
gree of pain.
Corticosteroids
Oral corticosteroids relieve pain, accelerate lesion healing
and hasten functional recovery; however, being immuno-
suppressive they cannot be given without concomitant
antiviral therapy. Moreover, corticosteroids should be used
with caution in patients with common comorbidities such
as diabetes and hypertension and do not prevent or relieve
PHN [643, 645, 646]. Nevertheless, corticosteroid injec-
tions have successfully treated cases of Ramsay Hunt syn-
drome and refractory PHN in Chinese patients [682, 683].
Analgesia
Pain relief should start early and be intensified as neces-
sary during acute HZ to control pain and reduce the likeli-
hood of developing PHN, which is much harder to treat
[656, 684, 685]. Pain management steps-up from first-line
acetaminophen or non-steroidal anti-inflammatory drugs
to opioid narcotics for moderate-to-severe pain, to which
anticonvulsants, tricyclic antidepressants or corticosteroids
are added if pain remains uncontrolled [646]. The same
second- and third-line analgesics are used to treat PHN if
topical agents prove ineffective [643, 646].
Indian physicians have reported rapid and effective
pain relief with topical acetylsalicylic acid dissolved in
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chloroform [686]. Others confirmed the efficacy of the
anticonvulsants pregabalin and gabapentin for relieving
acute herpetic pain [687, 688], and found pregabalin su-
perior to amitriptyline for PHN [684]. Compared with
placebo, pregabalin relieved PHN and was also associ-
ated with decreased sleep interference and significant
improvements in health-related QoL [689]. Gabapentin
is another effective and well-tolerated treatment for
PHN [690] and combined with morphine in another
trial, reduced pain more than either agent alone [691].
Chinese investigators found oxycodone-acetaminophen
effective, safe and superior to other analgesics in HZ and
PHN [692–696]. Reports from Australia, Japan, New
Zealand and Taiwan have affirmed the efficacy of topical
[697–699] or injected lidocaine [700, 701]. Transdermal
fentanyl was found to be more effective than tramadol,
providing excellent pain relief in HZ and PHN and im-
proving QoL, both alone [702, 703] and combined with
clodine [704]. Other experimental therapies with good
reported outcomes in patients from Asia-Pacific coun-
tries include: topical interferon alpha [705, 706], adenine
arabinoside (vidarabine) [707, 708], povidone-iodine
[709], transdermal ribavirin [710], bromovinyl deoxyuridine
(brivudin) [711], intravenous prostaglandin E1 [355,
712–715], the anticoagulant argatroban [716]; the tricyclic
antidepressant milnacipran [717], human immunoglobulin
[718], injected methylcobalamin [719], and botulinum
toxin [720].
Nerve blockade is increasingly popular for treating in-
tractable PHN or preventing PHN by reducing severe
pain, particularly in East Asia [363, 721–742]; ambulatory
patient-controlled systems have been successful in Taiwan
[743, 744]. However, the true efficacy of nerve blocks is
difficult to quantify because many trials were uncontrolled
[9]. Furthermore, epidural injections require utmost
caution due to the potential for infection and/or life-
threatening complications [745–755]. An implanted injec-
tion port may lessen the risk of infection [756].
Neurosurgery may trigger HZ [269–271] and though
neuroablation has also been used, its efficacy is unproven
and it may exacerbate PHN [757]; neuromodulation
may provide an alternative but needs further investi-
gation [758, 759].
Alternative treatment modalities
Asia-Pacific authors have contributed substantial literature
on alternative HZ therapies (Additional file 1). Success has
been reported with herbal decoctions, acupuncture and
other traditional Chinese medicine techniques, energy-
based modalities, and combination therapies. Treatments
evaluated in intractable HZ and PHN, include Ganoderma
lucidum [760, 761], Keishikajutsubuto and Bushi-matsu
[762], bee venom [763], intravenous vitamin C [764],
computed tomography-guided radiofrequency thermo-
coagulation [765], spinal cord stimulation [758],
ultrasound-guided pulsed radiofrequency [766], and
scrambler therapy [767]. Although many studies found
these alternatives superior to conventional medicine, the
strength of this evidence is dubious – due to conceptual
differences between traditional Asian and Western medi-
cine, many such studies do not conform to conventional
evidence-based precepts [768–770].
Unmet treatment needs
Despite an armamentarium of potentially effective medi-
cations, current therapies have limitations and are not
used to best advantage in older patients, who bear the
brunt of HZ [646]. In particular, many patients start
therapy too late, the optimal combination of therapies
remains uncertain, antiviral agents are underprescribed
[22, 645, 771], and even with prompt intervention a sub-
stantial proportion remain refractory to treatment; up to
20% of patients with PHN still have persistent neuralgia
after 6 months (Table 5) [18–20, 23, 28, 359, 771].
Aciclovir-resistant ocular VZV infections have been en-
countered [675, 676, 772, 773].
Given the substantial and rising burden of HZ and for-
midable treatment challenges facing physicians in the
Asia-Pacific region, especially among elderly, immuno-
compromised or other high risk adults, such as those
with renal disease, prevention is both rational and ap-
pealing [20, 25, 94–96, 104, 136, 140, 144–147, 160,
644]. Accordingly, investigators have evaluated HZ
prophylaxis with antiviral drugs or vaccines.
Prevention approaches
Antiviral prophylaxis in high-risk patients
HZ is a very common complication following HSCT
[170, 774]. Long-term prophylaxis with low-dose
aciclovir [775–778] or valaciclovir [779] significantly
reduces the incidence of VZV reactivation and serious
complications, and is recommended for the duration
of immunotherapy and continuing through 1 year
after HSCT [776, 778]. Such prophylaxis also prevents
HZ in patients receiving bortezomib [780, 781]. Simi-
larly, no bone marrow transplant recipients developed
HZ during 3–6 months of low-dose aciclovir and gan-
ciclovir therapy; however, rapid onset of HZ after
antiviral therapy was discontinued highlighted the
need for ongoing prophylaxis [782]. Immunisation
against VZV may be necessary to preclude HZ in
high-risk patients [776]; therefore, Asian researchers
have evaluated the potential of HZ prophylaxis with
varicella vaccines.
VZV immunisation
A survey of Japanese paediatricians, who might have en-
hanced immunity through VZV re-exposures, confirmed
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lower incidence of HZ than the general population, sug-
gesting that varicella vaccine may likewise protect
against HZ [319]. Also in Japan, immunisation with live
varicella vaccine (Oka/BIKEN) enhanced CMI to VZV in
adults age ≥50 years [783, 784], and in subjects aged 60–
70 with or without diabetes [785]. A case of recurrent
HZO cured by varicella vaccination was also reported
[786]. In studies that evaluated live-attenuated VZV vac-
cine in HSCT [774, 787], Oka/RIT (Varilrix™ Glaxo-
SmithKline Biologicals, Rixensart, Belgium) was safe but
poorly immunogenic. A systematic review concluded
that although inactivated VZV vaccine may reduce HZ
severity in stem cell transplant recipients, more research
was required [788]. Thus, alternative approaches to pre-
venting HZ in such patients are probably needed [787].
During a 20-year endeavour to develop the first specific
HZ vaccine, researchers reformulated Oka/Merck varicella
vaccine (Varivax® Merck & Co. Inc., Whitehouse Station,
NJ, USA.) to produce a higher-titre live-attenuated
VZV vaccine – Zostavax® (Merck & Co. Inc.) [10,
789]. In the culminating Shingles Prevention Study
(SPS), Zostavax® immunisation reduced the incidence
of HZ among adults ≥60 years old by 51%, PHN by
67% and the HZ-related burden of illness by 61%, as
well as improving QoL and performance of daily ac-
tivities in subjects who developed HZ [95]. The US
Food and Drug Administration licenced Zostavax® in
2006 [644]; it was also approved by the European
Medicines Agency [96] and subsequently by author-
ities in Australia [644] New Zealand [652], Korea
[790, 791], Malaysia [792], and other Asian countries
[793–796]. The US Centers for Disease Control and Pre-
vention Advisory Committee on Immunization Practices
(ACIP), recommends routine vaccination for all non-
contraindicated persons age ≥60 years; importantly
though, Zostavax® is not indicated to treat extant HZ or
PHN [10]. An independent review of SPS concluded that
there is insufficient proof that Zostavax® prevents PHN
beyond reducing the incidence of HZ. Further, since SPS
patients were predominantly Caucasian, its findings might
not apply to other races [797].
Zostavax® in Asia-Pacific Production shortfalls of
Zostavax® after initial licensure restricted its supply
[1, 2]. Though since resolved, this issue affected vaccine
availability and uptake in Asia-Pacific countries [2]. For ex-
ample, 2011 vaccination rates among Australian inpatients
in 2011 were 34% for HZ, compared with 52% for
pneumococcal vaccine and 64% for influenza [798]. This
explains the scarcity of Asian data on Zostavax®. One pilot
study of 21 healthy adults ≥30 years old, including eight
Filipinos, found Zostavax® to be immunogenic and gener-
ally well-tolerated [799].
Cost-effectiveness The substantial economic burden of
HZ includes direct healthcare costs as well as indirect
costs of disability and lost productivity [10, 30, 140]. US
and European researchers have modelled the pharmaco-
economics of HZ vaccination. US estimates of cost per
quality-adjusted life-years gained (QALY), varied widely
depending on the assumptions used. Routine immunisa-
tion at age 70 or 60 cost US$ 37000 and US$ 86000 re-
spectively, within the range of standard thresholds,
whereas the estimated cost of US$ 287000 at age 50 was
deemed too high [800]. Analyses in European countries
predicted that vaccinating adults above the ages of
50, 60, 65 or aged 70–79 would be cost-effective, with
high likelihood of not exceeding accepted thresholds
of £ 30000 in the United Kingdom or € 30000 in
Belgium [801]. A systematic review of 11 US and
European studies concluded that vaccination at age
65–70 would probably be cost-effective in terms of
QALYs gained, assuming it confers more than 10–15
years’ protection against PHN [802]; however, cost-
effectiveness data from high-income countries may not
apply worldwide, because healthcare provision and costs
differ considerably between nations [801, 802]. Although
high and rising healthcare costs of treating HZ docu-
mented in several Asia-Pacific countries [30, 104, 136,
137, 140] suggest that it would probably be no less cost-
effective to immunise elders from this region than others,
specific pharmacoeconomic data are lacking [790, 802];
such analyses are needed urgently to resolve current un-
certainties and inform evidence-based decision-making by
healthcare funders and providers.
HZ immunisation guidelines and recommendations
Given the potential for HZ immunisation to efficaciously
and safely reduce the associated burden of illness [10],
as well as cost-effectiveness considerations, organisations
in several Asia-Pacific countries have incorporated HZ
vaccination into adult immunisation schedules (Table 7)
[2, 5, 8, 642, 791–796]. Neither Japan nor Singapore has
such guidelines and The Association of Physicians of
India does not recommend HZ immunisation, due to
lack of national epidemiology data [803].
Most HZ immunisation guidelines are published by
professional societies, with only Australia and New
Zealand having government-issued guidelines [8, 642].
Since Asian epidemiological and clinical data are sparse,
local guidelines generally follow the ACIP [10], with very
similar recommendations for indicated and non-licenced
uses, administration, and precautions or contraindications
(Table 8). Like ACIP, most Asia-Pacific guidelines
recommend routine immunisation from age 60; however,
some age thresholds vary. The New Zealand Ministry of
Health and Indonesia Specialist Doctors Association both
recommend immunisation from age 50 [642, 793], though
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this is not state funded. The Korean Society of Infectious
Diseases recommends routine vaccination above age 65
[791], with vaccination from age 50 at patients’ own dis-
cretion. Similarly, The Australian Department of Health
[8] and the Malaysian Society of Geriatric Medicine [792]
do not recommend routine vaccination for persons aged
50–59, but sanction this as a personal option, with the ca-
veats that the duration of protection remains undeter-
mined. However, the Malaysian Society of Geriatric
Medicine does not recommend vaccinating patients older
than 80, due to lack of efficacy, and the Australian guide-
lines likewise note that vaccination may confer less clinical
benefit in this age group [8]. The New Zealand guidelines
[642] uniquely specify active untreated tuberculosis as a
contraindication and the Australian guidelines are alone
in indicating vaccination of persons from age 50 who are
household contacts of immunocompromised individuals
[8]. Based on evidence that co-administering Zostavax®
with pneumococcal polysaccharide vaccine may reduce its
immunogenicity compared with administration 4 weeks
apart [804], the Australian and New Zealand Society for
Geriatric Medicine recommended against giving these
vaccines concomitantly [5]; however, a later study sug-
gested that this may not compromise Zostavax® effective-
ness [8, 805], and the Australian 2015 guidelines
recommend that Zostavax® can be given at the same time
as pneumococcal polysaccharide vaccine, using separate
syringes and injection sites [8].
Discussion
Ours is the most comprehensive audit yet of HZ in the
Asia-Pacific region. We have reviewed almost every
available paper published on the subject over 21
years since 1994 in 14 countries whose populations
constitute the majority of not only Asians, but in-
deed the global population. The information collated
provides a valuable resource and reference by which
to gauge future progress.
Knowledge and data gaps
Contrary to a preconception that there may be a dearth
of Asian data, we discovered a wealth of evidence on all
aspects of HZ. However, our review does affirm that
Asian data are patchy; in particular, there is very little
information from South-East Asian populations number-
ing hundreds of millions, which probably reflects prag-
matic healthcare imperatives in resource-limited settings
[3]. Limiting the scope of the survey to 21 years may
have missed epidemiology data published prior to 1994.
The review may have excluded some relevant articles
which did not specify that VZV infection was reacti-
vated. It is also possible that some articles with no
country affiliation field in the databases searched may
have been overlooked; however, searching several da-
tabases reduced this possibility. Epidemiology data from
Indonesia, Malaysia, the Philippines, and Vietnam are
needed to provide a more balanced picture. There are
Table 7 Asia-Pacific guidelines for immunisation against herpes zoster
Country Title Issuing organisation Year
(last update)
Age thresholds
Name Status Routine Optional





Immunisation of Older People Australia & New Zealand Society
for Geriatric Medicine
Society 2011 ≥60
India [803] Medicine Update. Adult Immunization Association of Physicians of India Society 2013 No
recommendationa
Indonesia [793] Adult Immunization Schedule Specialist Doctors Association of
Indonesia
Society 2014 ≥50
Malaysia [792] Position Statement on Vaccination Against
the Herpes Zoster Virus in Older Adults
Malaysian Society of Geriatric
Medicine
Society 2014 60–79 50–59
New Zealand [642] Immunisation Handbook New Zealand Ministry of Health Government 2016 >50
Philippines [794] Handbook on Adult Immunization for
Filipinos
Philippine Society for Microbiology
and Infectious Diseases
Society 2012 ≥60
South Korea [791] Recommended Immunization Schedule
for Adults in Korea
Korean Society of Infectious
Diseases
Society 2012 >65 50–59
Taiwan [796] Clinical Handbook for Adult Immunization Taiwan Association of Family
Medicine
Society 2010 ≥60
Thailand [795] Recommended Adult and Elderly
Immunization Schedule
Thailand Royal College of
Physicians
Society 2014 ≥60
aThe Association of Physicians of India does not recommend herpes zoster vaccine for adults, due to lack of reliable data on the epidemiology and burden of
herpes zoster in India
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also limited Asian data on the safety and efficacy of the
HZ vaccine and, in particular, its cost-effectiveness
[137, 140, 790, 802].
Conclusions
Data gaps notwithstanding, there is compelling evidence
to conclude that the epidemiology and risk factors for
HZ in the Asia-Pacific region are not remarkably differ-
ent from those in Western populations [7]. However,
with a vastly larger absolute aged population, Asia bears
a unique burden of HZ. The estimated number of
Asians1 age >60 in 2015 is 489,397,421, which by 2035 will
nearly double to 924,520,454 [806]. Assuming an annual
incidence of HZ in unvaccinated individuals of approxi-
mately 12/1000 person-years [136, 137], this equates to
approximately 16089 new HZ cases daily in 2015 and
30395 in 2035, more than half of which might be pre-
vented by HZ immunisation. Data affirming rising inci-
dence of HZ in countries across Asia-Pacific bear out
these projections. Consequently, HZ in the Asia-Pacific
region exacts huge and increasing tolls of morbidity, debil-
ity and diminished life quality that incur significant health-
care expenditure and indirect socioeconomic costs [20,
25, 30, 96, 104, 136, 137, 140].
This review also highlights that HZ is uniquely com-
plex among infectious diseases, often complicated and
defies disciplinary boundaries. Despite a plethora of
conventional and alternative treatments, none is singu-
larly effective [25]; current approaches can go only so
far to alleviating the disease burden, especially among
the elderly who constitute most patients, and then at
considerable expense [95]. Thus, the rationale for pre-
vention is very strong [20, 102, 145]. Yet although a
specific HZ vaccine is available and recommended by
immunisation guidelines in many countries, it remains
underused. This typifies how preventive healthcare for
the elderly continues to be neglected in Asia, despite
repeated calls to make this a higher public health
priority [3, 4, 6]. It is more urgent now than ever to
address this situation.
Call to action
We look forward to being able to report in future that
advances in preventive healthcare have alleviated the
growing burden of HZ in the Asia-Pacific region. This
audit is just a beginning – realising this ambition will be
impossible without redoubled efforts by the medical fra-
ternity, healthcare authorities and all other stakeholders
to change prevailing mindsets and afford higher priority
to adult immunisation in general and HZ in particular.
We urge all concerned to heed this call to action.
Endnotes
1Afghanistan, Bangladesh, Bhutan, Brunei, Burma,
Cambodia, China, Hong Kong, India, Indonesia, Iran,
Japan, Laos, Macau, Malaysia, Maldives, Mongolia,
Nepal, North Korea, Pakistan, Philippines, Singapore,
South Korea, Sri Lanka, Taiwan, Thailand, Timor-Leste,
Vietnam.
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Table 8 Concordance between herpes zoster immunisation
recommendations from US ACIP and Asia-Pacific countries
Indications and
administration
• Routine immunisation with one dose of
HZ vaccine for all persons age ≥60:
– With or without prior HZ
– With chronic medical conditions (eg, chronic
kidney disease, diabetes, rheumatoid arthritis,
lung disease), except those listed as
contraindications or precautions
• HZ vaccine can be co-administered with other




• Persons immunised with varicella zoster vaccine
• Persons younger than the minimum
recommended or optional age threshold
• HZ vaccine is not to be used to treat existing
HZ or its complications
Precautions • Moderate/severe acute illness
• Anticipated immunosuppression
• Anti-herpetic pharmacotherapy
Contraindications • Hypersensitivity to vaccine components




– Systemic immunosuppressive therapy
(including high-dose steroids and recombinant
immune modulators
• Pregnancy
HZ Herpes zoster, US ACIP United States Centers for Disease Control and
Prevention Advisory Committee on Immunization Practices, HIV/AIDS human
immunodeficiency virus/acquired immunodeficiency syndrome
Chen et al. BMC Infectious Diseases  (2017) 17:213 Page 22 of 39
Availability of data and materials
All supporting data are either contained within the manuscript or were
excerpted from the sources cited, and can be shared upon request.
Authors’ contributions
LKC conceived and coordinated the study, acquired and interpreted data,
and revised manuscript drafts for important intellectual content. HA, LYC, SD,
BD, TK, XL, DM, JYP, PJHP, SR, TT, and CWW, refined the review protocol,
provided and/or reviewed or interpreted data, and revised manuscript drafts
for important intellectual content. MYC, KTK, HNL, EMFL, CKL, LNP, and ERSP,
contributed to refining the review protocol, and reviewed data and
manuscript drafts. All authors read and approved the final manuscript.
Competing interests
The authors are members of The Asia-Pacific Working Group for Herpes
Zoster, which is supported financially by Merck Sharp & Dohme (I.A.) Corp.
(MSD), Taiwan, and received honoraria for consultancy services in this
capacity. The authors declare no other competing interests besides membership
of this MSD Advisory Board.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Author details
1Center for Geriatrics and Gerontology, Taipei Veterans General Hospital, No.
201, Sec. 2, Shih-Pai Rd., Taipei 11217, Taiwan. 2Aging and Health Research
Center, National Yang Ming University, Taipei, Taiwan. 3National Center for
Geriatrics and Gerontology, 7-340 Morioka-cho, Obu, Aichi 474-8511, Japan.
4Center for Geriatrics and Gerontology, Kaohsiung Veterans General Hospital,
No. 386 Ta-Chun 1st Rd., Kaohsiung 81362, Taiwan. 5Department of Internal
Medicine, Faculty of Medicine, University of Indonesia, Salemba Raya No. 6,
Jakarta 10430, Indonesia. 6The Center of Gerontology and Geriatrics, West
China Medical School/West China Hospital, Sichuan University, No. 37 Guo
Xue Xiang, Renmin Nan Lu, Chengdu, Sichuan 610041, China. 7Department
of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo,
7-3-1, Jongo, Bunkyo-ku, Tokyo 113-8655, Japan. 8Division of Infectious
Diseases, Daegu Fatima Hospital, 99 Ayang-ro, Dong-gu, Daegu 710-600,
Korea. 9Rophi Clinic, 38 Irrawaddy Rd. #07-54/55, Mount Elizabeth Novena
Specialist Centre, Singapore 329563, Singapore. 10Geriatric Medicine Centre
(Healthy Ageing), Hong Kong Sanatorium and Hospital, 2 Village Rd. Happy
Valley, Hong Kong S.A.R., China. 11Division of Neurology, Department of
Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
12Division of Geriatrics, Department of Internal Medicine, Peking Union
Medical College Hospital, Beijing 100730, China. 13Apollo Institute of Medical
Sciences and Research, Apollo Health City Campus, Jubilee Hills, Hyderabad
500096, India. 14National Skin Centre, 1 Mandalay Rd., Singapore 308205,
Singapore. 15Geriatric Center, St. Luke’s Medical Center, 279 E. Rodriguez Sr.
Ave., Quezon City 1102, Philippines. 16Division of Geriatrics, Department of
Medicine, University Malaya Medical Centre, Lembah Pantai, 59100 Kuala
Lumpur, Malaysia. 17Ropata Medical Centre, Lower Hutt 5010, New Zealand.
18Division of Infectious Diseases, Department of Medicine, Chulalongkorn
University, Bangkok 10330, Thailand. 19Department of Family Medicine,
College of Medicine, Kyung Hee University, 1 Hoigi-dong, Dongdaemun-gu,
Seoul 130-720, Korea.
Received: 5 March 2016 Accepted: 9 January 2017
References
1. Harpaz R, Hales CM, Bialek S. Update on herpes zoster vaccine: licensure for
persons aged 50 through 59 years. MMWR Morb Mortal Wkly Rep. 2011;60:1528.
2. Heywood AE, Wang H, Macartney KK, McIntyre P. Varicella and herpes zoster
hospitalizations before and after implementation of one-dose varicella
vaccination in Australia: an ecological study. Bull World Health Organ. 2014;
92:593–604.
3. Isahak I. Steering Committee for Prevention and Control of Infectious
Diseases in Asia. Adult immunization—a neglected issue in Southeast Asia.
Southeast Asian J Trop Med Public Health. 2000;31:173–84.
4. Verma R, Khanna P, Chawla S. Vaccines for the elderly need to be
introduced into the immunization program in India. Hum Vaccin
Immunother. 2014;10:2468–70.
5. Woodward M. Immunisation of older people. J Pharm Pract Res. 2012;42:316–22.
6. Wong SY. Adult vaccination update 2014. The Singapore Fam Physician.
2014;40:27–32.
7. Araújo LQ, MacIntyre CR, Vujacich C. Epidemiology and burden of herpes
zoster and post-herpetic neuralgia in Australia, Asia and South America.
Herpes. 2007;14(Suppl 2):40–4.
8. Australian Technical Advisory Group on Immunisation. The Australian
Immunisation Handbook. 10th ed (updated June 2015). Canberra: Australian
Government Department of Health. 2015. http://www.health.gov.au/internet/
immunise/publishing.nsf/content/7B28E87511E08905CA257D4D001DB1F8/
$File/Aus-Imm-Handbook.pdf. Accessed 17 Jan 2017.
9. Thomas J. Herpes zoster: Complications and management. J Pak Assoc
Dermatol. 2004;14:237–43.
10. Harpaz R, Ortega-Saznchez IR, Seward JF. Centers for Disease Control and
Prevention (CDC). Prevention of herpes zoster: recommendations of the
Advisory Committee on Immunization Practices (ACIP). MMWR Recomm
Rep. 2008;57(RR-5):1–30.
11. Kim YM, Lee SY, Lee JS, Park YL, Whang KU, Cho MK, et al. Epidemiological
and clinical study on herpes zoster in the Province of Chungcheongnam-do
(2004–2006). Korean J Dermatol. 2008;46:1488–94.
12. Abdul Latheef EN, Pavithran K. Herpes zoster: a clinical study in 205 patients.
Indian J Dermatol. 2011;56:529–32.
13. Shukuwa T, Chen WY, Kobayashi A. Statistical analysis of herpes zoster
observed at Sasebo City General Hospital. Nishinihon J Dermatol. 2002;
64:477–82.
14. Naveen KN, Tophakane RS, Hanumanthayya K, Pv B, Pai VV. A study of HIV
seropositivity with various clinical manifestation of herpes zoster among
patients from Karnataka, India. Dermatol Online J. 2011;17:3.
15. Jara MFA, Roa FC. The clinical presentation of herpes zoster patients and
predictors of postherpetic neuralgia: A 5-year retrospective study at the
section of dermatology, University of the Philippines - Philippine General
Hospital. J Phil Dermatol Soc. 2010;19:8–12.
16. Leung AYH, Yuen KY, Cheng VCC, Lie AKW, Liang R, Kwong YL. Clinical
characteristics of and risk factors for herpes zoster after hematopoietic stem
cell transplantation. Haematologica. 2002;87:444–6.
17. Reid JS, Ah WB. Herpes zoster (shingles) at a large New Zealand general
practice: incidence over 5 years. N Z Med J. 2014;127:56–60.
18. Goh CL, Khoo L. A retrospective study of the clinical presentation and
outcome of herpes zoster in a tertiary dermatology outpatient referral clinic.
Int J Dermatol. 1997;36:667–72.
19. Song JY, Chung BS, Choi KC, Shin BS. A 5-year period clinical observation on
herpes zoster and the incidence of postherpetic neuralgia (2002–2006); a
comparative analysis with the historical control group of a previous study
(1995–1999). Korean J Dermatol. 2008;46:431–6.
20. Tsai TF, Yao CA, Yu HS, Lan CC, Chao SC, Yang JH, et al. Herpes zoster-
associated severity and duration of pain, health-related quality of life, and
healthcare utilization in Taiwan: a prospective observational study. Int J
Dermatol. 2015;54:529–36.
21. Song T. Statistical analysis of 522 cases of patient with herpes-zoster. Med J
Wuhan Univ. 2002;23:379–82.
22. Wallis KA, Hood LJ, Rao K. Herpes zoster: when do patients present and
who gets antiviral treatment? J Prim Health Care. 2014;6:108–13.
23. Kurokawa I, Kumano K, Murakawa K. Clinical correlates of prolonged pain in
Japanese patients with acute herpes zoster. J Int Med Res. 2002;30:56–65.
24. Kang CI, Choi CM, Hong SS, Kim HB, Kim NJ, Oh MD, et al. The incidence of
herpes zoster in otherwise healthy young soldiers of Korean army. Infect
Chemother. 2006;38:45–6.
25. Song H, Lee J, Lee M, Choi WS, Choi JH, Lee MS, et al. Burden of illness, quality of
life, and healthcare utilization among patients with herpes zoster in South Korea:
a prospective clinical-epidemiological study. Int J Infect Dis. 2014;20:23–30.
26. Park SY, Kim JY, Kim CD, Kim CW, Lee KS. A clinical study on herpes
zoster during the last 10-year-period (1994–2003). Korean J Dermatol.
2004;42:1531–5.
27. Das AL, Sayal SK, Gupta CM, Chatterjee M. Herpes zoster in patients with
HIV infection. Indian J Dermatol Venereol Leprol. 1997;63:101–4.
28. Kurokawa I, Murakawa K, Kumano K. The change in zoster-associated pain
treated with oral valaciclovir in immunocompetent patients with acute
herpes zoster. Int J Clin Pract. 2007;61:1223–9.
Chen et al. BMC Infectious Diseases  (2017) 17:213 Page 23 of 39
29. Sawhney MPS, Sharma YK, Sayal SK. Mode of detection of HIV infection - A
retrospective study of 612 cases. Med J Armed Forces India. 2005;61:220–3.
30. Aunhachoke K, Bussaratid V, Chirachanakul P, Chua-Intra B, Dhitavat J,
Jaisathaporn K, et al. Measuring herpes zoster, zoster-associated pain, post-
herpetic neuralgia-associated loss of quality of life, and healthcare utilization
and costs in Thailand. Int J Dermatol. 2011;50:428–35.
31. Achar A, Chakraborty PP, Ghosh T, Naskar B, Guharay T, Bisai S. Clinical
efficacy and tolerability of valacyclovir versus acyclovir in treatment of
herpes zoster. Iran J Dermatol. 2011;14:52–7.
32. Kim CG, Na CH, Choi KC, Shin BS. A comparative study of the clinical
findings associated with herpes zoster and according to age. Korean J
Dermatol. 2009;47:1338–44.
33. Kim HJ, Sung HC, Kim DW, Lee WJ, Lee SJ, Na GY. Clinical features of herpes
zoster according to immune state. Korean J Dermatol. 2006;44:149–56.
34. Cockburn DM, Douglas IS. Herpes zoster opthalmicus. Clin Exp Optom.
2000;83:59–64.
35. Naveen KN, Pradeep AV, Kumar JS, Hegde SP, Pai VV, Athanikar SB. Herpes
zoster affecting all three divisions of trigeminal nerve in an immunocompetent
male: a rare presentation. Indian J Dermatol. 2014;59:423.
36. Sangeeta N, Robindro Singh W, Brajach SO. Herpes zoster in a healthy
adult: Report of a case with oro-cutaneous presentations. JMS J Med
Soc. 2011;25:99–101.
37. Watanabe K, Funaki M. Images in clinical medicine: Zoster of the tympanic
membrane. N Engl J Med. 2011;365:e40.
38. Hong SB, Lee JW, Chang SG, Lee MH, Haw CR. Herpes zoster of the penis.
Korean J Urol. 2005;46:1001–3.
39. Gopalan V, Nair RG, Pillai S, Oberholzer T. Genital herpes zoster as a consequence
of cancer chemotherapy-induced immunosuppression: report of a case. J Infect
Chemother. 2012;18:955–7.
40. Watanabe D, Kuhara T, Ishida N, Takama H, Tamada Y, Matsumoto Y. Herpes
zoster of the nipple: rapid DNA-based diagnosis by the loop-mediated
isothermal amplification method. Int J STD AIDS. 2010;21:66–7.
41. Izu K, Yamamoto O, Yasumoto S, Hashimoto T, Sata T, Tokura Y. Herpes zoster
occurring as a solitary nodule on the index finger. Br J Dermatol. 2004;150:365–6.
42. Chen WH, Li TH, Lee LH, Huang CC. Varicella-zoster virus infection and
nummular headache: a possible association with epicranial neuralgia. Intern
Med. 2012;51:2439–41.
43. Hon C, Au WY, Cheng VC. Ophthalmic zoster sine herpete presenting as
oculomotor palsy after marrow transplantation for acute myeloid leukemia.
Haematologica. 2005;90 Suppl 12:EIM04.
44. Kim YH, Choi IJ, Kim HM, Ban JH, Cho CH, Ahn JH. Bilateral simultaneous facial
nerve palsy: clinical analysis in seven cases. Otol Neurotol. 2008;29:397–400.
45. Furuta Y, Fukuda S, Suzuki S, Takasu T, Inuyama Y, Nagashima K. Detection
of varicella-zoster virus DNA in patients with acute peripheral facial palsy by
the polymerase chain reaction, and its use for early diagnosis of zoster sine
herpete. J Med Virol. 1997;52:316–9.
46. Fujiwara K, Furuta Y, Fukuda S. A case of associated laryngeal paralysis caused
by varicella zoster virus without eruption. Case Rep Med. 2014;2014:916265.
47. Powell KF, Wilson HG, Croxson MC, Marshall MR, Wong EH, Anderson NE, et
al. Herpes zoster meningoencephalitis without rash: Varicella zoster virus
DNA in CSF. J Neurol Neurosurg Psychiatry. 1995;59:198–9.
48. Chen MJ, Chen KH, Chung YM, Li AF, Chou CK, Hsu WM. Detection of
varicella-zoster virus DNA in the iris of a zoster sine herpete patient. Int J
Biomed Sci. 2006;2:302–4.
49. Lo CH, Chiang CP. Herpes zoster duplex bilateralis. Intern Med. 2013;52:2841.
50. Shin JW, Kim DH, Whang KU, Lee J, Park Y, Cho MK, et al. A case of zoster
duplex bilateralis. Ann Dermatol. 2009;21:423–5.
51. Mabuchi T, Yamaoka H, Kato M, Ikoma N, Tamiya S, Song HJ, et al. Case of
disseminated vesicles of herpes zoster developing one day before the onset
of local eruption in a hospitalized immunocompromised patient. Tokai J
Exp Clin Med. 2013;38:52–4.
52. Kim H, Kang JN, Seol JE, Seo JK, Sung HS. Epidemiology and clinical features
of disseminated herpes zoster. Korean J Dermatol. 2013;51:507–12.
53. Qi X-L, Li C-X, Gao T-W. Herpes zoster generalisatus caused by long-term
treatment of cyclosporin: A case report. J Clin Dermatol. 2006;35:313–14.
54. Park S-H, Lee SY, Yi JH, Choi HS, Yun SK, Kim HU, Ihm CW. A case of herpes
zoster duplex unilateralis with herpes zoster generalisatus. Korean J
Dermatol. 2005;43:1579–81.
55. Takaoka Y, Miyachi Y, Yoshikawa Y, Tanioka M, Fujisawa A, Endo Y. Bilateral
disseminated herpes zoster in an immunocompetent host. Dermatol Online
J. 2013;19:13.
56. Gupta LK, Kuldeep CM, Mittal A, Singhal H. Multidermatomal herpes zoster in an
immunocompetent female. Indian J Dermatol Venereol Leprol. 2005;71:210–11.
57. Sun ZH, Guo YY, Li M, Yao ZR. Disseminated herpes zoster in
immunocompetent patients not due to varicella-zoster virus gene mutation.
Chin Med J. 2013;126:3193.
58. Mittal RR. Disseminated herpes zoster. Indian J Dermatol Venereol Leprol.
1995;61:148–9.
59. Gahalaut P, Chauhan S. Herpes zoster duplex bilateralis in an
immunocompetent host. Indian Dermatol Online J. 2012;3:31–3.
60. Lee H, Jung HJ, Park MY, Ann JY. Herpes zoster duplex symmetricus in a
healthy patient. Korean J Dermatol. 2011;49:1098–101.
61. Tsai YC, Tsai TF. Herpes zoster duplex bilateralis symmetricus. Dermatol Sin.
2015;33:37–8.
62. Yoon KJ, Kim SH, Lee EH, Choi JH. Disseminated herpes zoster in an
immunocompetent elderly patient. Korean J Pain. 2013;26:195–8.
63. Brar BK, Gupta RR, Saghni SS. Bilateral herpes - zoster of widely separated
dermatomes in a non-immunocompromised female. Indian J Dermatol
Venereol Leprol. 2002;68:48–9.
64. Agrawal S, Aara N, Bumb R. Herpes zoster duplex bilateralis symmetricus in
an immunocompetent subject. Int J Dermatol. 2014;53:e281–2.
65. Oh KH, Ahn C, Kim YS, Han JS, Kim S, Lee JS, et al. Atypical generalized
zoster with suspicious esophageal involvement and early relapse in an adult
renal transplant recepient. Transplant Proc. 2002;34:1174–7.
66. Tan HH, Goh CL. Viral infections affecting the skin in organ transplant
recipients: epidemiology and current management strategies. Am J Clin
Dermatol. 2006;7:13–29.
67. Kui YP, Hye IL, Ji YK, Kap SL, Seong JS, Chang KH. A case of herpes
zoster multiplex in five disparate dermatomes. Korean J Dermatol. 2008;
46:973–6.
68. Yoo KH, Park JH, Kim BJ, Kim MN, Song KY. Herpes zoster duplex bilateralis
in a patient with breast cancer. Cancer Res Treat. 2009;41:50–2.
69. Ko DH, Park SY, Yoon TJ. A case of bilateral recurrent herpes zoster in
multiple myeloma. Korean J Dermatol. 2006;44:1460–3.
70. Teranishi H, Sakiyama M, Nagatoshi Y, Nomura Y, Inagaki J, Yanai F, et al.
Acute lymphoblastic leukemia complicated with varicella zoster virus
meningoencephalitis and visceral dissemination after related bone marrow
transplantation. Rinsho Ketsueki. 2011;52:287–92.
71. Endoh K, Kawai N, Itoh K, Tominaga K, Kusumoto S, Fukuda M, et al. An
autopsy case of non-Hodgkin's lymphoma complicated by fulminant
infiltration by disseminated herpes zoster. Jpn J Chemother. 2000;48:75–8.
72. Ryu DJ, Jung JY, Lee S, Lee JH. A case of herpes zoster duplex bilateralis, a
diagnostic clue of human immunodeficiency virus infection. Korean J
Dermatol. 2010;48:339–41.
73. Rajashekar TS, Singh G, Shivakumar V, Okade R. Recurrent herpes zoster
duplex symmetricus in HIV infection. Indian J Dermatol. 2008;53:33–4.
74. Sundriyal D, Kapoor R, Kumar N, Walia M. Multidermatomal herpes zoster.
BMJ Case Rep. 2014. doi:10.1136/bcr-2014-205024.
75. Zhang B, Zhao HX, Lun WH, Sun N, Yang D, Liang HY, et al. Generalized
varicella-zoster virus infection: A case report. J Clin Dermatol. 2013;42:595–7.
76. Chacko S, John TJ, Babu PG, Jacob M, Kaur A, Mathai D. Clinical profile of
AIDS in India: a review of 61 cases. J Assoc Physicians India. 1995;43:535–8.
77. Higashitake I, Higaki T, Souda N, Yamada H. Recurrent herpes zoster seen in
the patient of human immunodeficiency virus infection. Skin Res. 2004;3:216–9.
78. Kar HK, Gautam RK, Jain RK, Puri P, Doda V. Disseminated cutaneous herpes
zoster: A clinical predictor of human immunodeficiency virus infection.
Indian J Dermatol Venereol Leprol. 1995;61:40–1.
79. Shin BS, Na CH, Song IG, Choi KC. A case of human immunodeficiency virus
infection initially presented with disseminated herpes zoster. Ann Dermatol.
2010;22:199–202.
80. Kim WJ, Park JW, Shin DH, Choi JS, Kim KH. A case of human
immunodeficiency virus infection in recurrent herpes zoster. Korean J
Dermatol. 2005;43:271–3.
81. Kim MS, Choi H, Na CH, Shin BS. A 5-year period clinical study of 16 cases with
disseminated herpes zoster (2008–2012). Korean J Dermatol. 2013;51:322–8.
82. Doki N, Miyawaki S, Tanaka M, Kudo D, Wake A, Oshima K, et al. Visceral
varicella zoster virus infection after allogeneic stem cell transplantation.
Transpl Infect Dis. 2013;15:314–8.
83. Saitoh H, Takahashi N, Nanjo H, Kawabata Y, Hirokawa M, Sawada K.
Varicella-zoster virus-associated fulminant hepatitis following allogeneic
hematopoietic stem cell transplantation for multiple myeloma. Intern Med.
2013;52:1727–30.
Chen et al. BMC Infectious Diseases  (2017) 17:213 Page 24 of 39
84. Ni XS, Ouyang J, Zhu WH, Wang C, Chen B. Autologous hematopoietic
stem cell transplantation for progressive multiple sclerosis: report of
efficacy and safety at three yr of follow up in 21 patients. Clin
Transplant. 2006;20:485–9.
85. Ohara F, Kobayashi Y, Akabane D, Maruyama D, Tanimoto K, Kim SW, et al.
Abdominal pain and syndrome of inappropriate antidiuretic hormone
secretion as a manifestation of visceral varicella zoster virus infection in a
patient with non-Hodgkin's lymphoma. Am J Hematol. 2007;82:416.
86. Yakushijin Y, Minamoto Y, Takada K, Otsuka M, Yasukawa M, Fujita S. A case
of fatal varicella zoster infection with refractory abdominal pain as an early
symptom. Kansenshogaku Zasshi. 2004;78:64–9.
87. Au WY, Ma SY, Cheng VC, Ooi CG, Lie AK. Disseminated zoster, hyponatraemia,
severe abdominal pain and leukaemia relapse: recognition of a new clinical
quartet after bone marrow transplantation. Br J Dermatol. 2003;149:862–5.
88. Kurtovic J, Webster GJM, Singh-Grewal I, Bullpitt P, Haindl W, Wakefield D, et
al. Acalculous cholecystitis, multifocal gastrointestinal infarction and
pancreatitis resulting from Varicella-zoster virus. Intern Med J. 2005;35:69–70.
89. Wang Z, Ye J, Han YH. Acute pancreatitis associated with herpes zoster:
Case report and literature review. World J Gastroenterol. 2014;20:18053–6.
90. Okimura H, Muto M, Ichimiya M, Mogami S, Takahata H, Asagami C. A case
of herpes zoster associated with colitis. J Dermatol. 1996;23:631–4.
91. Ching DW. Severe, disseminated, life threatening herpes zoster infection in
a patient with rheumatoid arthritis treated with methotrexate. Ann Rheum
Dis. 1995;54:155.
92. Hashizume H, Umayahara T. Acute respiratory distress syndrome due to
varicella zoster virus pneumonitis in an immunocompromised patient with
herpes zoster. J Dermatol. 2013;40:1064–5.
93. Nakamura M, Kanazawa M, Yamaguchi K, Akizuki M, Satoh S, Inada S.
Pneumonia caused by varicella-zoster virus in a patient with rheumatoid
arthritis. Nihon Kyobu Shikkan Gakkai Zasshi. 1996;34:610–5.
94. Miyazaki T, Tanabe Y, Iseki M. Treatment and recent topics of postherpetic
neuralgia. Japan Med Assoc J. 2005;48:505–10.
95. Sanford M, Keating GM. Zoster vaccine (Zostavax): a review of its use in
preventing herpes zoster and postherpetic neuralgia in older adults. Drugs
Aging. 2010;27:159–76.
96. Cheong C, Lee TJ. Prevalence and healthcare utilization of herpes zoster
and postherpetic neuralgia in South Korea: disparity among patients with
different immune statuses. Epidemiol Health. 2014;36:e2014012.
97. Higa K, Mori M, Hirata K, Hori K, Manabe H, Dan K. Severity of skin lesions of
herpes zoster at the worst phase rather than age and involved region most
influences the duration of acute herpetic pain. Pain. 1997;69:245–53.
98. Sagong C, Yeo KY, Kim JS, Yu HJ, Kim DH. The relationship among pain,
depression, and anxiety in patients with herpes zoster. Korean J Dermatol.
2009;47:403–10.
99. Decroix J, Partsch H, Gonzalez R, Mobacken H, Goh CL, Walsh JB, et al.
Factors influencing pain outcome in herpes zoster: An observational study
with valaciclovir. J Eur Acad Dermatol Venereol. 2000;14:23–33.
100. Noh TW, Park HJ, Kim SH, Kang YS, Lee UH, Park HS. A clinical study of
herpes zoster focused on the characteristics of pruritus in herpes zoster.
Korean J Dermatol. 2012;50:591–8.
101. Chant KG, Sullivan EA, Burgess MA, Ferson MJ, Forrest JM, Baird LM, et
al. Varicella-zoster virus infection in Australia. Aust N Z J Public Health.
1998;22:413–8.
102. MacIntyre CR, Chu CP, Burgess MA. Use of hospitalization and
pharmaceutical prescribing data to compare the prevaccination burden of
varicella and herpes zoster in Australia. Epidemiol Infect. 2003;131:675–82.
103. Lee BW. Review of varicella zoster seroepidemiology in India and Southeast
Asia. Trop Med Int Health. 1998;3:886–90.
104. Stein AN, Britt H, Harrison C, Conway EL, Cunningham A, Macintyre CR.
Herpes zoster burden of illness and health care resource utilisation in the
Australian population aged 50 years and older. Vaccine. 2009;27:520–9.
105. Dashraath P, Ong ES, Lee VJ. Seroepidemiology of varicella and the
reliability of a self-reported history of varicella infection in Singapore military
recruits. Ann Acad Med Singapore. 2007;36:636–41.
106. Chow VTK. Rapid detection of varicella-zoster viral antibodies by latex
agglutination assay: A practical experience for medical and science
undergraduates. Biochem Educ. 1998;26:248–51.
107. Fatha N, Ang LW, Goh KT. Changing seroprevalence of varicella zoster virus
infection in a tropical city state, Singapore. Int J Infect Dis. 2014;22:73–7.
108. Juffrie M, Graham RR, Tan RI, Widjaja S, Mulyadi S, Weil J, et al.
Seroprevalence of hepatitis A virus and varicella zoster antibodies in a
Javanese community (Yogyakarta, Indonesia). Southeast Asian J Trop Med
Public Health. 2000;31:21–4.
109. Sam IC, Tariman H, Chan YF, Bador MK, Yusof MY, Hassan H. Varicella-zoster
virus seroprevalence in healthcare workers in Kuala Lumpur, Malaysia. Med J
Malaysia. 2008;63:429–30.
110. Barzaga NG, Roxas JR, Florese RH. Varicella zoster virus prevalence in Metro
Manila, Philippines. J Am Med Assoc (SE Asia). 1994;274(Suppl):S633–35.
111. Lokeshwar MR, Agrawal A, Subbarao SD, Chakraborty MS, Ram Prasad AV,
Weil J, et al. Age related seroprevalence of antibodies to varicella in India.
Indian Pediatr. 2000;37:714–9.
112. Migasena S, Simasathien S, Desakorn V, Phonrat B, Suntharasamai P,
Pitisuttitham P, et al. Seroprevalence of varicella-zoster virus antibody in
Thailand. Int J Infect Dis. 1997;2:26–30.
113. Bhattarakosol P, Chantarabul S, Pittayathikhun K, Mung-mee V, Punnarugsa
V. Prevalence of anti-varicella zoster IgG antibody in undergraduate
students. Asian Pac J Allergy Immunol. 1996;14:129–31.
114. Lolekha S, Tanthiphabha W, Sornchai P, Kosuwan P, Sutra S, Warachit B, et al.
Effect of climatic factors and population density on varicella zoster virus
epidemiology within a tropical country. Am J Trop Med Hyg. 2001;64:131–6.
115. Srichomkwun P, Apisarnthanarak A, Thongphubeth K, Yuekyen C, Mundy LM.
Evidence of vaccine protection among Thai medical students and implications
for occupational health. Infect Control Hosp Epidemiol. 2009;30:585–8.
116. Suwanpakdee D, Laohapand C, Moolasart V, Lomtong P, Krairojananan N,
Srisawat P, et al. Serosurveillance of varicella and hepatitis B infection after
reported cases in medical students and the relationship between past
varicella disease history and immunity status. J Med Assoc Thai. 2012;95
Suppl 5:S80–5.
117. Kowitdamrong E, Pancharoen C, Thammaborvorn R, Bhattarakosol P. The
prevalence of varicella-zoster virus infection in normal healthy individuals
aged above 6 months. J Med Assoc Thai. 2005;88 Suppl 4:S7–11.
118. O'Grady KA, Merianos A, Patel M, Gilbert L. High seroprevalence of
antibodies to varicella zoster virus in adult women in a tropical climate.
Trop Med Int Health. 2000;5:732–6.
119. Gidding HF, MacIntyre CR, Burgess MA, Gilbert GL. The seroepidemiology
and transmission dynamics of varicella in Australia. Epidemiol Infect. 2003;
131:1085–9.
120. Lin YJ, Huang LM, Lee CY, Chih TW, Lee PL, Chang LY, et al. A
seroepidemiological study of Varicella-Zoster virus in Taipei City. Zhonghua
Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1996;37:11–5.
121. Wu MF, Yang YW, Lin WY, Chang CY, Soon MS, Liu CE. Varicella zoster virus
infection among healthcare workers in Taiwan: seroprevalence and
predictive value of history of varicella infection. J Hosp Infect. 2012;80:162–7.
122. Kangro HO, Osman HK, Lau YL, Heath RB, Yeung CY, Ng MH. Seroprevalence
of antibodies to human herpesviruses in England and Hong Kong. J Med
Virol. 1994;43:91–6.
123. Fung LW, Lao TT, Suen SS, Chan OK, Lau TK, Ngai KL, et al. Seroprevalence
of varicella zoster virus among pregnant women in Hong Kong: comparison
with self-reported history. Vaccine. 2011;29:8186–8.
124. Liu JJ, Wang ML, Gan L, Liao WJ, Chen J. Seroepidemiology of varicella-
zoster virus infection measured by the fluorescent antibody to membrane
antigen test. Zhonghua Liu Xing Bing Xue Za Zhi. 2009;30:371–5.
125. Zhou Z, Wang S, Chu Y, Xie G. Survey of seroprevalence of varicella zoster
virus in healthy population in Shanghai. Chin J Vaccin Immun. 2006;2:137–9.
126. Wang Y. Seroepidemiological survey of prevalence of varicella-zoster virus in
healthy population in Shenzen City. Chin Trop Med. 2006;7:1166–7.
127. Pan W, Zhang X, Cai Z, Zhang H. A sero-epidemiological investigation on
varicella-zoster virus in healthy people in Fujian. Pract Prev Med. 2003;6:
864–5.
128. Han SB, Kang KR, Huh DH, Lee HC, Kim JH, Kang JH, et al. Seroepidemiology
of varicella-zoster virus in Korean adolescents and adults using fluorescent
antibody to membrane antigen test. Epidemiol Infect. 2015;143:1643–50.
129. Kang CI, Choi CM, Park TS, Lee DJ, Oh MD, Choe KW. Incidence of herpes
zoster and seroprevalence of varicella-zoster virus in young adults of South
Korea. Int J Infect Dis. 2008;12:245–7.
130. Choi YJ, Kim KH, Oh MD. Genotype of varicella zoster virus isolated from
Korean elderly patients with herpes zoster. Infect Chemother. 2010;42:162–70.
131. Lee H, Cho HK, Kim KH. Seroepidemiology of varicella-zoster virus in Korea.
J Korean Med Sci. 2013;28:195–9.
132. Kang JH, Park YS, Park SY, Kim SB, Ko KP, Seo YH. Varicella seroprevalence
among health care workers in Korea: validity of self-reported history and cost-
effectiveness of prevaccination screening. Am J Infect Control. 2014;42:885–7.
Chen et al. BMC Infectious Diseases  (2017) 17:213 Page 25 of 39
133. Kim YH, Hwang JY, Lee KM, Choi JH, Lee TY, Choi JS, et al.
Seroepidemiologic survey of varicella-zoster virus in Korean adults using
glycoprotein enzyme immuno assay and fluorescent antibody to
membrane antigen test. Ann Dermatol. 2011;23:39–43.
134. Yoshida N, Tsumura N, Toyomasu K, Sagawa K. Antibody titers against
measles, rubella, mumps and varicella-zoster viruses in medical students.
Sangyo Eiseigaku Zasshi. 2007;49:21–6.
135. National Institute of Infectious Diseases, Japan. National Epidemiological
Surveillance of Vaccine-Preventable Diseases, 2015. Age distribution of
varicella EIA-IgG antibody positives in Japan, 2015. http://www.nih.go.
jp/niid/ja/y-graphs/6358-varicella-yosoku-serum2015.html. Accessed 27
Sept 2016.
136. Lin YH, Huang LM, Chang IS, Tsai FY, Lu CY, Shao PL, et al. Disease burden
and epidemiology of herpes zoster in pre-vaccine Taiwan. Vaccine. 2010;28:
1217–20.
137. Jih JS, Chen YJ, Lin MW, Chen YC, Chen TJ, Huang YL, et al. Epidemiological
features and costs of herpes zoster in Taiwan: a national study 2000 to
2006. Acta Derm Venereol. 2009;89:612–6.
138. Kim YJ, Lee CN, Lim CY, Jeon WS, Park YM. Population-based study of the
epidemiology of herpes zoster in Korea. J Korean Med Sci. 2014;29:1706–10.
139. Toyama N, Shiraki K. Epidemiology of herpes zoster and its relationship to
varicella in Japan: A 10-year survey of 48,388 herpes zoster cases in Miyazaki
prefecture. J Med Virol. 2009;81:2053–8.
140. Choi WS, Noh JY, Huh JY, Jo YM, Lee J, Song JY, et al. Disease burden of
herpes zoster in Korea. J Clin Virol. 2010;47:325–9.
141. Wu PY, Wu HD, Chou TC, Sung FC. Varicella vaccination alters the chronological
trends of herpes zoster and varicella. PLoS One. 2013;8:e77709.
142. Wu CY, Hu HY, Huang N, Pu CY, Shen HC, Chou YJ. Do the health-care
workers gain protection against herpes zoster infection? A 6-year
population-based study in Taiwan. J Dermatol. 2010;37:463–70.
143. Chao DY, Chien YZ, Yeh YP, Hsu PS, Lian IB. The incidence of varicella and
herpes zoster in Taiwan during a period of increasing varicella vaccine
coverage, 2000–2008. Epidemiol Infect. 2012;140:1131–40.
144. Pongsumpun P. Local stability analysis of age structural model for herpes
zoster in Thailand. Int J Math Comput Stat Nat Phys Eng. 2013;7:1146–52.
145. Nelson MR, Britt HC, Harrison CM. Evidence of increasing frequency of
herpes zoster management in Australian general practice since the
introduction of a varicella vaccine. Med J Aust. 2010;193:110–3.
146. Kelly HA, Grant KA, Gidding H, Carville KS. Decreased varicella and increased
herpes zoster incidence at a sentinel medical deputising service in a setting
of increasing varicella vaccine coverage in Victoria, Australia, 1998 to 2012.
Euro Surveill. 2014;19(41):pii=20926. http://www.eurosurveillance.org/
ViewArticle.aspx?ArticleId=20926.
147. Carville KS, Riddell MA, Kelly HA. A decline in varicella but an uncertain
impact on zoster following varicella vaccination in Victoria, Australia.
Vaccine. 2010;28:2532–8.
148. Bak H, Ahn SK. A statistical study of dermatoses (2000–2004). Korean J
Dermatol. 2005;43:1192–9.
149. Lee H-J, Choi SI, Ahn SK. A statistical study of dermatoses in Wonju (2005 ~
2009). Korean J Dermatol. 2010;48:460–7.
150. Bureau of Epidemiology, Department of Disease Control, Ministry of Public
Health, Thailand. Annual Epidemiological Surveillance Reports. 1993–2014.
http://www.boe.moph.go.th/boedb/surdata/disease.php?dcontent=old&ds=
77. Accessed 03 Aug 2015.
151. Ogunjimi B, Van Damme P, Beutels P. Herpes zoster risk reduction through
exposure to chickenpox patients: A systematic multidisciplinary review. PLoS
One. 2013;8:e66485.
152. Jardine A, Conaty SJ, Vally H. Herpes zoster in Australia: Evidence of increase
in incidence in adults attributable to varicella immunization? Epidemiol
Infect. 2011;139:658–65.
153. Jeong SK, Kim IH. Recurrence rate of herpes zoster during the previous
decade. Korean J Dermatol. 2012;50:287–9.
154. Tunsuriyawong S, Puavilai S. Herpes zoster, clinical course and associated
diseases: A 5-year retrospective study at Ramathibodi Hospital. J Med Assoc
Thai. 2005;88:678–81.
155. Ikeda M, Hiroshige K, Abiko Y, Onoda K. Impaired specific cellular immunity
to the varicella-zoster virus in patients with herpes zoster oticus. J Laryngol
Otol. 1996;110:918–21.
156. Tang H, Moriishi E, Okamoto S, Okuno Y, Iso H, Asada H, et al. A
community-based survey of varicella-zoster virus-specific immune responses
in the elderly. J Clin Virol. 2012;55:46–50.
157. Lin SY, Liu JH, Lin CL, Tsai IJ, Chen PC, Chung CJ, et al. A comparison of
herpes zoster incidence across the spectrum of chronic kidney disease,
dialysis and transplantation. Am J Nephrol. 2012;36:27–33.
158. Hata A, Kuniyoshi M, Ohkusa Y. Risk of Herpes zoster in patients with
underlying diseases: a retrospective hospital-based cohort study. Infection.
2011;39:537–44.
159. Kuo CC, Lee CT, Lee IM, Ho SC, Yang CY. Risk of herpes zoster in patients
treated with long-term hemodialysis: a matched cohort study. Am J Kidney
Dis. 2012;59:428–33.
160. Wu MY, Hsu YH, Su CL, Lin YF, Lin HW. Risk of herpes zoster in CKD: a matched-
cohort study based on administrative data. Am J Kidney Dis. 2012;60:548–52.
161. Chen HH, Chen YM, Chen TJ, Lan JL, Lin CH, Chen DY. Risk of herpes zoster
in patients with systemic lupus erythematosus: a three-year follow-up study
using a nationwide population-based cohort. Clinics (Sao Paulo). 2011;66:
1177–82.
162. Tsai SY, Yang TY, Lin CL, Tsai YH, Kuo CF, Kao CH. Increased risk of varicella
zoster virus infection in inflammatory bowel disease in an Asian population: a
nationwide population-based cohort study. Int J Clin Pract. 2015;69:228–34.
163. Chen JY, Cheng TJ, Chang CY, Lan KM, Weng SF, Sheu MJ, et al. Increased
incidence of herpes zoster in adult patients with peptic ulcer disease: A
population-based cohort study. Int J Epidemiol. 2013;42:1873–81.
164. Yang YW, Chen YH, Wang KH, Wang CY, Lin HW. Risk of herpes zoster
among patients with chronic obstructive pulmonary disease: a population-
based study. CMAJ. 2011;183:E275–80.
165. Umezawa Y, Fukuchi O, Ito T, Saeki H, Nakagawa H. Risk of herpes
zoster in psoriatic patients undergoing biologic treatment. J Dermatol.
2014;41:168–70.
166. Hu SC, Lin CL, Lu YW, Chen GS, Yu HS, Wu CS, et al. Lymphopaenia, anti-Ro/
anti-RNP autoantibodies, renal involvement and cyclophosphamide use
correlate with increased risk of herpes zoster in patients with systemic lupus
erythematosus. Acta Derm Venereol. 2013;93:314–8.
167. Zou Y, Lin M, Sheng Z, Niu S. Bortezomib and lenalidomide as front-line
therapy for multiple myeloma. Leuk Lymphoma. 2014;55:2024–31.
168. Lyu SM, Byun JY, Choi YW, Choi HY. Clinical features of dermatology-
consulted inpatients - Focus on the differences between individual
departments. Korean J Dermatol. 2014;52:215–21.
169. Oh SI, Oh BH, Rho JR, Kim KB, Kim JJ, Song MG, et al. Results of heart
transplantation in Korea. Korean J Med. 2001;60:228–33.
170. Tzeng CH, Liu JH, Fan S, Wang SY, Wang SR, Chen KY, et al. Varicella zoster
virus infection after allogeneic or autologous hemopoietic stem cell
transplantation. J Formos Med Assoc. 1995;94:313–7.
171. Nakasone H, Izutsu K, Wakita S, Yamaguchi H, Muramatsu-Kida M, Usuki K.
Autologous stem cell transplantation with PCR-negative graft would be
associated with a favorable outcome in core-binding factor acute myeloid
leukemia. Biol Blood Marrow Transplant. 2008;14:1262–9.
172. Tsukamoto H, Nagafuji K, Horiuchi T, Miyamoto T, Aoki K, Takase K, et al. A
phase I-II trial of autologous peripheral blood stem cell transplantation in
the treatment of refractory autoimmune disease. Ann Rheum Dis. 2006;65:
508–14.
173. Jiang Z, Xiao H, Pang Y, Xiao Y. The incidence of herpes zoster after
hematopoietic stem cell transplantation. Chin J Infect Chemother. 2012;12:88–91.
174. Chugh KS, Sharma SC, Singh V, Sakhuja V, Jha V, Gupta KL. Spectrum of
dermatological lesions in renal allograft recipients in a tropical environment.
Dermatology. 1994;188:108–12.
175. Prakash J, Singh S, Prashant GK, Kar B, Tripathi K, Singh PB. Mucocutaneous
lesions in transplant recipient in a tropical country. Transplant Proc.
2004;36:2162–4.
176. Hwang EA, Kang MJ, Han SY, Park SB, Kim HC. Viral infection following
kidney transplantation: long-term follow-up in a single center. Transplant
Proc. 2004;36:2118–9.
177. Ko GB, Kim T, Kim SH, Choi SH, Kim YS, Woo JH, et al. Increased incidence
of herpes zoster in the setting of cytomegalovirus preemptive therapy after
kidney transplantation. Transpl Infect Dis. 2013;15:416–23.
178. Vinod PB, Sharma RK. Opportunistic infections (non-cytomegalovirus) in live
related renal transplant recipients. Indian J Urol. 2009;25:161–8.
179. Ng P, McCluskey P, McCaughan G, Glanville A, MacDonald P, Keogh A.
Ocular complications of heart, lung, and liver transplantation. Br J
Ophthalmol. 1998;82:423–8.
180. Kreis H, Oberbauer R, Campistol JM, Mathew T, Daloze P, Schena FP, et al.
Long-term benefits with sirolimus-based therapy after early cyclosporine
withdrawal. J Am Soc Nephrol. 2004;15:809–17.
Chen et al. BMC Infectious Diseases  (2017) 17:213 Page 26 of 39
181. Tomonari A, Iseki T, Takahashi S, Ooi J, Takasugi K, Shimohakamada Y, et al.
Varicella-zoster virus infection in adult patients after unrelated cord
blood transplantation: a single institute experience in Japan. Br J
Haematol. 2003;122:802–5.
182. Onozawa M, Hashino S, Haseyama Y, Hirayama Y, Iizuka S, Ishida T, et al.
Incidence and risk of postherpetic neuralgia after varicella zoster virus
infection in hematopoietic cell transplantation recipients: Hokkaido
Hematology Study Group. Biol Blood Marrow Transplant. 2009;15:724–9.
183. Wu M, Huang F, Jiang X, Fan Z, Zhou H, Liu C, et al. Herpesvirus-associated
central nervous system diseases after allogeneic hematopoietic stem cell
transplantation. PLoS One. 2013;8:e77805.
184. Suzuki J, Ashizawa M, Okuda S, Wada H, Sakamoto K, Terasako K, et al.
Varicella zoster virus meningoencephalitis after allogeneic hematopoietic
stem cell transplantation. Transpl Infect Dis. 2012;14:E7–12.
185. Au WY, Hon C, Cheng VCC, Ma ESK. Concomitant zoster myelitis and cerebral
leukemia relapse after stem cell transplantation. Ann Hematol. 2005;84:59–60.
186. Fukuno K, Tomonari A, Takahashi S, Ooi J, Takasugi K, Tsukada N, et al.
Varicella-zoster virus encephalitis in a patient undergoing unrelated cord
blood transplantation for myelodysplastic syndrome-overt leukemia. Int J
Hematol. 2006;84:79–82.
187. Kang EH, Chung MP, Kang SJ, An CH, Ahn JW, Han J, Lee. Clinical features
and treatment response in 18 cases with idiopathic nonspecific interstitial
pneumonia. Tuberc Respir Dis. 2000;48:530–41.
188. Ozono Y, Harada T, Yamaguchi K, Taura K, Hara K, Taguchi T. Nephrotic
syndrome in the elderly–clinicopathological study. Nihon Jinzo Gakkai Shi.
1994;36:44–50.
189. Satoh N, Abe T, Nakajima A, Sakuragi S. Recurrent varicella-zoster virus
retinitis in a patient treated with systemic corticosteroids. Ocul Immunol
Inflamm. 1998;6:185–8.
190. Xiao X, Lu Y, Su H, Zhong K, Chen X, Da Y, et al. Clinical features and treatment
of angioimmunoblastic T-cell lymphoma. Chin J Clin Oncol. 2011;38:1103–6.
191. Usami E, Kimura M, Matsuoka T, Okada K, Nakao T, Yoshimura T, et al. The
frequency and risk factor of herpes zoster infection in non-Hodgkin's
lymphoma patients. Jpn J Cancer Chemother. 2011;38:243–7.
192. Mills AK, Taylor KM, Wright SJ, Bunce LH, Bashford J, White K, et al. Sustained
responses following alternating chlorodeoxyadenosine (2CDA) and VAC
regimen in poor-risk de-novo follicular non-hodgkin's lymphoma (NHL). In:
Blood 2000;96(11) Part II: The 2nd Annual Scientific Meeting of the Haematology
Society of Australia and New Zealand, Perth, WA, 25–28 July 2000. p. 243b.
193. Au WY, Kwong YL. Frequent varicella zoster reactivation associated with
therapeutic use of arsenic trioxide: portents of an old scourge. J Am Acad
Dermatol. 2005;53:890–2.
194. Zhang Q, Mu LJ, Wang XB, Li L, Kang ZJ, Yan JS. Clinical analysis of
hematologic disorders complicated with herpes zoster after treating with
arsenic trioxide. J Leuk Lymphoma. 2011;20:412–4.
195. Yamakura M, Tsuda K, Ugai T, Sugihara H, Nisihida Y, Takeuchi M, et al. High
frequency of varicella zoster virus reactivation associated with the use of
arsenic trioxide in patients with acute promyelocytic leukemia. Acta
Haematol. 2014;131:76–7.
196. Au WY, Kumana CR, Lee HK, Lin SY, Liu H, Yeung DY, et al. Oral arsenic
trioxide-based maintenance regimens for first complete remission of acute
promyelocytic leukemia: a 10-year follow-up study. Blood. 2011;118:6535–43.
197. Chan AYK, Hooi LS. Outcome of 85 lupus nephritis patients treated with
intravenous clophosphamide: A single centre 10 year experience. Med J
Malays. 2000;55:14–20.
198. Chan TM, Li FK, Wong RW, Wong KL, Chan KW, Cheng IK. Sequential therapy
for diffuse proliferative and membranous lupus nephritis: cyclophosphamide
and prednisolone followed by azathioprine and prednisolone. Nephron.
1995;71:321–7.
199. Chan TM, Li FK, Hao WK, Chan KW, Lui SL, Tang S, et al. Treatment of
membranous lupus nephritis with nephrotic syndrome by sequential
immunosuppression. Lupus. 1999;8:545–51.
200. Mok CC, Ho CT, Siu YP, Chan KW, Kwan TH, Lau CS, et al. Treatment of
diffuse proliferative lupus glomerulonephritis: a comparison of two
cyclophosphamide-containing regimens. Am J Kidney Dis. 2001;38:256–64.
201. Liu G, Chen Y, Zuo C, Xie Q, Wang Z, Wang L, et al. Study on bolus
cyclosphamide treatment for 64 cases of lupus nephritis. J West China Univ
Med Sci. 2001;32:129–130,139.
202. Mok CC, Ying KY, Mak A, To CH, Szeto ML. Outcome of protein-losing
gastroenteropathy in systemic lupus erythematosus treated with
prednisolone and azathioprine. Rheumatology (Oxford). 2006;45:425–9.
203. Kim JH, Cheon JH, Kim WH. The frequency and the course of the adverse
effects of azathioprine/6-mercaptopurine treatment in patients with
inflammatory bowel disease. Korean J Gastroenterol. 2008;51:291–7.
204. Eisen HJ, Kobashigawa J, Keogh A, Bourge R, Renlund D, Mentzer R, et al.
Three-year results of a randomized, double-blind, controlled trial of
mycophenolate mofetil versus azathioprine in cardiac transplant recipients.
J Heart Lung Transplant. 2005;24:517–25.
205. Zeher M, Doria A, Lan J, Aroca G, Jayne D, Boletis I, et al. Efficacy and safety
of enteric-coated mycophenolate sodium in combination with two
glucocorticoid regimens for the treatment of active lupus nephritis. Lupus.
2011;20:1484–93.
206. Hu W, Liu C, Xie H, Chen H, Liu Z, Li L. Mycophenolate mofetil versus
cyclophosphamide for inducing remission of ANCA vasculitis with moderate
renal involvement. Nephrol Dial Transplant. 2008;23:1307–12.
207. Kim YS, Moon JI, Kim SI, Park K. Clear benefit of mycophenolate
mofetil-based triple therapy in reducing the incidence of acute
rejection after living donor renal transplantations. Transplantation.
1999;68:578–81.
208. Lu F, Tu Y, Peng X, Wang L, Wang H, Sun Z, et al. A prospective multicentre
study of mycophenolate mofetil combined with prednisolone as induction
therapy in 213 patients with active lupus nephritis. Lupus. 2008;17:622–9.
209. Hegde S, Annamalai R, Biswas J. Extensive herpes zoster involvement
following mycophenolate mofetil therapy for sarcoidosis. J Ophthalmic
Inflamm Infect. 2012;2:47–8.
210. Satoh S, Tada H, Murakami M, Tsuchiya N, Inoue T, Togashi H, et al.
The influence of mycophenolate mofetil versus azathioprine and
mycophenolic acid pharmacokinetics on the incidence of acute
rejection and infectious complications after renal transplantation.
Transplant Proc. 2005;37:1751–3.
211. Yap DY, Yu X, Chen XM, Lu F, Chen N, Li XW, et al. Pilot 24 month study to
compare mycophenolate mofetil and tacrolimus in the treatment of
membranous lupus nephritis with nephrotic syndrome. Nephrology
(Carlton). 2012;17:352–7.
212. Mak SK, Lo KY, Lo MW, Chan SF, Tong GM, Wong PN, et al. Efficacy of
enteric-coated mycophenolate sodium in patients with active lupus
nephritis. Nephrology (Carlton). 2008;13:331–6.
213. Li L, Wang H, Lin S, et al. Mycophenolate mofetil treatment for diffuse
proliferative lupus nephritis: a multicenter clinical trial in China. Zhonghua
Nei Ke Za Zhi. 2002;41:476–9.
214. Xie QX, Han CX, Li JY, Lin XC, Zhao L, Huang HW, et al. Application of low-
dosage mycophenolate mofetil in living renal transplantation of lineal
consanguinity. J Clin Rehab Tissue Eng Res. 2009;13:924–6.
215. Jenks KA, Stamp LK, O'Donnell JL, Savage RL, Chapman PT. Leflunomide-
associated infections in rheumatoid arthritis. J Rheumatol. 2007;34:2201–3.
216. Yoo HG, Yu HM, Jun JB, Jeon HS, Yoo WH. Risk factors of severe infections
in patients with rheumatoid arthritis treated with leflunomide. Mod
Rheumatol. 2013;23:709–15.
217. Cui TG, Hou FF, Ni ZH, Chen XM, Zhang FS, Zhu TY, et al. Treatment of
proliferative lupus nephritis with leflunomide and steroid: a prospective
multi-center controlled clinical trial. Zhonghua Nei Ke Za Zhi. 2005;44:
672–6.
218. Muir VJ, Plosker GL. Cladribine tablets: in relapsing-remitting multiple
sclerosis. CNS Drugs. 2011;25:239–49.
219. Kim SJ, Moon JH, Kim H, Kim JS, Hwang YY, Intragumtornchai T, et al.
Non-bacterial infections in Asian patients treated with alemtuzumab: A
retrospective study of the Asian Lymphoma Study Group. Leuk Lymphoma.
2012;53:1515–24.
220. Chung BH, Kim Y, Jeong HS, Hong YA, Choi BS, Park CW, et al. Clinical
outcome in patients with chronic antibody-mediated rejection treated with
and without rituximab and intravenous immunoglobulin combination
therapy. Transpl Immunol. 2014;31:140–4.
221. Ito K, Okamoto M, Maruyama F, Handa K, Yamamoto Y, Watanabe M, et al.
Alteration in antibody-mediated immunity in patients with rituximab-
combined chemotherapy and incidence of herpes zoster. Gan To Kagaku
Ryoho. 2010;37:99–102.
222. Kurokawa T, Hase M, Tokuman N, Yoshida T. Immune reconstitution of B-
cell lymphoma patients receiving CHOP-based chemotherapy containing
rituximab. Hematol Oncol. 2011;29:5–9.
223. Lee SD, Kim SH, Kong SY, Kim YK, Lee SA, Park SJ. ABO-incompatible living
donor liver transplantation without graft local infusion and splenectomy.
HPB (Oxford). 2014;16:807–13.
Chen et al. BMC Infectious Diseases  (2017) 17:213 Page 27 of 39
224. Tu MF, Zheng W, Lin NJ, Zhang YT, Wang XP, Song YQ, et al. Efficacy
and safety of fludarabine-based combination chemotherapy in patients
with previously untreated follicular non-Hodgkin's lymphoma. Tumor.
2011;31:58–63.
225. Furie R, Nicholls K, Cheng TT, Houssiau F, Burgos-Vargas R, Chen SL, et al.
Efficacy and safety of abatacept in lupus nephritis: A twelve-month,
randomized, double-blind study. Arthritis Rheum. 2014;66:379–89.
226. Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, et al.
Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;
370:2377–86.
227. Winthrop KL, Yamanaka H, Valdez H, Mortensen E, Chew R, Krishnaswami S,
et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid
arthritis. Arthritis Rheum. 2014;66:2675–84.
228. Wang X, Zhao J, Zhu S, Xia B. Herpes zoster in Crohn's disease during
treatment with infliximab. Eur J Gastroenterol Hepatol. 2014;26:237–9.
229. Choi KD, Song HJ, Kim JS, Jung HC, Song IS. Efficacy and safety of treatment
with infliximab in Crohn's disease-the experience of single center in Korea.
Korean J Gastroenterol. 2005;46:48–55.
230. Kim YJ, Kim JW, Lee CK, Park HJ, Shim JJ, Jang JY, et al. Clinical outcome of
treatment with infliximab in Crohn's disease: a single-center experience.
Korean J Gastroenterol. 2013;61:270–8.
231. Yi YS, Chung JS, Song MK, Shin HJ, Seol YM, Choi YJ, et al. The risk factors
for herpes zoster in bortezomib treatment in patients with multiple
myeloma. Korean J Hematol. 2010;45:188–92.
232. Kim SJ, Kim K, Kim BS, Lee HJ, Kim H, Lee NR, et al. Bortezomib and the
increased incidence of herpes zoster in patients with multiple myeloma.
Clin Lymphoma Myeloma. 2008;8:237–40.
233. Kim MG, Kim YJ, Kwon HY, Park HC, Koo TY, Jeong JC, et al. Outcomes of
combination therapy for chronic antibody-mediated rejection in renal
transplantation. Nephrology (Carlton). 2013;18:820–6.
234. Tong Y, Qian J, Li Y, Meng H, Jin J. The high incidence of varicella herpes zoster
with the use of bortezomib in 10 patients. Am J Hematol. 2007;82:403–4.
235. Zhong YP, Chen SL, Li X, Hu Y, Zhang JJ. Bortezomib combined with other
drugs for treating 60 cases of multiple myeloma. Zhongguo Shi Yan Xue Ye
Xue Za Zhi. 2009;17:214–7.
236. Khalafallah AA, Woodgate M, Koshy K, Patrick A. Ophthalmic manifestations
of herpes zoster virus in patients with multiple myeloma following bone
marrow transplantation. BMJ Case Rep. 2013; doi:10.1136/bcr-2012-007625.
237. Zhang YQ, Liang R, Bai QX, Zhang T, Yang L, Wang YW, et al. PAD regimen
for relapsed or refractory patients with multiple myeloma. Zhonghua Xue
Ye Xue Za Zhi. 2009;30:260–3.
238. Muta T, Nakanishi H, Yasunaga M, Senba S, Murakami H, Kan S, et al. Safety
evaluation of bortezomib in multiple myeloma patients with severe renal
failure. Jpn J Cancer Chemother. 2011;38:237–41.
239. Li CM, Lu H, Wu HX, Qiu HX, Qian SX, Xu W, et al. Therapeutic efficacy of
bortezomib-based chemotherapy on 40 patients with multiple myeloma.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010;18:1511–4.
240. Yang G, Chen W, Wu Y. Bortezomib, dexamethasone plus thalidomide for
treatment of newly diagnosed multiple myeloma patients with or without
renal impairment. Chin J Cancer Res. 2013;25:155–60.
241. He J, Yang L, Han X, Zheng G, Zheng W, Wei G, et al. The choice of
regimens based on bortezomib for patients with newly diagnosed multiple
myeloma. PLoS One. 2014;9:e99174.
242. Huang B, Li J, Xu X, Zheng D, Zhou Z, Liu J. Successful treatment of renal
light chain (AL) amyloidosis with bortezomib and dexamethasone (VD).
Pathol Biol (Paris). 2015;63:17–20.
243. Zhang Y, Shi B, Chen X, Xia Y, Ye L, Liu L, et al. Bortezomib combined with
doxorubicin and dexamethasone for patients with refractory senile mantle
cell lymphoma. Chin J Clin Oncol. 2011;38:1092–4.
244. Zhong YP, Chen SL. Effect of treatment by bortezomib with other drugs for
the refractory multiple myeloma. J Leuk Lymphoma. 2009;18:538–40.
245. Zhu JJ, Li L, Ye XJ, He JS, Cai Z. Bortezomib combined with epirubicin and
dexamethasone in treatment of multiple myeloma. J Pract Oncol. 2013;28:520–2.
246. Ohguchi H, Sugawara T, Ishikawa I, Okuda M, Tomiya Y, Yamamoto J, et al.
A retrospective analysis of bortezomib therapy for Japanese patients with
relapsed or refractory multiple myeloma: beta2-microglobulin associated
with time to progression. Int J Hematol. 2009;89:342–7.
247. Coiffier B, Osmanov EA, Hong X, Scheliga A, Mayer J, Offner F, et al.
Bortezomib plus rituximab versus rituximab alone in patients with relapsed,
rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised
phase 3 trial. Lancet Oncol. 2011;12:773–84.
248. Yang GZ, Chen WM, Shen M, Fu LN, Jiang L, Gao W, et al. Sequential
therapy of BTD and MPT regimen for the newly-diagnosed multiple
myeloma patients no eligible for bone marrow transplantation. J Leuk
Lymphoma. 2011;20:350–2.
249. Zhai YP, Liu HN, Yu YP, Zhou XG, Song P, Li F, et al. Treatment of primary
systemic amyloidosis with the combination of bortezomib and
dexamethasone. Zhonghua Xue Ye Xue Za Zhi. 2010;31:319–22.
250. Gu HT, Shu MM, Gao GX, Dong BX, Liang R, Yang L, et al. Efficacy
comparison between standard and reduced doses of bortezomib combined
with adriamycin and dexamethasone in the treatment of patients with
multiple myeloma. Zhonghua Xue Ye Xue Za Zhi. 2013;34:622–5.
251. Zhao Y, Dou LP, Wang SH, Bo J, Wang QS, Huang WR, et al. The efficacy
and safety of PAD and VAD regimens for untreated multiple myeloma.
Zhonghua Nei Ke Za Zhi. 2010;49:762–4.
252. Hung MH, Kuo JR, Huang KF, Wang WC. Sacral herpes zoster presenting as
sciatica. CMAJ. 2010;182:E534.
253. Sachdeva S, Prasher P. Herpes zoster following saphenous venectomy for
coronary bypass surgery. J Card Surg. 2010;25:28–9.
254. Basavaraj S, Prakash BG, Shetty TS, Sandhya D, Kallada S. Delayed facial
nerve weakness after intact canal wall tympanomastoidectomy. Otol
Neurotol. 2014;35:1003–6.
255. Lee MR, Ryman W. Herpes zoster following cryosurgery. Australas J
Dermatol. 2005;46:42–3.
256. Brandon EL, Akers J, Rapeport D. Development of bilateral herpes zoster following
thoracoscopic splanchnicectomy. Anaesth Intensive Care. 2006;34:382–3.
257. Park KS, Yoon TR, Kim SK, Park HW, Song EK. Acute postoperative
herpes zoster with a sciatic nerve distribution after total joint
arthroplasty of the ipsilateral hip and contralateral knee. J Arthroplasty.
2010;25:497. e11-5.
258. Choi HJ, Kim JH, Lee YM. Herpes zoster developing within recent subciliary
incision scar. J Craniofac Surg. 2012;23:930–1.
259. Lin KC, Wang CC, Wang KY, Liao YC, Kuo JR. Reactivation of herpes zoster
along the trigeminal nerve with intractable pain after facial trauma: a case
report and literature review. BMJ Case Rep. 2009; doi:10.1136/bcr.07.2008.0525.
260. Furuta Y, Ohtani F, Fukuda S, Inuyama Y, Nagashima K. Reactivation of
varicella-zoster virus in delayed facial palsy after dental treatment and oro-
facial surgery. J Med Virol. 2000;62:42–5.
261. Furukawa K, Sakoh M, Kumon Y, Teraoka M, Ohta S, Ohue S, et al. Delayed
facial palsy after microvascular decompression for hemifacial spasm due to
reactivation of varicella-zoster virus. No Shinkei Geka. 2003;31:899–902.
262. Baba T, Yamasaki A, Miyake A, Funakoshi T, Yakura K, Miyazaki D, et al.
Varicella zoster virus iridocyclitis following macular hole surgery in a case of
von Hippel-Lindau disease. Jpn J Clin Ophthalmol. 2011;65:333–7.
263. Fujitani A, Hayasaka S. Herpes zoster ophthalmicus after cataract surgery
in a patient with a history of gastric cancer. Ann Ophthalmol Glaucoma.
1997;29:57–8.
264. Koide C. Multiple cranial nerve dysfunction after uncomplicated neurovascular
decompression for hemifacial spasm. Otolaryngol Head Neck Surg Tokyo.
1997;69:72–5.
265. Tsukahara T, Huang J, Oyamada T, Uchio E. Herpetic corneal endotheliitis in
a case after deep lamellar keratoplasty for bacterial keratitis. Jpn J Clin
Ophthalmol. 2010;64:1287–91.
266. Gyo K, Honda N. Delayed facial palsy after middle-ear surgery due to
reactivation of varicella-zoster virus. J Laryngol Otol. 1999;113:914–5.
267. Kohjitani A, Miyawaki T, Kasuya K, Shimada M. Sympathetic activity-
mediated neuropathic facial pain following simple tooth extraction: a case
report. Cranio. 2002;20:135–8.
268. Walland MJ. Presumed ophthalmic Herpes zoster after contralateral cataract
extraction. Acta Ophthalmol Scand. 1995;73:83–5.
269. Kam AC, Dan NG, Maclean J, Higgins D. Zoster related multiple cranial nerve
palsies: an unusual complication following percutaneous balloon
compression for trigeminal neuralgia. J Clin Neurosci. 1999;6:261–4.
270. Makkar JK, Singh NP, Rastogi V. Herpes zoster: Are selective nerve root
injections the treatment or the cause? Pain Phys. 2010;13:196–8.
271. Oh IH, Choi SK, Park BJ, Kim TS, Rhee BA, Lim YJ. The treatment outcome of
elderly patients with idiopathic trigeminal neuralgia : Micro-vascular
decompression versus gamma knife radiosurgery. J Korean Neurosurg Soc.
2008;44:199–204.
272. Chen YH, Rau RH, Keller JJ, Lin HC. Possible effects of anaesthetic management
on the 1 yr followed-up risk of herpes zoster after Caesarean deliveries. Br J
Anaesth. 2012;108:278–82.
Chen et al. BMC Infectious Diseases  (2017) 17:213 Page 28 of 39
273. Terao M, Yamamoto T, Umeda J, Shirabe H. Drug induced herpes zoster (Do
statin induce herpes zoster?). Skin Res. 2005;4:335–8.
274. Chung SD, Tsai MC, Liu SP, Lin HC, Kang JH. Herpes zoster is associated
with prior statin use: a population-based case–control study. PLoS One.
2014;9:e111268.
275. Kano Y, Horie C, Inaoka M, Tadashi I, Mizukawa Y, Shiohara T. Herpes zoster
in patients with drug-induced hypersensitivity syndrome/DRESS. Acta
Derm-Venereol. 2012;92:206–7.
276. Follezou JY, Lan NY, Lien TX, Lafon ME, Tram LT, Hung PV, et al. Clinical and
biological characteristics of human immunodeficiency virus- infected and
uninfected intravascular drug users in Ho Chi Minh City, Vietnam. Am J Trop
Med Hyg. 1999;61:420–4.
277. Sivayathorn A, Srihra B, Leesanguankul W. Prevalence of skin disease in
patients infected with human immunodeficiency virus in Bangkok, Thailand.
Ann Acad Med Singapore. 1995;24:528–33.
278. Supanaranond W, Desakorn V, Sitakalin C, Naing N, Chirachankul P.
Cutaneous manifestations in HIV positive patients. Southeast Asian J Trop
Med Public Health. 2001;32:171–6.
279. Li ZH, Hua YH. Clinical analysis of skin and mucosa manifestations in 130
patients with HIV. J Clin Dermatol. 2013;42:720–2.
280. Wiwanitkit V. Prevalence of dermatological disorders in Thai HIV-infected
patients correlated with different CD4 lymphocyte count statuses: a note on
120 cases. Int J Dermatol. 2004;43:265–8.
281. Sungkanuparph S, Vibhagool A, Mootsikapun P, Chetchotisakd P,
Tansuphaswaswadikul S, Bowonwatanuwong C. Opportunistic infections
after the initiation of highly active antiretroviral therapy in advanced AIDS
patients in an area with a high prevalence of tuberculosis. AIDS. 2003;17:
2129–31.
282. Tzung TY, Yang CY, Chao SC, Lee JY. Cutaneous manifestations of
human immunodeficiency virus infection in Taiwan. Kaohsiung J Med
Sci. 2004;20:216–24.
283. Dwiyana RF, Rowawi R, Lestari M, Alisjahbana B, van der Ven AJ,
Djajakusumah TS. Skin disorders in HIV-infected patients from West Java.
Acta Med Indones. 2009;41 Suppl 1:18–22.
284. Wong KH, Lee SS, Lo YC, Li PC, Ho HF, Sitt WH, et al. Profile of opportunistic
infections among HIV-1 infected people in Hong Kong. Zhonghua Yi Xue
Za Zhi (Taipei). 1995;55:127–36.
285. Huang XJ, Li HY, Chen DX, Wang XC, Li ZC, Wu YS, et al. Clinical analysis of
skin lesions in 796 Chinese HIV- positive patients. Acta Derm Venereol.
2011;91:552–6.
286. Chen XC, Lu XJ, Ye H, Gao YY. Clinical analysis of 109 HIV/AIDS patients.
Chin J Infect Chemother. 2008;8:183–6.
287. Oh MD, Park SW, Kim HB, Kim US, Kim NJ, Choi HJ, et al. Spectrum of
opportunistic infections and malignancies in patients with human
immunodeficiency virus infection in South Korea. Clin Infect Dis. 1999;
29:1524–8.
288. Wani KA. Clinical profile of HIV/Aids patients in Srinagar, Kashmir, India. Int J
Collab Res Intern Med Public Health. 2012;4:1703–12.
289. Wadia RS, Pujari SN, Kothari S, Udhar M, Kulkarni S, Bhagat S, et al.
Neurological Manifestations of HIV Disease. J Assoc Physicians India. 2001;
49:343–8.
290. Shobhana A, Guha SK, Neogi DK. Mucocutaneous manifestations of HIV
infection. Indian J Dermatol Venereol Leprol. 2004;70:82–6.
291. Arora U, Chopra S, Jindal N. HIV infection in families in and around Amritsar.
J Indian Acad Clin Med. 2008;9:184–7.
292. Ghate M, Deshpande S, Tripathy S, Nene M, Gedam P, Godbole S, et al.
Incidence of common opportunistic infections in HIV-infected individuals in
Pune, India: analysis by stages of immunosuppression represented by CD4
counts. Int J Infect Dis. 2009;13:e1–8.
293. Solomon SS, Hawcroft CS, Narasimhan P, Subbaraman R, Srikrishnan AK,
Cecelia AJ, et al. Comorbidities among HIV-infected injection drug users in
Chennai, India. Indian J Med Res. 2008;127:447–52.
294. Jindal N, Aggarwal A, Kaur S. HIV seroprevalence and HIV associated
dermatoses among patients presenting with skin and mucocutaneous
disorders. Indian J Dermatol Venereol Leprol. 2009;75:283–6.
295. Kar HK, Narayan R, Gautam RK, Jain RK, Doda V, Sengupta D, et al.
Mucocutaneous disorders in Hiv positive patients. Indian J Dermatol
Venereol Leprol. 1996;62:283–5.
296. Srirangaraj S, Venkatesha D. Opportunistic infections in relation to
antiretroviral status among AIDS patients from south India. Indian J Med
Microbiol. 2011;29:395–400.
297. Shahapur PR, Bidri RC. Recent trends in the spectrum of opportunistic
infections in human immunodeficiency virus infected individuals on
antiretroviral therapy in South India. J Nat Sci Biol Med. 2014;5:392–6.
298. Song JY, Lee JS, Jung HW, Choi HJ, Lee JS, Eom JS, et al. Herpes zoster
among HIV-infected patients in the highly active antiretroviral therapy
era: Korean HIV cohort study. J Acquired Immune Defic Syndr. 2010;53:
417–9.
299. Kim JM, Cho GJ, Hong SK, Chung JS, Jang KH, Kim CO, et al. Epidemiologic
and clinical features of HIV infection/AIDS in Koreans. Korean J Med. 2001;
61:355–64.
300. Nam TS, Seo KS, Lee KI, Kim YS, Hong JH, Kim GH, et al. The clinical study of
hematoimmunologic features and opportunistic infections of patients with
AIDS. Korean J Med. 1997;52:15–23.
301. Choe KW, Oh MD, Park SW, Kim HB, Kim US, Kang SW, et al. Opportunistic
infections and malignancies in 173 patients with HIV infection. Korean J
Infect Dis. 1998;30:507–15.
302. McNulty A, Li Y, Radtke U, Kaldor J, Rohrsheim R, Cooper DA, Donovan B.
Herpes zoster and the stage and prognosis of HIV-1 infection. Genitourin
Med. 1997;73:467–70.
303. Hung CC, Hsiao CF, Wang JL, Chen MY, Hsieh SM, Sheng WH, et al.
Herpes zoster in HIV-1-infected patients in the era of highly active
antiretroviral therapy: a prospective observational study. Int J STD AIDS.
2005;16:673–6.
304. Chopra S, Arora U. Skin and mucocutaneous manifestations: Useful clinical
predictors of HIV/AIDS. J Clin Diagn Res. 2012;6:1695–8.
305. Kore SD, Kanwar AJ, Vinay K, Wanchu A. Pattern of mucocutaneous
manifestations in human immunodeficiency virus-positive patients in North
India. Indian J Sex Transm Dis. 2013;34:19–24.
306. Mali RJ, Wankhade AB, Ghadage DP, Muley VA, Bhore AV. Cutaneous
manifestations in HIV infected patients in rural area. J Pure Appl Microbiol.
2012;6:467–70.
307. Panda S, Sarkar S, Mandal BK, Singh TB, Singh KL, Mitra DK, et al. Epidemic
of herpes zoster following HIV epidemic in Manipur, India. J Infect.
1994;28:167–73.
308. Panda S, Kamei G, Pamei M, Sarkar S, Sarkar K, Singh ND, et al. Clinical
features of HIV infection in drug users of Manipur. Natl Med J India. 1994;7:
267–9.
309. Antwal M, Gurjar R, Chidrawar S, Pawar J, Gaikwad S, Panchal N, et al.
Clinical profile of HIV infected patients attending a HIV referral clinic in
Pune. India Indian J Med Res. 2014;140:271–7.
310. Lloyd A. HIV infection and AIDS. P N G Med J. 1996;39:174–80.
311. Satishchandra P, Nalini A, Gourie-Devi M, Khanna N, Santosh V, Ravi V, et al.
Profile of neurologic disorders associated with HIV/AIDS from Bangalore,
south India (1989–96). Indian J Med Res. 2000;111:14–23.
312. Srikanth KP, Vijayakumar S, Aparna, Mallikarjun. A hospital based cross
sectional study of mucocutaneous manifestations in the HIV infected. Int J
Collab Res Intern Med Public Health. 2010;2:50–78.
313. Fernandes MS, Bhat RM. Spectrum of mucocutaneous manifestations in
human immunodeficiency virus-infected patients and its correlation with
CD4 lymphocyte count. Int J STD AIDS. 2015;26:414–9.
314. Singh HR, Singh NG, Singh TB. Estimation of CD4+ and CD8+ T-lymphocytes in
human immunodeficiency virus infection and acquired immunodeficiency
syndrome patients in Manipur. Indian J Med Microbiol. 2007;25:126–32.
315. Price P, Murdoch DM, Agarwal U, Lewin SR, Elliott JH, French MA. Immune
restoration diseases reflect diverse immunopathological mechanisms. Clin
Microbiol Rev. 2009;22:651–63.
316. Choi WR, Seo MC, Sung KU, Lee HE, Yoon HJ. Herpes zoster immune
reconstitution inflammatory syndrome in a HIV-infected patient: Case report
and literature review. Infect Chemother. 2012;44:391–4.
317. Handa S, Narang T, Wanchu A. Dermatologic immune restoration syndrome:
report of five cases from a tertiary care center in north India. J Cutan Med
Surg. 2008;12:126–32.
318. Sharma A, Makrandi S, Modi M, Sharma A, Marfatia Y. Immune
reconstitution inflammatory syndrome. Indian J Dermatol Venereol Leprol.
2008;74:619–21.
319. Terada K, Yoshihiro K, Kawano S, Morita T. Incidence of herpes zoster in
pediatricians and family practitioners Estimation of efficacy of varicella
vaccine for protection against herpes zoster in the elderly. Kawasaki Med J.
1994;20:99–102.
320. Mittal RR. Infectivity of varicella and herpes zoster. Indian J Dermatol
Venereol Leprol. 1996;62:196–7.
Chen et al. BMC Infectious Diseases  (2017) 17:213 Page 29 of 39
321. Chandak SO, Pandilwar PK. Epidemic of herpes zoster in a family. J Oral
Maxillofacial Surg Med Pathol. 2012;24:42–4.
322. Suzuki K, Yoshikawa T, Tomitaka A, Matsunaga K, Asano Y. Detection of
aerosolized varicella-zoster virus DNA in patients with localized herpes
zoster. J Infect Dis. 2004;189:1009–12.
323. Suzuki K, Yoshikawa T, Tomitaka A, Suzuki K, Matsunaga K, Asano Y.
Detection of varicella-zoster virus DNA in throat swabs of patients with
herpes zoster and on air purifier filters. J Med Virol. 2002;66:567–70.
324. Yoshikawa T, Ihira M, Suzuki K, Suga S, Tomitaka A, Ueda H, et al. Rapid
contamination of the environments with varicella-zoster virus DNA from a
patient with herpes zoster. J Med Virol. 2001;63:64–6.
325. Zhai JX, Ji J, Li M. Cutaneous tuberculosis complicated with squamous cell
carcinoma. J Clin Dermatol. 2010;39:713–5.
326. Kansal HM, Goel S. Cutaneous manifestations in cases of pulmonary
tuberculosis: A clinical profile. J Indian Acad Clin Med. 2013;14:284–6.
327. Kulkarni AG, Brid NS. Images in clinical medicine. Herpes zoster. N Engl J
Med. 1995;332:1684.
328. Regunath H, Shivashankara KN, Sundeep KB, Bhaskar AP. Reactivation of
Herpes zoster in an adult with Plasmodium infection. J Vector Borne Dis.
2008;45:251–3.
329. Park B, Yun SJ, Lee JB, Lee SC, Won YH, Kim SJ. Analysis of dermatoses in
pregnant patients. Korean J Dermatol. 2013;51:249–57.
330. Kim WJ, Kim JY, Lee WJ, Lee SJ, Kim DW, Ko HC, et al. Investigation of the
clinical manifestations of herpes zoster during pregnancy and its impact on
the perinatal outcome. Korean J Dermatol. 2010;48:941–7.
331. Thami GP, Kanwar AJ. Herpes zoster during pregnancy near term: to treat or
not to treat? Aust N Z J Obstet Gynaecol. 1999;39:371.
332. Tsai YG, Lai JH, Kuo SY, Chen HC, Chang DM. Thymoma and
hypogammaglobulinemia (Good’s syndrome): a case report. J Microbiol
Immunol Infect. 2005;38:218–20.
333. Chen JY, Chang CY, Lin YS, Hu ML. Nutritional factors in herpes zoster,
postherpetic neuralgia, and zoster vaccination. Popul Health Manag.
2012;15:391–7.
334. Chao CT, Lee SY, Yang WS, Yen CJ, Chiang CK, Huang JW, et al. Serum
vitamin D levels are positively associated with varicella zoster immunity in
chronic dialysis patients. Sci Rep. 2014;4:7371.
335. Chao CT, Lai CF, Huang JW. Risk factors for herpes zoster reactivation in
maintenance hemodialysis patients. Eur J Intern Med. 2012;23:711–5.
336. Chi CY, Chu CC, Liu JP, Lin CH, Ho MW, Lo WJ, et al. Anti-IFN-γ autoantibodies
in adults with disseminated nontuberculous mycobacterial infections are
associated with HLA-DRB1*16:02 and HLA-DQB1*05:02 and the reactivation of
latent varicella-zoster virus infection. Blood. 2013;121:1357–66.
337. Cho JW, Shin DH, Lee KS. Polymorphism of the IL-10 gene is associated
with susceptibility to herpes zoster in Korea. J Dermatol Sci. 2007;45:213–5.
338. Park SJ, Cho JW, Lee KS. Single nucleotide polymorphisms of interleukin-10
promoter gene in Korean herpes zoster patients. Korean J Dermatol. 2006;
44:1325–31.
339. Yuan LL, Wang LX, Xie YM, Yang W, Yang ZX, Zhuang Y, et al. Analysis on
clinical features and treatment of herpes zoster patients hospitalized in real
world. Zhongguo Zhongyao Zazhi. 2014;39:3469–73.
340. Oh HM, Ho AY, Chew SK, Monteiro EH. Clinical presentation of herpes
zoster in a Singapore hospital. Singapore Med J. 1997;38:471–4.
341. Vikrant S. Long-term clinical outcomes of peritoneal dialysis patients: 9-year
experience of a single center from north India. Perit Dial Int. 2014;34:426–33.
342. Sato T, Inoue T, Endo K, Watanabe Y, Kikuta T, Tsuda M, et al. End-stage
renal disease (ESRD) contributes to the increasing prevalence of herpes
zoster. NDT Plus. 2009;2:263–4.
343. Muraya Y. Clinical and immunological evaluation of infection in patients on
hemodialysis. J Infect Chemother. 1996;2:247–53.
344. Iwamoto M, Kamimura T, Nagashima T, Kamata Y, Aoki Y, Onishi S, et al.
Healthcare-associated infections in rheumatology in Japan. Rheumatol Int.
2012;32:801–4.
345. Nishimaki T, Watanabe K, Satho Y, Okubo M, Kaise S, Miyata M, et al. Viral,
fungal and mycobacterial infections in patients with systemic lupus
erythematosus. Jpn J Rheumatol. 1999;9:45–54.
346. Ishikawa O, Abe M, Miyachi Y. Herpes zoster in Japanese patients with
systemic lupus erythematosus. Clin Exp Dermatol. 1999;24:327–8.
347. Naganuma M, Kunisaki R, Yoshimura N, Takeuchi Y, Watanabe M. A
prospective analysis of the incidence of and risk factors for opportunistic
infections in patients with inflammatory bowel disease. J Gastroenterol.
2013;48:595–600.
348. Binitha MP, Sarita SP, Manju M. Photoletter to the editor: Squamous cell
carcinoma associated with and masquerading as molluscum contagiosum.
J Dermatol Case Rep. 2013;7:103–5.
349. Rajagopal R, Arora PN, Ramasastry CV, Kar PK. Skin changes in internal
malignancy. Indian J Dermatol Venereol Leprol. 2004;70:221–5.
350. Ayyamperumal A, Tharini G, Ravindran V, Parveen B. Cutaneous
manifestations of internal malignancy. Indian J Dermatol. 2012;57:260–4.
351. Okamoto S, Hata A, Sadaoka K, Yamanishi K, Mori Y. Comparison of varicella-
zoster virus-specific immunity of patients with diabetes mellitus and healthy
individuals. J Infect Dis. 2009;200:1606–10.
352. Mahajan S, Koranne R, Sharma S. Cutaneous manifestation of diabetes
melitus. Indian J Dermatol Venereol Leprol. 2003;69:105–8.
353. Yang YW, Chen YH, Lin HW. Risk of herpes zoster among patients with
psychiatric diseases: a population-based study. J Eur Acad Dermatol
Venereol. 2011;25:447–53.
354. Lee JY, Yoon NH, Park SD. A clinical study of the nature of pain associated
with herpes zoster. Korean J Dermatol. 2006;44:1298–303.
355. Yang YD, Wu JJ, Bi JJ, Lu YG, Zhu TY. Retrospective study of the
characteristics of postherpetic neuralgia in 178 cases. Chin J Clin Rehab.
2005;9:23–5.
356. Herr H. Prognostic factors of postherpetic neuralgia. J Korean Med Sci. 2002;
17:655–9.
357. Cho SI, Lee CH, Park GH, Park CW, Kim HO. Use of S-LANSS, a tool for
screening neuropathic pain, for predicting postherpetic neuralgia in
patients after acute herpes zoster events: a single-center, 12-month,
prospective cohort study. J Pain. 2014;15:149–56.
358. Zhu SM, Liu YM, An ED, Chen QL. Influence of systemic immune and
cytokine responses during the acute phase of zoster on the development
of postherpetic neuralgia. J Zhejiang Univ Sci B. 2009;10:625–30.
359. Imafuku S, Nakayama J, Higa K, Furue M, Takahara M, Katayama I, et al. One-
year follow-up of zoster-associated pain in 764 immunocompetent patients
with acute herpes zoster treated with famciclovir (FAMILIAR study). J Eur
Acad Dermatol Venereol. 2014;28:1716–22.
360. Kanbayashi Y, Onishi K, Fukazawa K, Okamoto K, Ueno H, Takagi T, et al.
Predictive factors for postherpetic neuralgia using ordered logistic
regression analysis. Clin J Pain. 2012;28:712–14.
361. Zhang DP, He L. Risk factors and prevention measures of postherpetic
neuralgia. Chin J Clin Rehab. 2005;9:118–9.
362. Nithyanandam S, Dabir S, Stephen J, Joseph M. Eruption severity and
characteristics in herpes zoster ophthalmicus: correlation with visual outcome,
ocular complications, and postherpetic neuralgia. Int J Dermatol. 2009;48:484–7.
363. Nahm FS, Kim SH, Kim HS, Shin JW, Yoo SH, Yoon MH, et al. Survey on the
treatment of postherpetic neuralgia in Korea; multicenter study of 1,414
patients. Korean J Pain. 2013;26:21–6.
364. Chen JY, Lan KM, Sheu MJ, Tseng SF, Weng SF, Hu ML. Peptic ulcer as a risk
factor for postherpetic neuralgia in adult patients with herpes zoster. J Med
Virol. 2015;87:222–9.
365. Sumiyama D, Kikkawa EF, Kita YF, Shinagawa H, Mabuchi T, Ozawa A, et al.
HLA alleles are associated with postherpetic neuralgia but not with herpes
zoster. Tokai J Exp Clin Med. 2008;33:150–3.
366. Sato M, Ohashi J, Tsuchiya N, Kashiwase K, Ishikawa Y, Arita H, et al.
Association of HLA-A*3303-B*4403-DRB1*1302 haplotype, but not of TNFA
promoter and NKp30 polymorphism, with postherpetic neuralgia (PHN) in
the Japanese population. Genes Immun. 2002;3:477–81.
367. Ozawa A, Sasao Y, Iwashita K, Miyahara M, Sugai J, Iizuka M, et al. HLA-A33
and -B44 and susceptibility to postherpetic neuralgia (PHN). Tissue Antigens.
1999;53:263–8.
368. Sato-Takeda M, Ihn H, Ohashi J, Tsuchiya N, Satake M, Arita H, et al. The
human histocompatibility leukocyte antigen (HLA) haplotype is associated with
the onset of postherpetic neuralgia after herpes zoster. Pain. 2004;110:329–36.
369. Kirizume K, Imataki O, Shintani T, Fujihara S, Waki F, Ohue Y, et al.
Aggravated post-herpetic neuralgia due to bortezomib. Rinsho Ketsueki.
2008;49:331–4.
370. Choi WS, Kwon SS, Lee J, Choi SM, Lee JS, Eom JS, et al. Immunity and the
burden of herpes zoster. J Med Virol. 2014;86:525–30.
371. Mehta J, Mahajan V, Khanna S. Disseminated zoster with polyneuritis cranialis
and motor radiculopathy: Letter to editor. Neurol India. 2002;50:228–9.
372. Kim SH, Suh MK. The clinical features of herpes zoster ophthalmicus in
inpatients. Korean J Dermatol. 2008;46:1337–43.
373. Ando K, Kohmoto H. Clinical features of herpes zoster ophthalmicus. Jpn J
Clin Ophthalmol. 2000;54:385–7.
Chen et al. BMC Infectious Diseases  (2017) 17:213 Page 30 of 39
374. Amaki S, Suzuki S, Shinbo R, Ando R, Oguchi Y, Shimizu H, et al. A statistical
study of ocular complications of herpes zoster ophthalmicus and its
prolongation factors. Nihon Ganka Gakkai Zasshi. 1995;99:289–95.
375. Yoshida M, Hayasaka S, Yamada T, Yanagisawa S, Hayasaka Y, Nakamura N,
et al. Ocular findings in Japanese patients with varicella-zoster virus
infection. Ophthalmologica. 2005;219:272–5.
376. Kimata N, Nakagawa H, Araki H. Clinical features of herpes zoster keratitis.
Jpn J Clin Ophthalmol. 1996;50:1113–6.
377. Matsuda A, Tagawa Y, Abe N, Tsuda K, Matsuda H. Classification of corneal
complications from varicella zoster virus. Jpn J Clin Ophthalmol. 1995;49:
1519–23.
378. McDonald EM, Patel DV, McGhee CN. A prospective study of the clinical
characteristics of patients with herpes simplex and varicella zoster
keratitis, presenting to a New Zealand emergency eye clinic. Cornea.
2015;34:279–84.
379. Zheng Y, Shi J. Clinical analysis of 58 cases of herpetic keratouveitis. Chin
Ophthalmic Res. 2009;27:809–11.
380. Thean JH, Hall AJ, Stawell RJ. Uveitis in Herpes zoster ophthalmicus. Clin
Experiment Ophthalmol. 2001;29:406–10.
381. Hanajiri M, Matsumoto T, Hatano H, Ohno S. Herpes zoster ophthalmicus
without skin eruptions. Jpn J Clin Ophthalmol. 1994;48:658–60.
382. Kwok SK, Ho PCP, Chau GKO. Herpes zoster ophthalmicus - A family
physician’s perspective. Hong Kong Pract. 2001;23:57–62.
383. Albietz JM, Lenton LM. Late reactivation of herpes zoster keratitis results in
band keratopathy. Optom Vis Sci. 2014;91:e149–55.
384. Cao L. Ophthalmic symptoms in AIDS. Int J Ophthalmol. 2009;9:393–4.
385. Nithyanandam S, Joseph M, Stephen J. Ocular complications and loss of
vision due to herpes zoster ophthalmicus in patients with HIV infection and
a comparison with HIV-negative patients. Int J STD AIDS. 2013;24:106–9.
386. Gupta N, Sachdev R, Sinha R, Titiyal JS, Tandon R. Herpes zoster
ophthalmicus: disease spectrum in young adults. Middle East Afr J
Ophthalmol. 2011;18:178–82.
387. Babu K, Kini R, Philips M, Subbakrishna DK. Clinical profile of isolated viral
anterior uveitis in a South Indian patient population. Ocul Immunol
Inflamm. 2014;22:356–9.
388. Ichikawa T, Sakai J, Yamauchi Y, Minoda H, Usui M. A study of 44 patients
with Kirisawa type uveitis. Nihon Ganka Gakkai Zasshi. 1997;101:243–7.
389. Tan WJ, Poh EW, Wong PY, Ho SL, Lim WK, Teoh SC. Trends in patterns of
anterior uveitis in a tertiary institution in Singapore. Ocul Immunol Inflamm.
2013;21:270–5.
390. Wang TJ, Hu CC, Lin HC. Increased risk of anterior uveitis following herpes
zoster: a nationwide population-based study. Arch Ophthalmol. 2012;
130:451–5.
391. Sims JL, Yeoh J, Stawell RJ. Acute retinal necrosis: A case series with clinical
features and treatment outcomes. Clin Exp Ophthalmol. 2009;37:473–7.
392. Roy R, Pal BP, Mathur G, Rao C, Das D, Biswas J. Acute retinal necrosis:
clinical features, management and outcomes–a 10 year consecutive case
series. Ocul Immunol Inflamm. 2014;22:170–4.
393. Sodeyama H, Todokoro D, Yamada N, Kishi S. Identification of causative
virus and clinical course of acute retinal necrosis. Jpn J Clin Ophthalmol.
2014;68:947–52.
394. Itoh N, Matsumura N, Ogi A, Nishide T, Imai Y, Kanai H, et al. High prevalence
of herpes simplex virus type 2 in acute retinal necrosis syndrome associated
with herpes simplex virus in Japan. Am J Ophthalmol. 2000;129:404–5.
395. Grover R, Ratho RK, Gupta V, Mahajan RC, Gupta A. Role of viral serology in
the diagnosis of acute retinal necrosis syndrome. Ind J Pathol Microbiol.
2002;45:269–71.
396. Madhavan HN. Laboratory investigations on viral and Chlamydia trachomatis
infections of the eye: Sankara Nethralaya experiences. Indian J Ophthalmol.
1999;47:241–6.
397. Mizuuchi K, Namba K, Kotake S, Ohno S. Clinical features of acute retinal
necrosis at Hokkaido University Hospital. Nihon Ganka Gakkai Zasshi.
2008;112:136–40.
398. Shimakawa M, Sato N. A case of AIDS complicated by progressive outer
retinal necrosis. Nihon Ganka Gakkai Zasshi. 1999;103:137–43.
399. Sittivarakul W, Aui-aree N. Clinical features, management and outcomes of
progressive outer retinal necrosis (PORN) in southern Thailand. J Med Assoc
Thai. 2009;92:360–6.
400. Oshitari K, Arimoto H, Suzuki S, Oguchi Y. Rapidly progressive outer retinal
necrosis in a patient with acquired immunodeficiency syndrome. Nihon
Ganka Gakkai Zasshi. 1994;98:1141–6.
401. Gill H, Cheung J, Wong I, Lie AK, Kwong YL. Varicella zoster virus progressive
outer retinal necrosis after allogeneic haematopoietic stem cell transplantation.
Br J Haematol. 2012;157:279.
402. Kim SJ, Park SJ, Yu HG, Kim NJ, Jang HC, Oh MD. Ocular manifestations of
acquired immunodeficiency syndrome in Korea. J Korean Med Sci. 2012;27:542–6.
403. Lim WK, Chee SP, Nussenblatt RB. Progression of varicella-zoster virus
necrotizing retinopathy in an HIV-negative patient with transient immune
deviation. Graefes Arch Clin Exp Ophthalmol. 2005;243:607–9.
404. Tseng CC, Chen SN, Hwang JF, Lin CJ, Chen HS. Progressive outer retinal
necrosis associated with occlusive vasculitis in acquired immunodeficiency
syndrome. J Formos Med Assoc. 2015;114:469–72.
405. Inoue Y, Takano M, Kawai H, Ichibe Y, Shimizu K. Progressive outer retinal necrosis
in a patient with interstitial nephritis. Jpn J Clin Ophthalmol. 2006;60:1087–90.
406. Miyaoka Y, Suzuki J, Yamauchi Y, Goto H. A bilateral case of progressive
outer retinal necrosis with retinal detachment resistant to antiviral
treatments. Jpn J Clin Ophthalmol. 2008;62:489–92.
407. Ozaki H, Jane H, Inoue H, Kozawa M, Kondo H, Uchio E. Outcome of
treatment for acute retinal necrosis. Jpn J Clin Ophthalmol. 2011;65:1819–25.
408. Hong J. Discuss on the diagnosis and treatment of viral cornea endotheliitis.
Ophthalmol China. 2010;19:158–60.
409. Wang AG, Liu JH, Hsu WM, Lee AF, Yen MY. Optic neuritis in herpes zoster
ophthalmicus. Jpn J Ophthalmol. 2000;44:550–4.
410. Menon V, Kumar G, Tandon R. Optic neuropathy secondary to herpes zoster
ophthalmicus. Indian J Ophthalmol. 1995;43:78–9.
411. Suraiya MS, Norazlina B, Carmen C, Muhaya M. Bilateral optic neuritis in
pregnancy. Med J Malaysia. 2003;58:771–3.
412. Obata H, Yamagami S, Saito S, Sakai O, Tsuru T. A case of acute dacryoadenitis
associated with herpes zoster ophthalmicus. Jpn J Ophthalmol. 2003;47:107–9.
413. Yokoyama C, Mori S, Kamada A, Kase S, Ishida S. A case of herpes zoster
ophthalmicus with acute dacryoadenitis as the initial manifestation. Jpn J
Clin Ophthalmol. 2011;65:945–8.
414. Yong VK, Yip CC, Yong VS. Herpes zoster ophthalmicus and the superior
orbital fissure syndrome. Singapore Med J. 2001;42:485–6.
415. Bourke RD, Pyle J. Herpes zoster ophthalmicus and the orbital apex
syndrome. Aust New Zealand J Ophthalmol. 1994;22:77–80.
416. Saxena R, Phuljhele S, Aalok L, Sinha A, Menon V, Sharma P, et al. A rare
case of orbital apex syndrome with herpes zoster ophthalmicus in a human
immunodeficiency virus-positive patient. Indian J Ophthalmol. 2010;58:527–30.
417. Biswas J, Deka S, Padmaja S, Madhavan HN, Kumarasamy N, Solomon S.
Central retinal vein occlusion due to herpes zoster as the initial presenting
sign in a patient with acquired immunodeficiency syndrome (AIDS). Ocul
Immunol Inflamm. 2001;9:125–30.
418. Min SU, Li K, Won CH, Cho S, Huh CH, Kim BJ, et al. Clinical analysis of
Ramsay Hunt syndrome. Korean J Dermatol. 2007;45:1121–6.
419. Gondivkar S, Parikh V, Parikh R. Herpes zoster oticus: A rare clinical entity.
Contemp Clin Dent. 2010;1:127–9.
420. Murakami S, Hato N, Horiuchi J, Miyamoto Y, Aono H, Honda N, et al.
Clinical features and prognosis of facial palsy and hearing loss in patients
with Ramsay Hunt syndrome. J Otolaryngol Jpn. 1996;99:1772–9.
421. Ou CY, Chao WY. Herpes zoster oticus. J Otolaryngol Soc Repub China.
1997;32:379–85.
422. Hung CW, Wang SJ, Chen SP, Lirng JF, Fuh JL. Trigeminal herpes zoster and
Ramsay Hunt syndrome with a lesion in the spinal trigeminal nucleus and
tract. J Neurol. 2010;257:1045–46.
423. McCullough MJ, Savage NW. Oral viral infections and the therapeutic use of
antiviral agents in dentistry. Aust Dent J. 2005;50 Suppl 2:S31–5.
424. Sengoku R, Yaguchi H, Matsushima S, Mochio S. Zoster sine herpete:
detection by skin exudates and contrast magnetic resonance imaging. Eur
Neurol. 2012;67:154.
425. Lu YC, Young YH. Vertigo from herpes zoster oticus: superior or inferior
vestibular nerve origin? Laryngoscope. 2003;113:307–11.
426. Isawa M. Unilateral deafness and vestibular dysfunction caused by herpes
zoster virus. Otolaryngol Head Neck Surg Tokyo. 2001;73:938–41.
427. Shim HJ, Jung H, Park DC, Lee JH, Yeo SG. Ramsay Hunt syndrome with
multicranial nerve involvement. Acta Oto-Laryngol. 2011;131:210–5.
428. Lee HH, Huang LK, Hu CJ, Chen CC. Atypical Ramsay Hunt syndrome. Acta
Neurol Taiwan. 2014;23:80–1.
429. Miyazaki Y, Tajima Y, Sudo K, Matsumoto A, Kikuchi S, Tashiro K. A case of
Ramsay Hunt syndrome initiated with hoarseness and dysphagia:
Consideration on spreading mechanisms of cranial neuropathy. Clin
Neurol. 2002;42:855–8.
Chen et al. BMC Infectious Diseases  (2017) 17:213 Page 31 of 39
430. Choi HN, Kim JE, Chung DY, Park SY, Oh JH. Herpes zoster oticus with
cranial polyneuropathy without involvement of facial nerve. Korean J
Audiol. 2011;15:155–8.
431. Sun WL, Yan JL, Chen LL. Ramsay Hunt syndrome with unilateral
polyneuropathy involving cranial nerves V, VII, VIII, and XII in a diabetic
patient. Quintessence Int. 2011;42:873–7.
432. Sakane S, Enomoto H, Tamaki N, Oridate N. Cases of laryngeal paralysis
caused by the varicella-zoster virus (VZV). Pract Oto-Rhino-Laryngol.
2014;107:399–404.
433. Kato T. Vocal cord paralysis caused by varicella zoster virus. Otolaryngol
Head Neck Surg Tokyo. 2005;77:389–91.
434. Wu CL, Linne OC, Chiang CW. Herpes zoster laryngis with prelaryngeal skin
erythema. Ann Otol Rhinol Laryngol. 2004;113:113–4.
435. Morinaka S. Herpes zoster laryngitis with intractable hiccups. Auris Nasus
Larynx. 2009;36:606–8.
436. Tamakawa S, Takada M. A case of herpes zoster affecting the
glossopharyngeal nerve. J Anesth. 1999;13:230–2.
437. Ling B, Novakovic D, Sulica L. Cough after laryngeal herpes zoster: a new
aspect of post-herpetic sensory disturbance. J Laryngol Otol. 2014;128:209–11.
438. Yoshida T, Fujisaki N, Nakachi R, Sueyoshi T, Suwazono S, Suehara M.
Persistent hiccups and vomiting with multiple cranial nerve palsy in a case
of zoster sine herpete. Intern Med. 2014;53:2373–6.
439. Shim JH, Park JW, Kwon BS, Ryu KH, Lee HJ, Lim WH, et al. Dysphagia in
Ramsay Hunt's Syndrome - A Case Report -. Ann Rehabil Med. 2011;35:738–41.
440. Ono N, Sakabe A, Nakajima M. Herpes zoster oticus-associated jugular
foramen syndrome. Brain Nerve. 2010;62:81–4.
441. Fang CW, Lin CC. Ramsay Hunt syndrome with hemiparesis and
hemihypoesthesia: report of 2 cases. Acta Neurol Taiwan. 2009;18:276–80.
442. Furuta Y, Ohtani F, Kawabata H, Fukuda S, Bergström T. High
prevalence of varicella-zoster virus reactivation in herpes simplex virus-
seronegative patients with acute peripheral facial palsy. Clin Infect Dis.
2000;30:529–33.
443. Kawaguchi K, Inamura H, Abe Y, Koshu H, Takashita E, Muraki Y, et al.
Reactivation of herpes simplex virus type 1 and varicella-zoster virus and
therapeutic effects of combination therapy with prednisolone and
valacyclovir in patients with Bell's palsy. Laryngoscope. 2007;117:147–56.
444. Terada K, Niizuma T, Kawano S, Kataoka N, Akisada T, Orita Y. Detection of
varicella-zoster virus DNA in peripheral mononuclear cells from patients with
Ramsay Hunt syndrome or zoster sine herpete. J Med Virol. 1998;56:359–63.
445. Takahash K, Aono T, Shichinohe M, Tamura M, Iwata Y, Yamanishi K, et al.
Herpesvirus DNA in peripheral blood mononuclear cells of some patients
with Meniere's disease. Microbiol Immunol. 2001;45:635–8.
446. Yazawa Y, Suzuki M, Hanamitsu M, Kimura H, Tooyama I. Detection of viral
DNA in the endolymphatic sac in Ménière's disease by in situ hybridization.
ORL J Otorhinolaryngol Relat Spec. 2003;65:162–8.
447. Hoshino C, Yamabe A. Where is reactivation after a long latency? BMJ Case
Rep. 2012; doi:10.1136/bcr.01.2012.5538.
448. Son HH, Sim HS, Lee SK. Clinical study of motor paresis in in-patients with
herpes zoster. Korean J Dermatol. 2011;49:961–8.
449. Gopal KVT, Sarvani D, Krishnam Raju PV, Rao GR, Venkateswarlu K. Herpes
zoster motor neuropathy: A clinical and electrophysiological study. Indian J
Dermatol Venereol Leprol. 2010;76:569–71.
450. Takahashi T, Tamura M, Miki K, Yamaguchi M, Kanno A, Nunomura S, et
al. Varicella zoster virus myelitis in two elderly patients: diagnostic value
of nested polymerase chain reaction assay and antibody index for
cerebrospinal fluid specimens. Case Rep Neurol. 2013;5:81–90.
451. Liu W, Zhu YY, Jiang FX, He J, Hu B. A case of systemic lupus erythematosus
with herpes zoster myelitis. J Clin Dermatol. 2013;42:412–3.
452. Ong OL, Churchyard AC, New PW. The importance of early diagnosis of
herpes zoster myelitis. Med J Aust. 2010;193:546–7.
453. Mehndiratta MM, Bansal J, Gupta M, Puri V. Herpes zoster cervical myelitis in
an immunocompetent subject. Neurol India. 2000;48:189–90.
454. Akiyama N. Herpes zoster infection complicated by motor paralysis. J Dermatol.
2000;27:252–7.
455. Tak WJ, Chong YS, Seo SJ, Hong CK. A case of motor paralysis caused by
herpes zoster. Korean J Dermatol. 2002;40:1157–60.
456. Shin SJ, Yoo CS, Kil MS, Kim CW, Kim SS. A case of motor paralysis of the
limb caused by herpes zoster. Korean J Dermatol. 2012;50:621–3.
457. Fujimoto S, Matsuno O, Matsumoto T, Kumamoto T, Tsuda T. A case of
diaphragmatic paralysis following herpes zoster. Clin Neurol. 1996;36:
345–7.
458. Her Y, Kim CW, Kim SS. A clinical study of motor involvement by herpes
zoster. Korean J Dermatol. 2010;48:468–73.
459. Lee CC, Wu JC, Huang WC, Shih YH, Cheng H. Herpes zoster cervical
myelitis in a young adult. J Chin Med Assoc. 2010;73:605–10.
460. Hosaka A, Nakamagoe K, Watanabe M, Tamaoka A. Magnetic resonance
images of herpes zoster myelitis presenting with Brown-Séquard syndrome.
Arch Neurol. 2010;67:506.
461. Lee MH, Song JH, Lee DI, Ahn HS, Park JW, Cha YD. Newly developed
urinary retention and motor weakness of lower extremities in a
postherpetic neuralgia patient. Korean J Pain. 2013;26:76–9.
462. Tseng YH. Acute orbital myositis heralding herpes zoster ophthalmicus:
report of a case. Acta Neurol Taiwan. 2008;17:47–9.
463. Kang JH, Sheu JJ, Lin HC. Increased risk of Guillain-Barré Syndrome
following recent herpes zoster: a population-based study across Taiwan.
Clin Infect Dis. 2010;51:525–30.
464. Wakasugi K, Imaizumi T, Nishimura Y, Fujimoto H, Ayabe M, Shoji H, et al.
Guillain-Barré syndrome associated with herpes zoster. Intern Med.
2001;40:552.
465. Nagane Y, Utsugisawa K, Obara D. A case of herpes zoster associated
Guillain-Barré syndrome with a relapse of eruptions after intravenous
immunoglobulin therapy. Clin Neurol. 2006;46:664–7.
466. Sheu JJ, Keller JJ, Lin HC. Increased risk of cancer after Bell's palsy: a 5-year
follow-up study. J Neurooncol. 2012;110:215–20.
467. Sanjay S, Chan EW, Gopal L, Hegde SR, Chang BC. Complete unilateral
ophthalmoplegia in herpes zoster ophthalmicus. J Neuroophthalmol.
2009;29:325–37.
468. Shin HM, Lew H, Yun YS. A case of complete ophthalmoplegia in herpes
zoster ophthalmicus. Korean J Ophthalmol. 2005;19:302–4.
469. Sato R, Yamada M, Tamai K. Total ophthalmoplegia in a case of herpes
zoster ophthalmicus. Jpn J Clin Ophthalmol. 2008;62:1279–83.
470. Im M, Kim BJ, Seo YJ, Park JK, Lee JH. Complete ophthalmoplegia after
herpes zoster. Clin Exp Dermatol. 2007;32:162–4.
471. Nakazawa T, Omura M, Sugita R. A case of herpes zoster ophthalmicus with
total ophthalmoplegia. Jpn J Clin Ophthalmol. 1998;52:1933–7.
472. Ying XH, Wagle AM, Tan L, Sanjay S, Hedge SR, Chew YC, et al. A rare case
of herpes zoster ophthalmicus with complete ophthalmoplegia. J Am
Geriatr Soc. 2008;56:2160–2.
473. Jang SJ, Choe YB, Ahn KJ. A Case of motor paralysis caused by herpes
zoster. Korean J Dermatol. 2004;42:236–8.
474. Tam TC, Chan KY, Ho SL, Luk JK, Chu LW. Herpetic shoulder paresis in a
Chinese elderly patient. Hong Kong Med J. 2005;11:399–402.
475. Kang SH, Song HK, Jang Y. Zoster-associated segmental paresis in a patient
with cervical spinal stenosis. J Int Med Res. 2013;41:907–13.
476. Siddalingappa K, Lokanatha K. Segmental motor paralysis of the right
upper limb in herpes zoster. Indian J Dermatol Venereol Leprol. 2006;
72:252.
477. Wu CM, Hsu CY, Shie HH. Herpes zoster motor neuropathy in an elderly
man. Eur Geriatr Med. 2014;5:216–7.
478. Kawajiri S, Tani M, Noda K, Fujishima K, Hattori N, Okuma Y. Segmental
zoster paresis of limbs: report of three cases and review of literature.
Neurologist. 2007;13:313–7.
479. Namekawa M, Kameda T, Kumabe A, Mise J. Segmental zoster paresis of the
right shoulder. Intern Med. 2013;52:2839.
480. Fabian VA, Wood B, Crowley P, Kakulas BA. Herpes zoster brachial plexus
neuritis. Clin Neuropathol. 1997;16:61–4.
481. Choi JY, Kang CH, Kim BJ, Park KW, Yu SW. Brachial plexopathy following
herpes zoster infection: two cases with MRI findings. J Neurol Sci.
2009;285:224–6.
482. Bessho M, Nakajima H, Ito T, Kitaoka H. A case of incomplete Brown-Séquard
syndrome after thoracic herpes zoster infection. Clin Neurol. 2010;50:175–89.
483. Seo DH, Lee SJ, Hyun JK, Kim TU. A case of herpes zoster peripheral
polyneuropathy manifested by foot drop in chronic myeloid leukemia. Ann
Rehabil Med. 2012;36:724–8.
484. Kim JB, Jung HJ, Lee JM, Im KS, Joo CH, Kim JW. Disseminated herpes zoster
with a zoster paresis-induced femoral fracture. Geriatr Gerontol Int.
2012;12:168–71.
485. Kim SY, Hwang KE, Jung JH, Park JH, Kim HJ, Kim HR, et al.
Diaphragmatic paralysis following cervical herpes zoster. Tuberc Respir
Dis. 2006;61:80–2.
486. Koh YM, Baik JJ, Woo SI, Park KW, Chung Y. Diaphragmatic paralysis induced
by herpes zoster. Tuberc Respir Dis. 1996;43:92–5.
Chen et al. BMC Infectious Diseases  (2017) 17:213 Page 32 of 39
487. Lin CM, Shieh WB, Chiang PC, Shieh MG, Liu YC, Chiou CC, et al. An unusual
cause of dyspnea in a patient with cervical herpes zoster. J Clin Neurosci.
2012;19:608–9.
488. Zhou SR, Liu CY. A case report of abdominal distention caused by herpes
zoster. World J Gastroenterol. 2012;18:4627–8.
489. Lee UH, Park HS, Choi JC, Chun DK. A case of abdominal protrusion caused
by herpes zoster. Korean J Dermatol. 2004;42:659–61.
490. Chang TCC, Chin YY, Lan CCE. Herpes zoster with autonomic dysregulation
presented as alteration in local microcirculation: A case report. Dermatol Sin.
2011;29:72–4.
491. Sharma PK, Gautam RK, Basistha C, Jain RK, Kar HK. Abdominal hernia
following abdominal herpes zoster. Indian J Dermatol Venereol Leprol.
2001;67:39–40.
492. Tashiro S, Akaboshi K, Kobayashi Y, Mori T, Nagata M, Liu M. Herpes zoster-
induced trunk muscle paresis presenting with abdominal wall
pseudohernia, scoliosis, and gait disturbance and its rehabilitation: a case
report. Arch Phys Med Rehabil. 2010;91:321–5.
493. Kim ED, Kang BG, Kim JH, Roh M, Jo DH. Abdominal distention and
constipation followed by herpes zoster infection. Korean J Anesthesiol.
2013;65 Suppl 6:S143–4.
494. Maeda K, Furukawa K, Sanada M, Kawai H, Yasuda H. Constipation and
segmental abdominal paresis followed by herpes zoster. Intern Med.
2007;46:148–8.
495. Kim JH, Lee SH, Na GJ, Lee SJ, Jo YG, Lee TH, et al. A rare case of Ogilvie
syndrome associated with herpes zoster. Intest Res. 2012;10:379–82.
496. Hiramatsu S, Nebiki H, Ueno A, Wakahara Y, Maruyama H, Suekane T, et al. A
case of paralytic ileus associated with varicella zoster virus infection. Nihon
Shokakibyo Gakkai Zasshi. 2013;110:1007–13.
497. Imafuku S, Takahara M, Uenotsuchi T, Iwato K, Furue M. Herpes zoster-
associated voiding dysfunction in hematopoietic malignancy patients. Int J
Dermatol. 2008;47:36–9.
498. Chen PH, Hsueh HF, Hong CZ. Herpes zoster-associated voiding
dysfunction: a retrospective study and literature review. Arch Phys Med
Rehabil. 2002;83:1624–8.
499. Tsai HN, Wu WJ, Huang SP, Su CM, Chen CC, Wang CJ, et al. Herpes zoster
induced neuropathic bladder–a case report. Kaohsiung J Med Sci. 2002;18:39–44.
500. Hiraga A, Nagumo K, Sakakibara R, Kojima S, Fujinawa N, Hashimoto T. Loss
of urinary voiding sensation due to herpes zoster. Neurourol Urodyn. 2003;
22:335–7.
501. Matsuo T, Oba K, Miyata Y, Igawa T, Sakai H. Four cases of urinary dysfunction
associated with sacral herpes zoster. Acta Urol Jpn. 2014;60:87–90.
502. Addison B, Harvey M. Herpes zoster-induced acute urinary retention. Emerg
Med Australas. 2013;25:279–81.
503. Yamanishi T, Yasuda K, Sakakibara R, Hattori T, Uchiyama T, Minamide M, et
al. Urinary retention due to herpes virus infections. Neurourol Urodyn. 1998;
17:613–9.
504. Fukao M, Isogai R, Kawada A, Shimizu N, Matsumoto S. Herpes zoster
associated with bladder/rectum symptom. Skin Res. 2005;4:386–9.
505. Matsumoto H, Shimizu T, Tokushige S, Mizuno H, Igeta Y, Hashida H. Rectal
ulcer in a patient with VZV sacral meningoradiculitis (Elsberg syndrome).
Intern Med. 2012;51:651–4.
506. Chen JH, Chen KY. Acute sciatica in a patient with herpes zoster infection.
Acta Clin Belg. 2011;66:70–1.
507. Kang JH, Ho JD, Chen YH, Lin HC. Increased risk of stroke after a herpes
zoster attack: a population-based follow-up study. Stroke. 2009;40:3443–8.
508. Lin HC, Chien CW, Ho JD. Herpes zoster ophthalmicus and the risk of stroke:
a population-based follow-up study. Neurology. 2010;74:792–7.
509. Chen WH, Chui C, Yin HL. Zoster sine herpete, vertebral artery stenosis, and
ischemic stroke. J Stroke Cerebrovasc Dis. 2013;22:e234–7.
510. Verma R, Lalla R, Patil TB. Extensive extracranial and intracranial Varicella
zoster vasculopathy. BMJ Case Rep. 2012; doi:10.1136/bcr-2012-006845.
511. Hoshino S, Hayashi A, Yoshizawa T, Tamaoka A, Shoji S. A case of delayed
cerebral infarction occurring in puerperium preceded by herpes zoster
ophthalmicus in late pregnancy. No To Shinkei. 1999;51:529–33.
512. Kim MJ, Lee KO, Lee KY, Oh SH, Na SJ, Yoon B, et al. Hemichorea caused by
intracranial hemorrhage following contralateral herpes zoster ophthalmicus.
J Clin Neurosci. 2013;20:738–9.
513. Song HJ, Hong WK, Lee HS, Choi GS, Shin JH. Herpes zoster complicated by
delayed intracranial haemorrhage. Clin Exp Dermatol. 2009;34:518–9.
514. Verma R, Singh D, Sharma P. Contralateral stroke with rapid recovery in a
patient of herpes zoster ophthalmicus. Neurol Asia. 2011;16:247–50.
515. Kalita J, Das M, Misra UK. Herpes zoster ophthalmicus leading to middle
cerebral artery infarction: A case report. Int J Angiol. 2004;13:51–3.
516. Fukutake T, Hatakeyama H, Shinotoh H, Hattori T. Herpes zoster
ophthalmicus and delayed contralateral hemiparesis: a case of ipsilateral
midbrain involvement. Eur Neurol. 1998;40:57–8.
517. Lee SJ, Lee DG. Isolated gait ataxia as a sole manifestation of right lateral
medullary infarct following ipsilateral trigeminal herpes zoster. Case Rep
Neurol. 2014;6:193–6.
518. Yasuda C, Okada K, Ohnari N, Akamatsu N, Tsuji S. Cerebral infarction and
intracranial aneurysm related to the reactivation of varicella zoster virus in a
Japanese acquired immunodeficiency syndrome (AIDS) patient. Clin Neurol.
2013;53:701–5.
519. Bhat G, Mathur DS, Saxena GN, Jain S, Singh AP, Bhaduria D. Granulomatous
angiitis of the central nervous system associated with herpes zoster. J Assoc
Physicians India. 2002;50:977–8.
520. Vibha D, Prabhakar S, Khurana D, Khandelwal N. Varicella zoster vasculopathy
presenting as lateral medullary syndrome. J Neurovirol. 2012;18:538–40.
521. Nagafuchi M, Nagafuchi Y, Sato R, Imaizumi T, Ayabe M, Shoji H, et al. Adult
meningism and viral meningitis, 1997–2004: Clinical data and cerebrospinal
fluid cytokines. Intern Med. 2006;45:1209–12.
522. Fujita H, Kurokawa S, Imaizumi S, Kawasaki H, Harada K. Two cases of
meningitis developed while undergoing therapy for herpes zoster.
Nishinihon J Dermatol. 1994;56:992–5.
523. Takeshima S, Neshige S, Himeno T, Hara N, Yoshimoto T, Takamatsu K, et al.
Clinical, epidemiological, and etiological studies of aseptic meningitis in
adults. Clin Neurol. 2014;54:791–7.
524. Choi R, Kim GM, Jo IJ, Sim MS, Song KJ, Kim BJ, et al. Incidence and clinical
features of herpes simplex viruses (1 and 2) and varicella-zoster virus
infections in an adult Korean population with aseptic meningitis or
encephalitis. J Med Virol. 2014;86:957–62.
525. Srivastava T, Nagpal K. Herpes zoster meningoencephalitis complicated with
peripheral vascular disease: an uncommon presentation of a common
disease. Scand J Infect Dis. 2014;46:716–8.
526. Ohtomo R, Shirota Y, Iwata A, Shimizu J, Tsuji S. Cerebral microbleeding in
varicella-zoster viral meningitis: an early sign of vasculopathy? Neurology.
2014;82:814–5.
527. Park HK, Lee JH. A case of ramsay hunt syndrome complicated by
cerebellitis. J Clin Neurol. 2006;2:198–201.
528. Saxena A, Khiangte B, Tiewsoh I, Jajoo UN. Herpes zoster encephalitis
presenting as multiple cerebral hemorrhages - a rare presentation: a case
report. J Med Case Rep. 2013;7:155.
529. Baek W, Lee SG, Kim YS, Kim JH, Jun JB, Kim HY. Fatal varicella-zoster virus
vasculopathy associated with adalimumab therapy. Arch Neurol. 2012;69:1193–6.
530. Sasson SC, Oon A, Chagantri J, Brew BJ, Carr A. Posterior reversible
encephalopathy syndrome (PRES) in an HIV-1 infected patient with
disseminated varicella zoster virus: a case report. BMC Infect Dis.
2013;13:396.
531. Wang L, Holthaus EA, Jimenez XF, Tavee J, Li Y. MRI evolution of CLIPPERS
syndrome following herpes zoster infection. J Neurol Sci. 2015;348:277–8.
532. McKelvie PA, Collins S, Thyagarajan D, Trost N, Sheorey H, Byrne E.
Meningoencephalomyelitis with vasculitis due to varicella zoster virus: a
case report and review of the literature. Pathology. 2002;34:88–93.
533. Douglas A, Harris P, Francis F, Norton R. Herpes zoster meningoencephalitis:
Not only a disease of the immunocompromised? Infection. 2010;38:73–5.
534. Sugisaki K, Yoshida H. Varicella zoster virus meningoencephalitis
accompanied by sporadic skin lesions in an older immunocompetent adult.
J Infect Chemother. 2007;13:270–2.
535. Chun WC, Kin MT, Wing KT, Tin CL, Wai KK. Hypoglycorrhachia in herpes
zoster associated encephalitis of an immunocompetent young male: An
unusual presentation. J Neurol. 2005;252:987–8.
536. Miyazaki Y, Riku Y, Goto Y, Mano K, Yoshida M, Hashizume Y. VZV
vasculopathy associated with myelo-radiculoganglio-meningo-encephalitis:
an autopsy case of an immunocompetent 66-year-old male. J Neurol Sci.
2008;275:42–5.
537. Byun JW, Song HJ, Choi GS, Shin JH. A clinical study on herpes zoster
meningoencephalitis. Korean J Dermatol. 2011;49:328–33.
538. Yoshifuku A, Ueki Y, Tamai M, Miyoshi H, Higashi Y, Kanekura T, et al. A case
of herpes zoster associated with meningoencephalitis. Nishinihon J
Dermatol. 2009;71:494–6.
539. Pandey PK, Garg D, Bhatia A, Jain V. Horner’s syndrome and sixth nerve
palsy due to herpes zoster ophthalmicus arteritis. Eye. 2005;19:224–6.
Chen et al. BMC Infectious Diseases  (2017) 17:213 Page 33 of 39
540. Kobayashi Y, Yamamoto T. A case of Horner’s syndrome associated with
ophthalmic herpes zoster. Clin Neurol. 2007;47:105–8.
541. Tsuda H, Tanaka K. Internal carotid artery involvement in herpes zoster
ophthalmicus. Intern Med. 2012;51:2067–8.
542. Nishitani M, Kodama T, Ohashi Y, Tatematsu Y, Maruo H. A case of
cavernous sinus syndrome following herpes zoster ophthalmicus. Folia
Ophthalmol Jpn. 2002;53:898–903.
543. Cho BJ, Kim JS, Hwang JM. Horner’s syndrome and contralateral abducens nerve
palsy associated with zoster meningitis. Korean J Ophthalmol. 2013;27:474–7.
544. Camuglia JE, Beltz JE, Khurana K, Hall AJ. An unusual cause of visual loss
after Herpes zoster ophthalmicus: a case report. Cases J. 2010;3:17.
545. Roberts TV, Francis IC, Kappagoda MB, Dick AD. Herpes zoster
chorioretinopathy. Eye (Lond). 1995;9:594–8.
546. Wang CC, Lin CL, Chang YJ, Wang GJ, Sung FC, Kao CH. Herpes zoster
infection associated with acute coronary syndrome: a population-based
retrospective cohort study. Br J Dermatol. 2014;170:1122–9.
547. Wu PY, Lin CL, Sung FC, Chou TC, Lee YT. Increased risk of cardiovascular
events in patients with herpes zoster: a population-based study. J Med Virol.
2014;86:772–7.
548. Maity PK, Chakrabarti N, Mondal M, Patar K, Mukhopadhyay M. Deep vein
thrombosis: A rare signature of herpes zoster. J Assoc Physicians India.
2014;62:72–4.
549. Kundu AK. Herpes zoster-induced myocarditis in a patient with diabetes
mellitus. J Assoc Physicians India. 1999;47:286–7.
550. Cheung MY, Viney M. A unique case of recurrent asystole secondary to
paroxysmal pain of acute herpetic ophthalmicus. Anesth Analg. 2007;105:
1127–9.
551. Kume T, Hirose M, Yamashita T, Mizuno S, Hosokawa T, Sekimoto M, et al.
Analysis of blood pressure in elderly patients with postherpetic neuralgia.
Pain Clinic. 2001;13:153–7.
552. Lee HW, Kim KJ, Chang SE, Lee MW, Choi JH, Moon KC, et al. A case of
generalized herpes zoster associated with herpetic folliculitis and syringitis.
Korean J Dermatol. 2005;43:274–6.
553. Park JS, Ryu H, Ha SH, Park HS, Lee J, Son SJ. Two cases of herpetic
syringitis. Korean J Dermatol. 2002;40:1449–51.
554. Tanaka A, Hayaishi N, Kondo Y, Kurachi K, Tanemura A, Katayama I. Severe
gangrene accompanied by varicella zoster virus-related vasculitis mimicking
rheumatoid vasculitis. Case Rep Dermatol. 2014;6:103–7.
555. Khong JJ, Casson RJ, Huilgol SC, Selva D. Madarosis. Surv Ophthalmol. 2006;
51:550–60.
556. Baek JH, Hong KC, Lee DY, Kim MS, Lee UH, Park HS. Alopecia areata
associated with Herpes zoster. J Dermatol. 2013;40:672.
557. Garg P, Mathur U, Athmanathan S, Rao GN. Treatment outcome of
Moraxella keratitis: our experience with 18 cases–a retrospective review.
Cornea. 1999;18:176–81.
558. Yang SC, Ho HC, Lay CJ, Tsai CC. Aspergillus invasive otitis externa as a
complication of herpes zoster oticus. Tzu Chi Med J. 2011;23:28–30.
559. Seo JK, Lee SM, Lee SK. Clinical observation of bacterial studies in the skin
lesions of patients with herpes zoster. Korean J Dermatol. 2007;45:1031–40.
560. Yamada Y, Ito R, Bito M, Tashima S, Sakamoto K, Konishi K. A case of
subcutaneous abscess at the site of herpes zoster in a patient with poorly
controlled diabetes. Skin Res. 2014;13:13–5.
561. Jarrett P, Ha T, Oliver F. Necrotizing fasciitis complicating disseminated
cutaneous herpes zoster. Clin Exp Dermatol. 1998;23:87–8.
562. Ong CW, Ang BS, Lee CC. Severe varicella infection occurring after herpes
zoster reactivation in a patient with AIDS. BMJ Case Rep. 2009; doi:10.1136/
bcr.09.2008.0952
563. Gupta S, Gupta S, Thomas M, Mahendra A, Jindal N, Bhaskar G, et al. Herpes
Zoster with disseminated lesions. What is it? J Med Life. 2013;6:84–5.
564. Garg G, Thami GP. Psoriasis herpeticum due to varicella zoster virus: A
Kaposi's varicelliform eruption in erythrodermic psoriasis. Indian J Dermatol.
2012;57:213–4.
565. Gupta S. Many faces of Koebner phenomenon in psoriasis. Indian J
Dermatol Venereol Leprol. 2002;68:222–4.
566. Terao M, Tanemura A, Katayama I. Vitiligo exacerbated after herpes zoster. J
Dermatol. 2012;39:938–9.
567. Huang CW, Tu ME, Wu YH, Lin YC. Isotopic response of fungal granuloma
following facial herpes zoster infections - report of three cases. Int J
Dermatol. 2007;46:1141–5.
568. Ghorpade A. Wolf’s isotopic response - Furuncles at the site of healed
herpes zoster in an Indian male. Int J Dermatol. 2010;49:105–7.
569. Kim SM, Lee SY, Rhee CH, Lee JS, Yun SK, Kim HU, et al. A case of papular
granuloma annulare occurring on the site of herpes zoster: Isotopic
response. Korean J Dermatol. 2008;46:818–20.
570. Ohata C, Shirabe H, Takagi K, Kawatsu T. Granuloma annulare in herpes
zoster scars. J Dermatol. 2000;27:166–9.
571. Wang T, Liu YH, Zheng HY, Yu BT, Fang K. A case of nonspecific granulomatous
perivasculitis on herpes zoster scars. J Clin Dermatol. 2010;39:163–4.
572. Inaoka M, Kano Y, Horie C, Shiohara T. Cutaneous granulomatous reaction
after herpes zoster in drug-induced hypersensitivity syndrome. Am J
Dermatopathol. 2011;33:872–4.
573. Suh KS, Choi SY, Jeon YS, Sim HJ, Kim ST. A case of granuloma annulare
occurring on herpes zoster. Korean J Dermatol. 2005;43:834–6.
574. Chang SE, Bae GY, Moon KC, Do SH, Lim YJ. Subcutaneous granuloma
annulare following herpes zoster. Int J Dermatol. 2004;43:298–9.
575. Ohmori S, Sugita K, Ikenouchi-Sugita A, Nakamura M. Erythema annulare
centrifugum associated with herpes zoster. J UOEH. 2012;34:225–9.
576. Sugita K, Kabashima K, Tokura Y. Erythema annulare centrifugum associated
with herpes zoster. Eur J Dermatol. 2008;18:205–6.
577. Lee HW, Lee DK, Rhee DY, Chang SE, Choi JH, Moon KC, et al. Erythema
annulare centrifugum following herpes zoster infection: Wolf’s isotopic
response? Br J Dermatol. 2005;153:1241–3.
578. Onishi I, Kishimoto S. Erythema multiforme after resolution of herpes zoster
by acyclovir. Eur J Dermatol. 2002;12:370–2.
579. Kim JS, Kim MH, Choi HY, Myung KB. A Case of zosteriform lichen planus
occurring on herpes zoster lesions. Korean J Dermatol. 2004;42:217–9.
580. Choi HJ, Chang SE, Lee MW, Choi JH, Moon KC, Koh JK. A case of
zosteriform lichen planus on the site of healed herpes zoster: Wolf’s isotopic
response. Korean J Dermatol. 2004;42:456–9.
581. Noh TW, Park SH, Kang YS, Lee UH, Park HS, Jang SJ. Morphea developing
at the site of healed herpes zoster. Ann Dermatol. 2011;23:242–5.
582. Qu T, Fang K. Bullous morphea arising at the site of a healed herpes zoster.
J Dermatol. 2014;41:553–4.
583. Endo Y, Tanioka M, Tanizaki H, Mori M, Kawabata H, Miyachi Y. Bullous
variant of Sweet's syndrome after herpes zoster virus infection. Case Rep
Dermatol. 2011;3:259–62.
584. Ghorpade AK. Reactive perforating collagenosis with a giant lesion at the site
of healed herpes zoster. Indian J Dermatol Venereol Leprol. 2011;77:202–3.
585. Bang SW, Kim YK, Whang KU. Acquired reactive perforating collagenosis:
unilateral umbilicated papules along the lesions of herpes zoster. J Am
Acad Dermatol. 1997;36:778–9.
586. Lee HJ, Roh KY, Ha SJ, Kim JW. Pitted keratolysis of the palm arising after
herpes zoster. Br J Dermatol. 1999;140:974–5.
587. Miura T, Yamamoto T. Post-herpes zoster sarcoidosis. J Dermatol. 2014;41:458–9.
588. Watanabe D, Kuhara T, Ishida N, Tamada Y, Matsumoto Y. Sarcoid tissue
reaction on herpes zoster scars in a myelodysplastic syndrome patient:
Wolf's isotopic response. J Eur Acad Dermatol Venereol. 2009;23:475–7.
589. Verma KK, Mittal R. Cutaneous lesions of multicentric reticulohystiocytosis
developing in herpes zoster lesions. Acta Derm Venereol. 2000;80:150.
590. Yamamoto T, Yokoyama A. Nodular solar degeneration following herpes
zoster. Br J Dermatol. 1996;134:606.
591. Mittal RR, Singh SP, Gupta S, Sethi PS. Nodular colloid degeneration over
herpes zoster scars. Indian J Dermatol Venereol Leprol. 1996;62:181–2.
592. Kwon JI, Cho JW, Lee KS. A case of verrucous hyperplasia at the site of
healed herpes zoster: Isotopic response. Korean J Dermatol. 2011;49:726–9.
593. Kim MB, Jwa SW, Ko HC, Kim SJ, Kwon KS, Oh CH. A case of secondary
cutaneous mucinosis following herpes zoster: Wolf’s isotopic response. Int J
Dermatol. 2009;48:212–4.
594. Lee HJ, Ahn WK, Chae KS, Ha SJ, Kim JW. Localized chronic urticaria at the
site of healed herpes zoster. Acta Derm Venereol. 1999;79:168.
595. De D, Dogra S, Kanwar AJ. Prurigo nodularis in healed herpes zoster scar:
An isotopic response. J Eur Acad Dermatol Venereol. 2007;21:711–2.
596. Lee YB, Park HJ, Lee JY, Cho BK. Two cases of chronic cutaneous graft-
versus-host-reaction on the site of healed herpes zoster as an isotopic
response. Korean J Dermatol. 2008;46:90–3.
597. Matsumura T, Watanabe H, Batchelor J, Sueki H, Iijima M. Drug eruption
caused by the nonionic contrast medium iohexol. Recall-like phenomenon'
appearing on an area previously affected by herpes zoster. J Dermatol.
2006;33:705–8.
598. Na SY, Lee HY, Baek JO, Roh JY, Lee JR. A case of cutaneous zosteriform
metastatic carcinoma arising on the healed site of herpes zoster. Korean J
Dermatol. 2008;46:347–51.
Chen et al. BMC Infectious Diseases  (2017) 17:213 Page 34 of 39
599. Hapgood G, Mooney E, Dinh HV, Gin D, McLean C, Ting SB. Leukaemia cutis
in chronic lymphocytic leukaemia following varicella zoster virus
reactivation. Intern Med J. 2012;42:1355–8.
600. Kim TH, Kim DH, Yeom JS, Lee GY, Kim WS, Kim KJ. A case of AIDS-
associated Kaposi's sarcoma on the site of healed herpes zoster as an
isotopic response. Korean J Dermatol. 2009;47:1172–6.
601. Kim CY, Nam YH, Kim GD, Oh CW. Tufted angioma in site of healed herpes
zoster: Isotopic response. Clin Exp Dermatol. 2006;31:714–5.
602. Siwamogstham P, Kuansuwan C, Reichart PA. Herpes zoster in HIV infection
with osteonecrosis of the jaw and tooth exfoliation. Oral Dis. 2006;12:500–5.
603. Volvoikar P, Patil S, Dinkar A. Tooth exfoliation, osteonecrosis and neuralgia
following herpes zoster of trigeminal nerve. Indian J Dent Res. 2002;13:11–4.
604. Pillai KG, Nayar K, Rawal YB. Spontaneous tooth exfoliation, maxillary
osteomyelitis and facial scarring following trigeminal herpes zoster
infection. Prim Dent Care. 2006;13:114–6.
605. Jain MK, Manjunath KS, Jagadish SN. Unusual oral complications of herpes
zoster infection: report of a case and review of literature. Oral Surg Oral
Med Oral Pathol Oral Radiol Endod. 2010;110:e37–41.
606. Lambade P, Lambade D, Saha TK, Dolas RS, Pandilwar PK. Maxillary
osteonecrosis and spontaneous teeth exfoliation following herpes zoster.
Oral Maxillofac Surg. 2012;16:369–72.
607. Yamamoto K, Inagake K, Tatebayashi S, Yamakawa N, Inoue M, Yasumoto J,
et al. Alveolar osteonecrosis of the mandible after varicella zoster infection
of the trigeminal nerve. Asian J Oral Maxillofac Surg. 2004;16:204–8.
608. Badjate SJ, Cariappa KM, Shenoi SR, Nakhate S. Ramsay-Hunt syndrome
complicating osteonecrosis of edentulous maxilla and mandible: report of a
rare case. J Maxillofac Oral Surg. 2009;8:188–91.
609. Pushpanshu K, Kaushik R, Srivastava S, Punyani SR. An unusual complication
of tooth exfoliation and osteonecrosis following herpes zoster infection of
trigeminal nerve: a case report and literature review. Minerva Stomatol.
2013;62:241–5.
610. Mahima VG, Patil K, Srikanth HS. Herpes zoster induced alveolar necrosis in
an immunocompetent patient. Iran J Clin Infect Dis. 2010;5:235–8.
611. Liu YC, Yang YH, Hsiao HH, Yang WC, Liu TC, Chang CS, et al. Herpes zoster
is associated with an increased risk of subsequent lymphoid malignancies -
a nationwide population-based matched-control study in Taiwan. BMC
Cancer. 2012;12:503.
612. Ho JD, Xirasagar S, Lin HC. Increased risk of a cancer diagnosis after herpes
zoster ophthalmicus: a nationwide population-based study. Ophthalmology.
2011;118:1076–81.
613. Yamamoto M, Mine H, Akazawa K, Maehara Y, Sugimachi K. Gastrointestinal
cancer and herpes zoster in adults. Hepatogastroenterology. 2003;50:1043–6.
614. Lin SY, Liu JH, Yeh HC, Lin CL, Tsai IJ, Chen PC, et al. Association between
herpes zoster and end stage renal disease entrance in chronic kidney
disease patients: a population-based cohort study. Eur J Clin Microbiol
Infect Dis. 2014;33:1809–15.
615. Jiang ZM, Gao YH, Meng W, Wu WY, Jin L, Shen FM. The study on familial
aggregation of systemic lupus erythematosus. Fudan Univ J Med Sci. 2005;
32:270–4.
616. Kang JH, Sheu JJ, Kao S, Lin HC. Increased risk of multiple sclerosis following
herpes zoster: a nationwide, population-based study. J Infect Dis. 2011;204:
188–92.
617. Tsai SY, Yang TY, Chen HJ, Chen CS, Lin WM, Shen WC, et al. Increased risk
of chronic fatigue syndrome following herpes zoster: a population-based
study. Eur J Clin Microbiol Infect Dis. 2014;33:1653–9.
618. Chen MH, Wei HT, Su TP, Li CT, Lin WC, Chang WH, et al. Risk of depressive
disorder among patients with herpes zoster: a nationwide population-based
prospective study. Psychosom Med. 2014;76:285–91.
619. Wang X, Zhang L, Lei Y, Liu X, Zhou X, Liu Y, et al. Meta-analysis of
infectious agents and depression. Sci Rep. 2014;4:4530.
620. Chen YH, Chen YK, Keller JJ, Lin HC. A population-based case–control
analysis of the association between herpes zoster and erectile dysfunction. J
Infect. 2012;65:150–6.
621. Chiu HF, Chen BK, Yang CY. Herpes zoster and subsequent risk of cancer: a
population-based study. J Epidemiol. 2013;23:205–10.
622. Wang YP, Liu CJ, Hu YW, Chen TJ, Lin YT, Fung CP. Risk of cancer among
patients with herpes zoster infection: a population-based study. CMAJ. 2012;
184:E804–9.
623. Wang CC, Shiang JC, Chen JT, Lin SH. Syndrome of inappropriate secretion
of antidiuretic hormone associated with localized herpes zoster
ophthalmicus. J Gen Intern Med. 2011;26:216–20.
624. O'Rourke F, Chilov M. Localised herpes zoster infection and SIADH. Aust
Fam Physician. 2006;35:789–90.
625. Furuta E, Yasuda M, Yoshioka K, Isayama T, Nobunaga M. Syndrome of
inappropriate secretion of antidiuretic hormone in elderly patients with
rheumatoid arthritis associated with infections: Report of two cases. Intern
Med. 1996;35:478–81.
626. Reid AB, Gome JJ. Localized herpes zoster infection causing the syndrome
of inappropriate antidiuretic hormone secretion. Intern Med J. 2009;39:486–7.
627. Tsutsumi R, Adachi K, Yoshida Y, Yamamoto O. Drug-induced
hypersensitivity syndrome in association with varicella. Acta Derm Venereol.
2015;95:503–4.
628. Tamayose K, Sugimoto K, Ando M, Oshimi K. Mononucleosis syndrome and
acute monocytic leukemia. Eur J Haematol. 2002;68:236–8.
629. Eun YB, Bo KK, Seok GC, Jin WK. A case of disseminated herpes zoster with
thrombocytopenia. Korean J Dermatol. 2005;43:410–12.
630. Kawano N, Gondo H, Kamimura T, Aoki K, Iino T, Ishikawa F, et al. Chronic
graft-versus-host disease following varicella-zoster virus infection in
allogeneic stem cell transplant recipients. Int J Hematol. 2003;78:370–3.
631. Park BC, Choe YS, Kim DW, Lee WJ, Lee SJ, Na GY. Clinical study on
dermatologic disease of the elderly. Korean J Dermatol. 2006;44:818–23.
632. Furue M, Yamazaki S, Jimbow K, Tsuchida T, Amagai M, Tanaka T, et al.
Prevalence of dermatological disorders in Japan: a nationwide, cross-sectional,
seasonal, multicenter, hospital-based study. J Dermatol. 2011;38:310–20.
633. Yoon NY, Hong SP, Jeon SY, Shin JS, Ahn SK. A clinical study of
dermatologic diseases in elderly patients. Korean J Dermatol. 2011;49:
887–95.
634. Go JW, Cho HK, Kang WH, Ro BI. A statistical study of dermatoses in Goyang
City (2004 ∼ 2008). Korean J Dermatol. 2009;47:896–903.
635. Choi HS, Yun SK, Kim HU, Ihm CW. A statistical study of dermatoses in the
Jeonbuk Province (1979–1980, 1987–2002). Korean J Dermatol. 2005;43:606–18.
636. Hong S, Lee ES, Yoon KH. A statistical study of dermatoses in the Suwon
area and southern area of Kyonggi (1995–2001). Korean J Dermatol. 2003;41:
728–39.
637. Shin BJ, Choe SW, Seo SJ, Hong CK. A clinical study of skin diseases in
elderly patients(IV). Korean J Dermatol. 2002;40:1346–52.
638. Wang E, Lim BL, Than KY. Dermatological conditions presenting at an
emergency department in Singapore. Singapore Med J. 2009;50:881–4.
639. Chan CY, Kam KL, Graham CA, Rainer TH, Luk NM. Clinical profile of skin
diseases in accident and emergency department attenders. Hong Kong J
Dermatol Venereol. 2007;15:4–9.
640. Zhang Y, Zhou SX, Zhang TF, Huang GF. Analysis of the distribution of
diseases in 6435 inpatients from the department of acupuncture and
moxibustion. Zhongguo Zhen Jiu. 2011;31:941–4.
641. Park EJ, Han KR, Kim DW, Kim C. A clinical survey of the patients in neuro-
pain clinic at Ajou University. Korean J Pain. 2007;20:181–5.
642. Ministry of Health. Immunisation Handbook 2014 (3rd edn). Wellington:
Ministry of Health. 2016. http://www.health.govt.nz/system/files/documents/
publications/imm-handbk-2014-3rd-edn-dec16.pdf. Accessed 17 Jan 2017.
643. Gan EY, Tian EA, Tey HL. Management of herpes zoster and post-herpetic
neuralgia. Am J Clin Dermatol. 2013;14:77–85.
644. Wehrhahn MC, Dwyer DE. Herpes zoster: Epidemiology, clinical features,
treatment and prevention. Aust Prescr. 2012;35:143–7.
645. Cunningham AL, Litt J. Shingles: How to prevent it, how to treat it. Med
Today. 2014;15:20–7.
646. Cunningham AL, Breuer J, Dwyer DE, Gronow DW, Helme RD, Litt JC, et al. The
prevention and management of herpes zoster. Med J Aust. 2008;188:171–6.
647. Chopra A, Jassal JS, Bahl RK. Role of acyclovir and laser therapy in herpes
zoster. Indian J Dermatol Venereol Leprol. 1994;60:208–9.
648. Hayashibe K, Ichihashi M. Efficacy of acyclovir 400 mg tablet (Zovirax® tablet
400) in herpes zoster. Skin Res. 1994;36:543–50.
649. Sugiyama Y, Tamura T, Seguchi T, Yoshida M, Tezuka T. Evaluation of
efficacy of oral acyclovir in herpes zoster Trial of 2400 mg 3 times daily. Skin
Res. 1994;36:459–64.
650. Yoshikawa K, Doi T. Clinical evaluation of Zovirax® (acyclovir) tablet 400 on
herpes zoster. Skin Res. 1994;36:441–58.
651. Chen YH. Observation of oral acyclovir combined with sodium hyaluronate
and fluorometholone eye drops on the treatment of herpes zoster keratitis.
Intern Eye Sci. 2014;14:729–30.
652. McDonald EM, de Kock J, Ram FS. Antivirals for management of herpes
zoster including ophthalmicus: a systematic review of high-quality
randomized controlled trials. Antivir Ther. 2012;17:255–64.
Chen et al. BMC Infectious Diseases  (2017) 17:213 Page 35 of 39
653. Lin WR, Lin HH, Lee SS, Tsai HC, Huang CK, Wann SR, et al.
Comparative study of the efficacy and safety of valaciclovir versus
acyclovir in the treatment of herpes zoster. J Microbiol Immunol Infect.
2001;34:138–42.
654. Shen MC, Lin HH, Lee SS, Chen YS, Chiang PC, Liu YC. Double-blind,
randomized, acyclovir-controlled, parallel-group trial comparing the safety
and efficacy of famciclovir and acyclovir in patients with uncomplicated
herpes zoster. J Microbiol Immunol Infect. 2004;37:75–81.
655. Chen A, Sun X. Comparative study of treatment of herpes zoster with
valaciclovir and acyclovir. Med J Wuhan Univ. 2006;27:537–8.
656. Gopal MG, Shannoma, Sharath Kumar BC, Ramesh M, Nandini AS,
Manjunath NC. A comparative study to evaluate the efficacy and safety of
acyclovir and famciclovir in the management of herpes zoster. J Clin Diagn
Res. 2013;7:2904–7.
657. Liao R, Wu J, Yang H. Contrast of acycloguanosine, famciclovir, ribavirin in
treatment of herps zoster pruritus. Chin J Clin Rehab. 2003;7:904–5.
658. Li W, Guo ZP, Xiong L. Domestic penciclovir powder through injection for
improving cutaneous deficiency and residual neuralgia in patients with
herpes zoster: A randomized, double-blind and controlled trial. Chin J Clin
Rehab. 2005;9:34–7.
659. Sodhi PK, Ratan SK. A case of chronic renal dysfunction following treatment
with oral acyclovir. Scand J Infect Dis. 2003;35:770–2.
660. Kitching AR, Fagg D, Hay NM, Hatfield PJ, Macdonald A. Neurotoxicity
associated with acyclovir in end stage renal failure. New Zealand Med J.
1997;110:167–9.
661. Takayanagi A, Maehana T, Kyoda Y, Yanase M. Neurotoxicity of valacyclovir
in a peritoneal dialysis patient. Hinyokika Kiyo. 2010;56:617–9.
662. Asahi T, Tsutsui M, Wakasugi M, Tange D, Takahashi C, Tokui K, et al.
Valacyclovir neurotoxicity: clinical experience and review of the literature.
Eur J Neurol. 2009;16:457–60.
663. Yang HH, Hsiao YP, Shih HC, Yang JH. Acyclovir-induced neuropsychosis
successfully recovered after immediate hemodialysis in an end-stage renal
disease patient. Int J Dermatol. 2007;46:883–4.
664. Fujii H, Tanioka M, Matsumura Y, Miyachi Y, Matsubara T. A case of
valaciclovir induced encephalopathy in a patient with peritoneal dialysis.
Skin Res. 2007;6:372–5.
665. Sagawa N, Tsurutani Y, Nomura K, Okuyama T, Kondo M, Sata A, et al.
Acyclovir-Induced neurotoxicity and acute kidney injury in an elderly
diabetic patient treated with valacyclovir: Report of a case. Nihon Ronen
Igakkai Zasshi. 2014;51:581–5.
666. Ng HW, Pang CT. Confusion in patients with shingles and renal failure:
Acyclovir neurotoxicity or herpes encephalitis. Hong Kong J Emerg Med.
2012;19:205–9.
667. Matsumoto R, Yoshida T, Tabata KI, Nakagawa SI, Yanagisawa N. A patient
with thyroid carcinoma who developed consciousness disturbance during
acyclovir administration for herpes zoster. Clin Neurol. 1996;36:590–3.
668. Mihara A, Mori T, Nakazato T, Ikeda Y, Okamoto S. Acute renal failure caused
by intravenous acyclovir for disseminated varicella zoster virus infection.
Scand J Infect Dis. 2007;39:94–5.
669. Yamamoto Y, Suganuma A, Mishima N, Horibe C, Saito Y. A case of acute
renal failure due to valacyclovir in an elderly patient with progressive
supranuclear palsy. IRYO Jpn J Natl Med Serv. 2009;63:735–9.
670. Kusakari Y, Tanita M, Egawa T, Yoshida H, Shingou T, Nakamura K, et al.
Efficacy and safety of famciclovir for the treatment of herpes zoster patients
with renal dysfunction. Nishinihon J Dermatol. 2014;76:44–51.
671. Yoon H, Rhew KY. Famciclovir as an antiviral agent for a patient with acute
renal failure. Int J Clin Pharm. 2013;35:173–5.
672. Okamoto S, Ishibashi Y, Inoue Y, Uchio E, Ohashi Y, Kitagawa K, et al.
Multicentered survey of ocular complications of acyclovir ophthalmic
ointment. Jpn J Clin Ophthalmol. 1997;51:1112–4.
673. Zhang JS. Clinical effect comparison of ganciclovir ophthalmic gel and
ganciclovir eye drops in the treatment of herpes zoster keratitis. Int J
Ophthalmol. 2011;11:309–10.
674. Li SQ, Jia J, Zhang ZY. Clinical observation on eyelid herpes zoster with
external use ganciclovir ophthalmic gel. Intern Eye Sci. 2014;14:1356–7.
675. Nakamura H, Ishimoto S, Fujisawa K, Okada T, Tahara Y, Nakamura T, et al.
Systemic ganciclovir with vitrectomy was effective in two cases of acute
retinal necrosis. Jpn J Clin Ophthalmol. 1999;53:1599–603.
676. Lee MY, Kim KS, Lee WK. Intravitreal foscarnet for the treatment of acyclovir-
resistant acute retinal necrosis caused by varicella zoster virus. Ocul
Immunol Inflamm. 2011;19:212–3.
677. Hwangbo H, Jung SW, Son HH, Lee SK. Comparison between famciclovir
and valacyclovir for the treatment of herpes zoster in adults. Korean J
Dermatol. 2014;52:720–7.
678. Ono F, Yasumoto S, Furumura M, Hamada T, Ishii N, Gyotoku T, et al.
Comparison between famciclovir and valacyclovir for acute pain in adult
Japanese immunocompetent patients with herpes zoster. J Dermatol.
2012;39:902–8.
679. Bodsworth NJ, Boag F, Burdge D, Généreux M, Borleffs JC, Evans BA, et
al. Evaluation of sorivudine (BV-araU) versus acyclovir in the treatment
of acute localized herpes zoster in human immunodeficiency virus-
infected adults. The Multinational Sorivudine Study Group. J Infect Dis.
1997;176:103–11.
680. Watabe T, Okuda H, Ogura K. Lethal drug interactions of the new antiviral,
sorivudine, with anticancer prodrugs of 5-fluorouracil. Yakugaku Zasshi.
1997;117:910–21.
681. Chen N, Li Q, Yang J, Zhou M, Zhou D, He L. Antiviral treatment for
preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2014;2:
CD006866.
682. Liu G, Zhan H, Deng R. A clinical study of 32 Hunt syndrome. Acta Acad
Med Hubei. 1996;17:73.
683. Ho KY, Pasutharnchat K. Intrathecal dexamethasone for the treatment of
intractable postherpetic neuralgia: A case report. Internet J Pain Symptom
Control Palliative Care. 2009;6:4.
684. Achar A, Chakraborty PP, Bisai S, Biswas A, Guharay T. Comparative study of
clinical efficacy of amitriptyline and pregabalin in postherpetic neuralgia.
Acta Dermatovenerol Croat. 2012;20:89–94.
685. Wrigley P, Cousins M. Postherpetic neuralgia: An update on management
and prevention. Med Today. 2008;9:36–44.
686. Kochar DK, Agarwal RP, Joshi A, Kumawat BL. Herpes zoster and post-
herpetic neuralgia – a clinical trial of aspirin in chloroform for anodyne. J
Assoc Physicians India. 1998;46:337–40.
687. Kanodia SK, Singhal KC. A study on efficacy of Pregabalin in acute Herpetic
Neuralgia. Ann Neurosci. 2011;18:148–50.
688. Kanodia SK, Seth AK, Dixit AM. Dose related efficacy of gabapentin in
acute herpetic neuralgia among geriatric patients. Indian J Dermatol.
2012;57:362–5.
689. Sabatowski R, Galvez R, Cherry DA, Jacquot F, Vincent E, Maisonobe P, et al.
Pregabalin reduces pain and improves sleep and mood disturbances in
patients with post-herpetic neuralgia: Results of a randomised, placebo-
controlled clinical trial. Pain. 2004;109:26–35.
690. Meng FY, Zhang LC, Liu Y, Pan LH, Zhu M, Li CL, et al. Efficacy and safety of
gabapentin for treatment of postherpetic neuralgia: a meta-analysis of
randomized controlled trials. Minerva Anestesiol. 2014;80:556–7.
691. Doggrell SA. Pregabalin or morphine and gabapentin for neuropathic pain.
Expert Opin Pharmacother. 2005;6:2535–9.
692. Zhang LX, Li GL. Effect of oxycodone-acetaminophen therapy in patients
with intractable postherpetic neuralgia. Chin J New Drugs. 2009;18:427–8.
693. Zhao G, Zhang H. Analgesic effect of oxycodone-acetaminophen tablets on
herpes zoster. Chin J New Drugs. 2009;18:720–1.
694. Liu GH, Liu JM. Efficacy of oxycodone-acetamainophen on postherpetic
neuralgia in patients with zoster. Chin J New Drugs. 2009;18:722–3. 740.
695. Wu XM, Zhu SM. Effect of oxycodone-acetaminophen in 58 patients with
herpes zoster. Chin J New Drugs. 2009;18:718–9. 721.
696. Yang Y, Yan JQ, Guo QL, Chen ZG. Safety and efficacy of oral oxycodone-
acetaminophen versus tramadol in treatment of postherpetic neuralgia.
Chin J New Drugs. 2009;18:527–9.
697. Lin PL, Fan SZ, Huang CH, Huang HH, Tsai MC, Lin CJ, et al. Analgesic effect
of lidocaine patch 5% in the treatment of acute herpes zoster: a double-
blind and vehicle-controlled study. Reg Anesth Pain Med. 2008;33:320–5.
698. Garnock-Jones KP, Keating GM. Lidocaine 5% medicated plaster: a review of
its use in postherpetic neuralgia. Drugs. 2009;69:2149–65.
699. Iseki M, Mitsuhata H, Miyazaki T, Toriumi E, Yoshino K. Relief of subacute
herpetic pain and postherpetic neuralgia with repeated application of 10%
lidocaine cream. Jpn J Anesthesiol. 2000;49:1204–9.
700. Cousins MJ, Pickthorn K, Huang S, Critchley L, Bell G. The safety and efficacy
of KAI-1678– an inhibitor of epsilon protein kinase C (εPKC)–versus lidocaine
and placebo for the treatment of postherpetic neuralgia: a crossover study
design. Pain Med. 2013;14:533–40.
701. Chen SM, Chen JT, Kuan TS, Hong CZ. Myofascial trigger points in
intercostal muscles secondary to herpes zoster infection of the intercostal
nerve. Arch Phys Med Rehabil. 1998;79:336–8.
Chen et al. BMC Infectious Diseases  (2017) 17:213 Page 36 of 39
702. Xiao LZ, Zhang DR, Jiang J, Zhang KL, Zhang M, Zhu HQ. Feasibility of
transdermal fentanyl for pain relief of herpes zoster and postherpetic
neuralgia. Chin J Clin Rehab. 2004;8:216–7.
703. Lee GY. The effect of fentanyl patch in the treatment of intractable
postherpetic neuralgia. Korean J Dermatol. 2007;45:422–8.
704. Guo WJ, Xiao ZY, Yang YX. Effectiveness of transdermal fentanyl combined
with clodine for pain control of acute herpes zoster. J Dalian Med Univ.
2007;29:255–6.
705. Pan BC, Hou XW, Li XP. Curative effect of recombinant human interferon
α2b gel combined with aciclovir on herpes zoster. Chin J Biol. 2008;21:711–2.
706. Miyoshi H, Hirotsuji N, Kino T, Katsu K. Interferon alpha gel for herpes zoster.
Dermatology. 1997;194:306.
707. Akimoto T. Clinical evaluation of 3% Ara-A ointment on herpes zoster and
herpes simplex. Skin Res. 1995;37:164–79.
708. Ishii N, Baba N, Nakajima H, Yoshida S, Katoh Y. Clinical studies of Arasena-
A® ointment I Clinical effects on herpes zoster. Skin Res. 1994;36:220–7.
709. Shann F. Povidone-iodine for herpes zoster. Lancet. 2004;364:502.
710. Sun W, Xiang X, Zeng X. Compound ribavirin paint: Preparation and
application. Chin Pharm J (China). 1996;31:150–3.
711. Keam SJ, Chapman TM, Figgitt DP. Brivudin (bromovinyl deoxyuridine).
Drugs. 2004;64:2091–7.
712. Kanai A, Osawa S, Suzuki A, Ishimaru R, Hoka S. Effectiveness of
prostaglandin E1 for the treatment of patients with neuropathic pain
following herpes zoster. Pain Med. 2007;8:36–40.
713. Kanai A, Wang G, Hoshi K, Okamoto H. Effects of intravenous prostaglandin
E1 on pain and body temperature in patients with post-herpetic neuralgia.
Pain Med (USA). 2010;11:609–16.
714. Lu YG, Wu JJ, Yang YD. Study of efficacy of Lipo PGE1 in treatment of
postherpetic neuralgia in patients with herpes zoster. Chin J Clin Rehab.
2002;6:3092–3.
715. Kushida Y, Yoshida M, Akaike Y, Yamada K, Nishizuka K, Kita M, et al. The
effects of Lipo-PGE1 on shooting pain of postherpetic neuralgia. Hokuriku J
Anesthesiol. 1999;33:59–62.
716. Fujii K, Kanno Y, Konishi K, Ohgou N. A specific thrombin inhibitor, argatroban,
alleviates herpes zoster-associated pain. J Dermatol. 2001;28:200–7.
717. Komori M, Fukuuchi A, Mae T, Nishiyama K, Kawamata M, Ozaki M.
Milnacipran hydrochloride for the treatment of postherpetic neuralgia. Pain
Clinic. 2006;18:421–3.
718. Sekiguchi T, Fujihara K, Sato H. Clinical effects of immunoglobulin
(Polyglobin® N) for severe infectious disorders in dermatology. Jpn
Pharmacol Ther. 1995;23:195–208.
719. Xu G, Lv ZW, Feng Y, Tang WZ, Xu GX. A single-center randomized
controlled trial of local methylcobalamin injection for subacute herpetic
neuralgia. Pain Med. 2013;14:884–94.
720. Han G, Kim SH, Lee KS, Cho JW. Effect of botulinum toxin a on acute
and chronic pain in herpes zoster patients. Korean J Dermatol. 2014;52:
845–50.
721. Zacest A, Anderson VC, Burchiel KJ. The glass half empty or half full – how
effective are long-term intrathecal opioids in post-herpetic neuralgia? A
case series and review of the literature. Neuromodulation. 2009;12:219–23.
722. Ji G, Niu J, Shi Y, Hou L, Lu Y, Xiong L. The effectiveness of repetitive
paravertebral injections with local anesthetics and steroids for the
prevention of postherpetic neuralgia in patients with acute herpes zoster.
Anesth Analg. 2009;109:1651–5.
723. Ji CM, Li XM, Sun DH, Jiang CL, Li SL. Clinical study on stellate ganglion
block combined with pregabalin for treating postherpetic neuralgia at chest
and back. Chin J New Drugs. 2012;21:1503–6.
724. Wang JS. The comparison of therapeutic effect of three methods for the
treatment of acute herpes zoster. Curr Opin Clin Exp Res. 2002;4:12–5.
725. Manabe H, Dan K, Hirata K, Hori K, Shono S, Tateshi S, et al. Optimum pain
relief with continuous epidural infusion of local anesthetics shortens the
duration of zoster-associated pain. Clin J Pain. 2004;20:302–8.
726. Bhargava R, Bhargava S, Haldia KN, Bhargava P. Jaipur block in postherpetic
neuralgia. Int J Dermatol. 1998;37:465–8.
727. Puri N. Modified Jaipur block for the treatment of post-herpetic neuralgia.
Int J Dermatol. 2011;50:1417–20.
728. Chaturvedi A, Dash HH. Sympathetic blockade for the relief of chronic pain.
J Indian Med Assoc. 2001;99:698–703.
729. Hwang SM, Kang YC, Lee YB, Yoon KB, Ahn SK, Choi EH. The effects of
epidural blockade on the acute pain in herpes zoster. Arch Dermatol. 1999;
135:1359–64.
730. Ahn HJ, Lim HK, Lee YB, Hwang SM, Lee WS, Ahn SK, et al. The effects of
famciclovir and epidural block in the treatment of herpes zoster. J Dermatol.
2001;28:208–16.
731. Ahn SY, Lee YB, Lee KH, Lim HK, Lee WS, Ahn SK, et al. The effect of stellate
ganglion block on herpes zoster. Korean J Dermatol. 2006;44:681–7.
732. Jun JH, Ro YS, Kim JH, Shim JC. The effects of continuous epidural blockade
in the treatment of postherpetic neuralgia. Korean J Dermatol. 1998;36:584–8.
733. Koh WS, Park SM, Kim BS, Shin DY. The effect of sympathetic blocks in the
prevention of postherpetic neuralgia. Korean J Dermatol. 1997;35:620–6.
734. Shin HY, Kim DS, Kim SS. Superficial cervical plexus block for management
of herpes zoster neuralgia in the C3 dermatome: a case report. J Med Case
Rep. 2014;8:59.
735. Lee JY, Sim WS, Kim KM, Oh MS, Lee JE. The effect of ketamine as an
additive in epidural block on the intractable herpetic neuralgia: a case
report. Korean J Anesthesiol. 2014;66:64–6.
736. Chau SW, Soo LY, Lu DV, Chen TI, Cheng KI, Chu KS. Clinical experience of
pain treatment for postherpetic neuralgia in elderly patients. Acta
Anaesthesiol Taiwan. 2007;45:95–101.
737. Dan K. Nerve block therapy and postherpetic neuralgia. Crit Rev Phys
Rehabil Med. 1995;7:93–112.
738. Higa K, Hori K, Harasawa I, Hirata K, Dan K. High thoracic epidural block
relieves acute herpetic pain involving the trigeminal and cervical regions:
Comparison with effects of stellate ganglion block. Reg Anesth. 1998;23:25–9.
739. Mizuno J, Sugimoto S, Ikeda M, Kamakura T, Machida K, Kusume S.
Treatment with stellate ganglion block, continuous epidural block and
ulnar nerve block of a patient with postherpetic neuralgia who
developed complex regional pain syndrome (CRPS). Jpn J Anesthesiol.
2001;50:548–51.
740. Tajima K, Iseki M, Inada E, Miyazaki T. The effects of early nerve blocks for
prevention of postherpetic neuralgia and analysis of prognostic factors. Jpn
J Anesthesiol. 2009;58:153–9.
741. Tajima K, Kawagoe I, Kanai M, Mitsuhata H. Effective treatment of acute pain
and related symptoms in elderly with herpes zoster. Jpn J Anesthesiol. 2008;
57:874–8.
742. Kishimoto N, Kato J, Suzuki T, Arakawa H, Ogawa S, Suzuki H. A case of RSD
with complete disappearance of symptoms following intravenous ketamine
infusion combined with stellate ganglion block and continuous epidural
block. Jpn J Anesthesiol. 1995;44:1680–4.
743. Tsai YC, Wang LK, Chen BS, Chen HP. Home-based patient-controlled
epidural analgesia with bupivacaine for patients with intractable herpetic
neuralgia. J Formos Med Assoc. 2000;99:659–62.
744. Kang FC, Chang PJ, Chen HP, Tsai YC. Patient-controlled epidural analgesia
for postherpetic neuralgia in an HIV-infected patient as a therapeutic
ambulatory modality. Acta Anaesthesiol Sin. 1998;36:235–9.
745. Okano K, Kondo H, Tsuchiya R, Naruke T, Sato M, Yokoyama R. Spinal
epidural abscess associated with epidural catheterization: report of a case
and a review of the literature. Jpn J Clin Oncol. 1999;29:49–52.
746. Taga K, Tomita M, Watanabe I, Sato K, Awamori K, Fujihara H, et al.
Complete recovery of consciousness in a patient with decorticate rigidity
following cardiac arrest after thoracic epidural injection. Br J Anaesth.
2000;85:632–4.
747. Iseki M, Okuno S, Tanabe Y, Mitsuhata H, Miyazaki T. Methicillin-resistant
Staphylococcus aureus sepsis resulting from infection in paravertebral
muscle after continuous epidural infusion for pain control in a patient with
herpes zoster. Anesth Analg. 1998;87:116–8.
748. Hamaguchi K, Ikegami S, Morita N, Fukushima H, Miyata K, Fujiki N, et al. A
case of dyspnea caused by deep cervical hematoma following stellate
ganglion block. Pract Oto-Rhino-Laryngol. 2007;100:391–5.
749. Miyamoto T, Nakatani T, Narai Y, Sakakibara M, Hashimoto T, Saito Y. A case
of spinal epidural abscess after continuous epidural block to manage the
pain of herpes zoster. Jpn J Anesthesiol. 2014;63:353–7.
750. Son H, Sakuma Y, Kamada T, Kawano M, Suwa I, Kotani J, et al. A patient
with respiratory arrest after stellate ganglion blockade. J Jpn Dent Soc
Anesthesiol. 1996;24:489–92.
751. Sugino N, Ohta A, Abe H, Mori H. Three cases of bacterial contaminations
associated with epidural catheterization in patients of herpes zoster.
Hokuriku J Anesthesiol. 1995;29:47–9.
752. Suzuki T, Takemura H, Shida K, Higuchi H, Ohtsuka N, Masuda Y. The
development of methicillin-resistant Staphylococcus aureus sepsis in a
patient with herpes zoster during treatment with continuous epidural
infusion. Jpn J Anesthesiol. 2002;51:293–5.
Chen et al. BMC Infectious Diseases  (2017) 17:213 Page 37 of 39
753. Uematsu H, Hiei K, Kawasaki H. Unknown fever and abnormal liver functions
after repeated epidural blocks with lidocaine for management of herpes
zoster pain. Jpn J Anesthesiol. 1994;43:405–8.
754. Wajima Z, Ishikawa G, Kaneko K, Inoue T, Ogawa R. A case of using
continuous double-tapped epidural analgesia for herpes zoster duplex. Jpn
J Anesthesiol. 1995;44:841–4.
755. Jeon Y, Baek SU, Yeo JS. Spinal myoclonus developed during cervical epidural
drug infusion in postherpetic neuralgia patient. Korean J Pain. 2011;24:169–71.
756. Min BM, Kim JH. Epidural catheterization with a subcutaneous injection port
for the long-term administration of opioids and local anesthetics to
treat zoster-associated pain -a report of two cases-. Korean J Anesthesiol.
2013;65:462–7.
757. Higa K, Shono S, Nitahara K. Postherpetic neuralgia. Jpn J Anesthesiol. 2010;
59:1342–9.
758. Moryama K. Effect of temporary spinal cord stimulation on postherpetic
neuralgia in the thoracic nerve area. Neuromodulation. 2009;12:39–43.
759. Hirabayashi H, Kawata K, Hoshida T, Tamura K, Youngsu P, Nakase H.
Neuromodulation therapy for neuropathic pain. Jpn J Neurosurg.
2011;20:93–102.
760. Hijikata Y, Yamada S. Effect of Ganoderma lucidum on postherpetic
neuralgia. Am J Chin Med. 1998;26:375–81.
761. Hijikata Y, Yasuhara A, Sahashi Y. Effect of an herbal formula containing
Ganoderma lucidum on reduction of herpes zoster pain: a pilot clinical trial.
Am J Chin Med. 2005;33:517–23.
762. Nakanishi M, Arimitsu J, Kageyama M, Otsuka S, Inoue T, Nishida S, et al.
Efficacy of traditional Japanese herbal medicines-Keishikajutsubuto (TJ-18)
and Bushi-matsu (TJ-3022)-against postherpetic neuralgia aggravated by
self-reported cold stimulation: a case series. J Altern Complement Med.
2012;18:686–92.
763. Lee SM, Lim J, Lee JD, Choi DY, Lee S. Bee venom treatment for refractory
postherpetic neuralgia: a case report. J Altern Complement Med. 2014;20:
212–4.
764. Byun SH, Jeon Y. Administration of Vitamin C in a Patient with Herpes
Zoster - A case report -. Korean J Pain. 2011;24:108–11.
765. Huang B, Zhou XY, Lu YP, Zhu ZF, Hou J, Sun JL, et al. Selective
percutaneous dorsal root ganglion radiofrequency thermocoagulation
guided by CT scanning in treatment of post-herpetic neuralgia. Nat Med J
China. 2008;88:885–8.
766. Lim SM, Park HL, Moon HY, Kang KH, Kang H, Baek CH, et al.
Ultrasound-guided infraorbital nerve pulsed radiofrequency treatment
for intractable postherpetic neuralgia - a case report -. Korean J Pain.
2013;26:84–8.
767. Ko YK, Lee HY, Lee WY. Clinical experiences on the effect of scrambler therapy
for patients with postherpetic neuralgia. Korean J Pain. 2013;26:98–101.
768. Chen HM. Zoster Chinese medicine treatment. Zhonghua Shi Yan He Lin
Chuang Bing Du Xue Za Zhi. 2007;21:285–7.
769. Cao H, Li X, Liu J. An updated review of the efficacy of cupping therapy.
PLoS One. 2012;7:e31793.
770. Bourke A, Hui B. Weak evidence that HBOT is of benefit in the treatment of
patients with herpes zoster. Diving Hyperbaric Med. 2013;43:174.
771. National Centre for Immunisation Research & Surveilance. Zoster vaccine for
Australian adults | NCIRS Fact sheet: July 2015. http://www.ncirs.edu.au/
assets/provider_resources/fact-sheets/herpes-zoster-vaccine-fact-sheet.pdf.
Accessed 3 Sept 2015.
772. Fujiwara O, Mitamura Y, Ohtsuka K. Herpes zoster panuveitis progression
despite acyclovir treatment in a patient following bone marrow
transplantation. Jpn J Ophthalmol. 2005;49:536–8.
773. Abe T, Kuboki J, Tamai M. Sensitivity to acyclovir in acute retinal necrosis
syndrome. Jpn J Clin Ophthalmol. 1997;51:1161–3.
774. Leung AY, Chow HC, Kwok JS, Lui CK, Cheng VC, Yuen KY, et al. Safety of
vaccinating sibling donors with live-attenuated varicella zoster vaccine
before hematopoietic stem cell transplantation. Bone Marrow Transplant.
2007;39:661–5.
775. Kanda Y, Mineishi S, Saito T, Saito A, Yamada S, Ohnishi M, et al. Long-term
low-dose acyclovir against varicella-zoster virus reactivation after allogeneic
hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;
28:689–92.
776. Kawamura K, Wada H, Yamasaki R, Ishihara Y, Sakamoto K, Ashizawa M, et al.
Prophylactic role of long-term ultra-low-dose acyclovir for varicella zoster
virus disease after allogeneic hematopoietic stem cell transplantation. Int J
Infect Dis. 2014;19:26–32.
777. Uchiyama M, Tamai Y, Ikeda T. Low-dose acyclovir against reactivation of
varicella zoster virus after unrelated cord blood transplantation. Int J Infect
Dis. 2010;14:e451–2.
778. Asano-Mori Y, Kanda Y, Oshima K, Kako S, Shinohara A, Nakasone H, et al.
Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation
after allogeneic hematopoietic stem cell transplantation. Am J Hematol.
2008;83:472–6.
779. Oshima K, Takahashi T, Mori T, Matsuyama T, Usuki K, Asano-Mori Y, et al.
One-year low-dose valacyclovir as prophylaxis for varicella zoster virus
disease after allogeneic hematopoietic stem cell transplantation. A
prospective study of the Japan Hematology and Oncology Clinical Study
Group. Transpl Infect Dis. 2010;12:421–7.
780. Aoki T, Nishiyama T, Imahashi N, Kitamura K. Efficacy of continuous, daily,
oral, ultra-low-dose 200 mg acyclovir to prevent herpes zoster events
among bortezomib-treated patients: a report from retrospective study. Jpn J
Clin Oncol. 2011;41:876–81.
781. Fukushima T, Sato T, Nakamura T, Iwao H, Nakajima A, Miki M, et al. Daily
500 mg valacyclovir is effective for prevention of Varicella zoster virus
reactivation in patients with multiple myeloma treated with bortezomib.
Anticancer Res. 2012;32:5437–40.
782. Steer CB, Szer J, Sasadeusz J, Matthews JP, Beresford JA, Grigg A. Varicella-
zoster infection after allogeneic bone marrow transplantation: Incidence,
risk factors and prevention with low-dose aciclovir and ganciclovir. Bone
Marrow Transplant. 2000;25:657–64.
783. Takahashi M, Kamiya H, Asano Y, Shiraki K, Baba K, Otsuka T, et al.
Immunization of the elderly to boost immunity against varicella-zoster virus
(VZV) as assessed by VZV skin test reaction. In: Gershon AA, Arvin AM,
Calisher CH, editors. Archives of Virology, Supplement 17: Immunity to and
prevention of herpes zoster. Vienna: Springer; 2001. p. 161–72. doi:10.1007/
978-3-7091-6259-0_17.
784. Takahashi M, Okada S, Miyagawa H, Amo K, Yoshikawa K, Asada H, et al.
Enhancement of immunity against VZV by giving live varicella vaccine to
the elderly assessed by VZV skin test and IAHA, gpELISA antibody assay.
Vaccine. 2003;21:3845–53.
785. Hata A, Inoue F, Yamasaki M, Fujikawa J, Kawasaki Y, Hamamoto Y, et al.
Safety, humoral and cell-mediated immune responses to herpes zoster
vaccine in subjects with diabetes mellitus. J Infect. 2013;67:215–9.
786. Marumoto T, Ono K. Varicella vaccine was effective in a case of recurrent
ophthalmic zoster sine herpete. Jpn J Clin Ophthalmol. 2013;67:575–9.
787. Sasadeusz J, Prince HM, Schwarer A, Szer J, Stork A, Bock HL, et al.
Immunogenicity and safety of a two-dose live attenuated varicella vaccine
given to adults following autologous hematopoietic stem cell
transplantation. Transplant Infect Dis. 2014;16:1024–31.
788. Cheuk DK, Chiang AK, Lee TL, Chan GC, Ha SY. Vaccines for prophylaxis of
viral infections in patients with hematological malignancies. Cochrane
Database Syst Rev. 2011;3:CD006505.
789. Frazer IH, Levin MJ. Paradigm shifting vaccines: prophylactic vaccines
against latent varicella-zoster virus infection and against HPV-associated
cancer. Curr Opin Virol. 2011;1:268–79.
790. Choi WS. Herpes zoster vaccine in Korea. Clin Exp Vaccine Res. 2013;2:92–6.
791. Recommended immunization schedule for adults in Korea, by the
Korean Society of Infectious Diseases, 2012. Clin Exp Vaccine Res. 2014;
3:110–2.
792. Chun GTW, Chong LP, Bailey P. Malaysian Society of Geriatric Medicine
position statement on vaccination against the herpes zoster virus in older
adults (updated June 2014). https://sites.google.com/a/ummc.edu.my/
msgm/position-statements/the-herpes-zoster-vaccine. Accessed 2 Feb 2015.
793. Specialist Doctors Association of Indonesia. Adult Immunization Schedule.
2014. http://pbpapdi.net/images/file_unduh/Catatan Imunisasi &Jadwal
Imunisasi Dewasa_103.zip. Accessed 18 Jan 2017.
794. Philippine Society for Microbiology and Infectious Diseases. Handbook on
Adult Immunization for Filipinos. 2012. www.psmid.org.ph/contents/
handbook-on-adult-immunization-2012.pdf. Accessed 1 Apr 2015.
795. Thailand Royal College of Physicians. Recommended Adult and Elderly
Immunization Schedule, 2014. www.rcpt.org/index.php/2012-10-03-16-53-39/
category/6-2013-02-02-09-02-52.html?download=140:-2014. Accessed 1 Apr 2015.
796. Taiwan Association of Family Medicine. Clinical Handbook for Adult
Immunization. 1st ed. Taipei: Taiwan Association of Family Medicine;
2010. p. 31–6.
797. Chen N, Li Q, Zhang Y, Zhou M, Zhou D, He L. Vaccination for preventing
postherpetic neuralgia. Cochrane Database Syst Rev. 2011;3:CD007795.
Chen et al. BMC Infectious Diseases  (2017) 17:213 Page 38 of 39
798. Loke XY, Tran W, Alderman CP. Survey of Australian inpatients on vaccination
status and perceptions of influenza vaccination. Consult Pharm. 2012;27:553–63.
799. Macaladad N, Marcano T, Guzman M, Moya J, Jurado F, Thompson M, et al.
Safety and immunogenicity of a zoster vaccine in varicella-zoster virus
seronegative and low-seropositive healthy adults. Vaccine. 2007;25:2139–44.
800. Hales CM, Harpaz R, Ortega-Sanchez I, Bialek SR. Centers for Disease Control
and Prevention (CDC). Update on recommendations for use of herpes
zoster vaccine. MMWR Morb Mortal Wkly Rep. 2014;63:729–31.
801. Keating GM. Shingles (herpes zoster) vaccine (zostavax®): a review of its use
in the prevention of herpes zoster and postherpetic neuralgia in adults
aged ≥50 years. Drugs. 2013;73:1227–44.
802. World Health Organization, SAGE Working Group on Varicella and Herpes
Zoster Vaccines. Background paper on herpes zoster. SAGE Meeting 1–3
April 2014, Geneva, Switzerland. at: http://www.who.int/immunization/sage/
meetings/2014/april/2_Background_document_Herpes_Zoster.pdf. Accessed
3 Oct 2016.
803. Association of Physicians of India. Medicine Update (Volume 23, 2013). Adult
immunization. http://www.apiindia.org/medicine_update_2013/chap101.pdf.
Accessed 9 Feb 2015.
804. MacIntyre CR, Egerton T, McCaughey M, et al. Concomitant administration
of zoster and pneumococcal vaccines in adults ≥60 years old. Hum Vaccin.
2010;6:894–902.
805. Tseng HF, Smith N, Sy LS, Jacobsen SJ. Evaluation of the incidence of
herpes zoster after concomitant administration of zoster vaccine and
polysaccharide pneumococcal vaccine. Vaccine. 2011;29:3628–32.
806. United States Census Bureau, International Programs, International Data
Base. Revised December 19, 2013. https://www.census.gov/population/
international/data/idb/informationGateway.php. Accessed 8 May 2015.
807. MacIntyre R, Stein A, Harrison C, Britt H, Mahimbo A, Cunningham A,
Thompson R. Increasing Trends of Herpes Zoster in Australia. PLoS One.
2015;10:e0125025.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Chen et al. BMC Infectious Diseases  (2017) 17:213 Page 39 of 39
